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MMP     matrix metalloproteinase 
mRNA     messenger ribonucleic acid 
MS     mass spectrometry 
N     amino-terminal 
n     nano 
Na2HPO4     disodium hydrogen phosphate  
Na3VO4     sodium orthovanadate  
NaCl     sodium chloride  
NEB     New England Biolabs 
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N-ERMAD     amino ezrin/radixin/moesin associated domain 
NGF     nerve growth factor 
Ni     nickel 
NiSO4     nickel (II)- sulfate  
NLS     nuclear localisation signal 
NMD     nonsence-mediated decay 
NMR     nuclear magnetic resonance 
NRPTP     non-receptor-like protein tyrosine phosphatase 
NSCLC   non-small cell lung cancer 
OMFP     3-O-methylfluorescein phosphate 
OD     optical density 
p130Cas     p130 Crk-associated substrate 
pACF     para-Acetylphenylalanine 
PAGE     polyacrylamide gel electrophoresis 
pBPA/pBzF     para-Benzoyl-(L)-Phenylalanine 
PBS     phosphate buffer saline 
PCBP1     poly-C-ribonucleic acid binding protein 1 
PDB     protein data bank 
PDGFR     platelet-derived growth factor receptor 
pErk1/2     phosphorylated extracellular signal-regulated kinase1/2 
PFA     paraformaldehyde 
PI(3,4,5)P2     phosphatidylinositol (3,4,5)-trisphosphate  
PI(4,5)P2     phosphatidylinositol (4,5)-bisphosphate  
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PI3K     phosphatidylinositol 3-kinase 
PIC     protease inhibitor coctail  
PIEC     phosphatase of regenerating liver-1 intron enhancer complex 
PIP     phosphoinositide 
PIRH2     RCHY1 ring finger and CHY zinc finger domain containing 1 
PK     protein kinase 
PL     phospholipase  
P-loop     phosphate-binding loop 
pNPP     para-nitrophenylphosphate 
p     pico 
PP     protein phosphatase 
PRL     phosphatase of regenerating liver 
PS     PhosSTOP 
pSer/pThr     phosphorylated serine/threonine 
PT     prenyl-transferase 
PTEN     phosphatase and tensin homologue deleted on chromosome ten 
PTK     protein tyrosine kinase 
PTM     posttranslational modification 
PTP     protein tyrosine phosphatase 
pTyr     phosphorylated tyrosine 
QCL     QuickChangeLightning 
RBD     RhoA binding domain 
REP     Rab escort protein 
 21 
RNA     ribonucleic acid      
ROCK     Rho-coiled coil kinase 
ROS     reactive oxygen specie 
rpm     round per minute 
RPTP     receptor-like protein tyrosine phosphatase 
Rsk     ribosomal S6 kinase 
rt     room temperature 
RTK     receptor tyrosine kinase 
s     second 
S. cerevisiae     Saccharomyces cerevisiae    
SAGE     serial analysis of gene expression 
Sap1     stomach-cancer associated protein tyrosine phosphatase 
SAPK     stress-activated protein kinase 
SAPK     stress-activated protein kinase 
SDS     sodium dodecylsulfate 
SEM     standard error of the mean 
SFK     Sarcoma family kinase 
SFM     serum-free medium 
SH2     Src homology 2 
SH3     Src homology 3 
shRNA     short hairpin ribonucleic acid      
siRNA     small interfering ribonucleic acid      
Smad     mothers against decapentaplegic homologue 
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SO2H     sulfinic acid 
SO3H     sulfonic acid 
SOH     sulfenic acid 
Sos     son of sevenless 
SPPS     solid phase peptide synthesis 
SRE     serum response element 
SRF     serum response factor 
STAT     signal transducers and activators of transcription 
STEP     Striatal Enriched Phosphatase 
TAE     Tris-acetate-EDTA  
TAG     amber STOP codon 
TB     terrific broth 
TBS     tris buffer saline 
TBST     tris buffer saline with Tween20 
TCEP     Tris(2-carboxyethyl)phosphine hydrochloride 
TCTP     Translationally controlled tumor protein 
TEV     tobacco etch virus 
TGFβ     transforming growth factor beta 
Tm     melting temperature 
TMDP     testis and skeletal muscle specific dual-specificity phosphatase 
tRNA     transfer ribonucleic acid 
TRP32     thioredoxin-related protein 32 
Tyk-2     tyrosine kinase-2 
U     uracil 
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UAA     ochre STOP codon 
UPLC     ultra performance liquid chromatography 
UTR     untranslated 
UV     ultraviolet 
VEGF     vascular endothelial growth factor 
VH1     Vaccinia H1 
VHR     Vaccinia H1 related 
VRK3     Vaccinia-related kinase 3 
v-Src     viral Sarcoma 
wt     wild type 
Y2H     yeast-two hybrid 
α     alpha 
β     beta 
γ     gamma 
δ/Δ     delta 
ε     epsilon 
μ     micro 
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Abstract 
Abnormalities in the coordinated activities of protein phosphatases (PPs) and 
protein kinases (PKs) contribute to the development of many diseases. 
Phosphatase of regenerating liver (PRL)-3 and Vaccinia H1-Related (VHR) are 
two members of the protein tyrosine phosphatase (PTP) family shown to be 
involved in cancer. PRL-3 is a member of the PRL phosphatases containing a 
unique post-translationally modifiable prenylation CAAX motif at the carboxy 
(C)- terminal end. There is an immense body of evidence to support a role for 
PRL-3 in the development of various types of cancer and in progression to 
metastasic disease. However, many questions are still pending, especially with 
respect to the identity of physiological substrates, and interacting partners in 
general, of PRL-3. VHR is a model for a group of atypical dual specificity 
protein phosphatases (DUSPs) with a role in cell cycle progression. Only a few 
of VHR’s physiological substrates have been reported to date and there are 
very few studies addressing its regulation and physiological role(s). 
Generally, in order to isolate and identify transient phosphatase-substrate 
interactions, substrate-trapping mutants of PTPs are employed. Mutants which 
can function as substrate traps have the ability to recognise and bind 
substrates, yet they lack functionality of the key catalytic residues and cannot 
efficiently process the hydrolysis of the substrate. However, it is acknowledged 
that the efficiency of such standard substrate-trapping mutants of PTPs is low.  
In this work, the expanded genetic code approach was applied to develop more 
efficient substrate trapping variants of the PTPs by incorporating the photo-
cross-linkable amino acid para-benzoylphenylalanine (pBPA). The concept was 
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optimised for PRL-3 and VHR, and for both proteins, pBPA-containing variants 
were expressed at excellent yields and were highly purified.  
By utilizing the photo-cross-linkable F68pBPA variant of VHR, dimerisation of 
VHR was detected in an in vitro ultraviolet (UV) exposure-mediated cross-
linking assay. VHR dimerisation was further demonstrated to be a potential 
novel regulatory mechanism for VHR, having a negative effect on the catalytic 
activity of the protein. A specific region in VHR known as the variable insert 
segment was pinpointed as a region in the protein, which is either at the dimer 
interface or heavily contributing to dimeric association. Furthermore, the 
intrinsic ability of VHR to self-associate was also demonstrated by 
complementary methods. 
For PRL-3 it was demonstrated that its D72pBPA variant could recognise and 
bind to lipids, with a stronger signal detected in the UV-exposed sample, and 
without altering the lipid binding profile with respect to the native protein. Lastly, 
the potential of exploiting photo-cross-linkable variants of the PTPs was also 
demonstrated by incubating PRL-3 variants, with or without selectively 
introduced pBPA, with mammalian cell lysates, followed by UV exposure. 
Western blot analysis detected new bands corresponding to covalently cross-
linked PRL-3-protein complexes. Future work in our laboratory will follow up on 
these newly identified interactions. 
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1: Introduction 
1.1 Cell signaling and protein phosphorylation 
The term cell signaling can be referred to as a cell’s ability to sense signals in 
the environments, intra- or extracellular, and to respond to them in an 
appropriate and rigorously regulated way (DeVita, Jr., Lawrence, Rosenberg et 
al., 2011; Neel and Tonks, 1997; Tonks, 2005). The responses are diverse and 
can include modulation of protein expression, subcellular localisation, 
conformation, stability or protein-protein interactions. Many cellular responses 
are a result of protein modifications at the post-translational level. Protein 
phosphorylation is a prevalent post-translational modification (PTM) with a 
pivotal role in the regulation of various biological processes including cell cycle 
progression, cell growth, differentiation, metabolism, motility, gene 
transcription, immune response or apoptosis (Burke and Zhang, 1998; Zhang, 
2003a; Zhang, 2005). It is believed that protein phosphorylation accounts for 
modification of around 30% of proteins encoded in the human genome (Cohen, 
2002). Mass spectrometry (MS) based study of temporal dynamics of 
phosphorylated proteins in Henrietta Lacks (HeLa) cells following epidermal 
growth factor (EGF) stimulation yielded several intriguing revelations (Olsen, 
Blagoev, Gnad et al., 2006). 2,244 phosphoproteins were identified, and over 
90% of them had not been reported in SwissProt. Moreover, the authors noted 
that the abundance of phosphorylation on Tyr (pTyr) was around ten-fold higher 
than estimated in an earlier study. The difference was not just the result of a 
stimulus-triggered response, but also of the presence of pTyr modification on 
less abundant cellular proteins. Unraveling protein phosphorylation sites is 
expected to help in integrating cell signaling research efforts, with special 
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emphasis on cancer-linked aberrations (Julien et al., 2011; Motiwala and 
Jacob, 2006; Olsen, Blagoev, Gnad et al., 2006; van Huijsduijnen et al. 2002).  
1.2 PPs 
The homeostasis of protein tyrosine phosphorylation (Figure 1) in cellular milieu 
is achieved through complementary activities of PKs, which catalyse the 
transfer of a phosphoryl moiety donated by the adenosine triphosphate (ATP) 
to the hydroxyl group of a particular residue (tyrosine, serine or threonine) and 
PPs, with counteracting hydrolysis of the phosphate monoester finally resulting 
in the recuperated active enzyme and dissociation of the inorganic phosphate 
(Arantes, 2006; Elchebly  et al., 1999; Jackson and Denu, 2001; Klaman et al., 
2000; Kolmodin and Åqvist, 2001; Zhang, 1998). Perturbations in the balanced 
activities of PKs and PPs, yielding abnormalities in the phosphorylation level of 
protein tyrosine residues, have been linked to the aetiology of a plethora of 
human diseases, including cancer development and progression, diabetes or 
immune disorders (Barford, 1995; He et al., 2012; Hendrix, W.J.A.J. et al., 
2013; Myers, M.P. et al., 1998; van Huijsduijnen et al., 2002; Julien et al., 2011; 
Tiganis and Bennett, 2007; Zhang, 2005).  
 
Figure 1: PPs and PKs maintain homeostasis of protein phosphorylation. 
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According to the substrate specificity, PPs can be divided into two large 
superfamilies, protein serine/threonine phosphatases (STPs) and protein 
tyrosine phosphatases (PTPs) (Denu et al., 1996a; Jackson and Denu, 2001; 
Zhang, 1998). In stark contrast to PKs, which developed from a common 
ancestor (Tonks, 2006), STPs and PTPs are characterised by diversities in 
sequence, fold or catalytic mechanism (Barford et al., 1998; Hoffman et al., 
2004).  
STPs function as metalloenzymes with a dinuclear bivalent metal ion center 
(Fe2+/3+, Mn2+, Zn2+) at the active site, which is essential for both the enzymatic 
activity and maintenance of the structural integrity (Barford, 1995; Denu et al., 
1996a; Hoffman et al., 2004). The metal ions are coordinated by an 
asparagine, two aspartates and three histidines, one of which acts as a general 
acid and helps to expel the leaving group of a substrate (Denu et al., 1996a). 
The catalytic mechanism of STPs consists of a single step. It involves a direct 
nucleophilic attack of a substrate by the activated water molecule. The water 
molecule is positioned optimally for catalysis by the two metal ions, which are 
also important for proper positioning of a substrate. It is interesting to note that 
fewer STPs (about 40) are opposed by as many as 428 STKs (Li et al., 2013). 
This apparent discrepancy in number can be assigned to the fact that STPs 
function in vivo as holoenzymatic complexes consisting of a catalytic subunit 
decorated by diverse regulatory or targeting subunits, thus generating 
combinatorial complexity.  
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1.3 PTPs 
The research focus on tyrosine phosphorylation was stimulated by the finding 
that viral (v)-Src of Rous sarcoma virus could phosphorylate protein tyrosine 
residues (Cohen, 2002), thus implying involvement of tyrosine phosphorylation 
in growth regulation. PTP1B was the first PTP to be isolated, from human 
placenta, and characterised (Charbonneau et al., 1989; Cohen, 2002; Zhang, 
1998). Comparing the sequences of the catalytic subunits of protein 
phosphatase (PP) 1, PP2A and PP2B/calcineurin, and to the available acid and 
alkaline phosphatases revealed PTP1B’s membership to a novel class of 
phosphatases, further fueling complexity in the study of PTPs (Tonks, 2013). 
Many growth factor receptors (GFRs) were shown to have protein tyrosine 
kinase (PTK) activity (Cohen, 2002; Hunter, 2000; Zhang, 1998). Nevertheless, 
PTPs were long misconceptionally considered promiscuous housekeeping 
enzymes that merely served to reverse the activities of PTKs (Tonks, 2006; 
Zhang, 1998). They are sporting remarkable structural complexity and 
sophisticated substrate specificity (Andersen et al., 2001; Barr et al., 2009; Flint 
et al., 1997; He et al., 2012; Tiganis and Bennett, 2007; Tonks, 2006; Zhang, 
2005). Historically, the discovery of PTKs dates almost a decade before PTPs 
(Cohen, 2002; Tiganis and Bennett, 2007). Signal transduction pathways were 
viewed as cascades igniting from the receptor PTKs which were associated 
with growth factors or peptide hormones (Hunter, 2000; Seger and Krebs, 
1995; Zhang, 2005). This association led to receptor dimerisation and tyrosine 
transphosphorylation (Schlessinger, 1988), thus creating binding sites for 
proteins bearing Src homology-2 (SH2) domains (Hunter, 2000; Yaffe and 
Cantley, 1999). This, in turn, triggered activation of downstream targets, 
eventually eliciting a particular effect. Since the discovery of PTKs by Tony 
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Hunter and colleagues (Cohen, 2002; Eckhart et al., 1979; Julien et al., 2011), 
their preponderance in the regulation of fundamental cellular processes has 
been highlighted by the findings that aberrations in the PTK-linked signaling 
pathways provide a causal link to various diseases (Hunter, 2000; Lemmon and 
Schlessinger, 2010; Zhang, 1998). Consequentially, this urged the research 
focus on the enzymes with the counteracting activity, namely the PTPs. It is 
now well established that PTPs can act as positive or negative switches for 
signal transduction (Zhang, 2003b; Zhang, 2005). 
The hallmark which defines PTPs is the presence of the consensus motif 
HisCys(X)5Arg(Ser/Thr) (where X represents any amino acid) in the catalytic 
domain (Denu et al., 1996a; Zhang, 1998; Zhang, 2005). This conserved amino 
acid signature is also termed the phosphate-binding loop, P-loop or the 
signature motif (Burke and Zhang, 1998; Jackson and Denu, 2001). The 
catalytic domain of the classical PTPs spans around 280 amino acid residues 
(Barr et al., 2009), and the sequence alignment identified ten conserved motifs 
which are essential for conserved structural fold, substrate recognition and 
catalytic mechanism (Andersen et al., 2001; Tiganis and Bennett, 2007). 
The presence of the conserved signature motif was utilised in an attempt to 
provide systematic classification of PTPs (Alonso et al., 2004). Identification of 
107 PTP-encoding genes in the human genome cemented the view of PTPs as 
significant contributors to the balance of the cellular pTyr level. A recent study 
(Li et al., 2013) reported 96 PTP-encoding genes in the human genome, 
focusing only on the catalytically active PTPs. The number of PTPs, in contrast 
to 90 genes encoding PTKs, is suggestive of their comparable complexity at 
structural and functional levels (Alonso et al., 2004; He et al., 2012; Li et al., 
2013; Tonks, 2006). Whereas previous subdivision of PTPs into four classes 
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was solely based on the amino acid composition of the catalytic domains 
(Alonso et al., 2004), the recent study by Li et al. also included structural 
considerations (Li et al., 2013). The Classes I-III are cysteine-based PTPs 
(Alonso et al., 2004), whereas the representatives of the Class IV were re-
classified into haloacid dehalogenase (HAD) superclass (Li et al., 2013). 
The Class I of cysteine-based PTPs is the most abundant and will be discussed 
in the later section. 
The basic catalytic mechanism of the PTPs encompasses two distinct 
enzymatic steps (shown in Figure 2) (Barford, 1995; Jackson and Denu, 2001; 
Kolmodin and Åqvist, 2001; Zhang, 2003a and b). It proceeds via catalytic 
cysteine and arginine residues, which belong to the consensus active site motif, 
and of an aspartate which resides on the flexible general acid/base loop (so-
called WPD loop) separated from the signature motif in the primary sequence. 
The catalytic cysteine exists in the form of a thiolate ion under physiological 
conditions due to its unique microenvironment. In the first step of the hydrolytic 
reaction, it performs a nucleophilic attack on a phosphate ester of a substrate 
bound in the active site, leading to the formation of a cysteinylphosphate 
intermediate. The reaction is helped by the aspartate residue which acts as an 
acid and donates a proton to the oxygen of the leaving group. In the second 
step, the aspartate residue functions as a base and facilitates hydrolysis of the 
intermediate by extracting a proton from a water molecule, leading to a release 
of inorganic phosphate and recuperation of the active site cysteine. The 
conserved arginine residue of the PTP signature motif is important for binding 
of a substrate and stabilization of the phospho-enzyme intermediate by forming 
bidentate hydrogen bonds with two oxygens of the bound substrate. A 
conserved serine or threonine residue immediately following the conserved 
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arginine residue of the P-loop is important for facilitating the breakdown of a  
cysteinylphosphate intermediate in the second step of the catalytic reaction 
(Zhang, 2003a). 
 
 
 
Figure 2: Catalytic mechanism of PTPs. Adapted from Tonks, 2006. The key 
catalytic resiudes are labeled based on VHR. 
 
It has been well acknowledged that PTPs are susceptible to inactivation 
through oxidation of the catalytic cysteine in response to diverse stimuli (den 
Hertog et al., 2008; Meng et al., 2002; Tonks, 2006; Traore et al., 2008 and 
shown in Figure 3). PTPs are targets for reactive oxygen species (ROS) 
because they possess the catalytic cysteine residue that, under physiological 
conditions, exists in the form of a thiolate ion, which serves two functions- it 
enables it to function as a nucleophile in the first step of catalytic reaction and it 
renders it sensitive to oxidation (den Hertog, 2003; Meng et al., 2002; Miki and 
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Funato, 2012; Tonks, 2005). PTPs have different predispositions towards 
oxidative inactivation of their catalytic domains, which was demonstrated on 
RPTPα, whose membrane distal D2 domain proved to be more prone to 
oxidation-induced catalytic inactivation than D1 domain (den Hertog et al., 
2008; Groen et al., 2005; Östman et al., 2011). It was also suggested that ROS 
could be generated in a spatio-restricted manner thus providing a mechanism 
for selective inhibition of the PTPs that are co-localised with the sites where 
ROS were generated (Böhmer et al., 2013).  
 
 
 
 
Figure 3: Principle of regulation of PTPs through oxidation. Active site Cys is 
present in the form of a thiolate ion at physiological conditions. In the presence 
of ROS, such as H2O2, it can be reversibly oxidised to sulfenic acid, thus 
rendering PTPs catalytically inactive. Sulfenic acid can be reduced back to the 
thiolate form through actions of thiol reductants, restoring the active form of the 
enzyme. Oxidations of cysteine residue to sulfinic and sulfonic acids are 
irreversible.  
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For oxidation to represent a general regulatory mechanism of PTPs, the 
oxidation of the catalytic cysteine must be reversible, which means that it must 
not proceed further than sulfenic acid (SOH-) (Finkel, 2012; Roos and 
Messens, 2011; Tonks, 2005; Tonks, 2006). Oxidations to sulfinic (SO2H-) and 
sulfonic acid (SO3H-) are considered irreversible, but there are several 
mechanisms for PTPs to prevent excessive oxidation. These include formation 
of cyclic sulphenamide, which induces conformational change preventing 
association of the phosphatase with a substrate and also exposing the oxidised 
residue to the reducing environment of the cell. Another mechanism is 
intramolecular disulfide bridge formation between the active site cysteine and 
proximal regulatory (“backdoor”) cysteine (Buhrman, 2005; Funato and Miki, 
2013; Östman et al., 2011; Poole and Nelson, 2008; Tonks, 2006). ROS for 
example, superoxide, hydroxyl radical and hydrogen peroxide (H2O2)) are 
generated by partial reduction of oxygen and are produced by molecules of 
oxygen catching electrons escaped from mitochondrial electron transport chain 
(METC), and also as a result of various environmental stresses, such as 
irradiative damage, heat-shock, infections or toxins (Freuhauf and Meyskens, 
Jr., 2007; Groen et al., 2005; Roos and Messens, 2011; Traore et al., 2008). 
Furthermore, ROS are not only regarded as cellular damaging agents, but are 
known to participate in intracellular signaling as second messengers generated 
at low levels after growth factor or cytokine stimulation (Finkel, 2012; Freuhauf 
and Meyskens, Jr., 2007; Gough and Cotter, 2011; Kamata et al., 2005; Meng 
et al., 2006; Miki and Funato, 2012; Rhee, 2006; Rhee et al., 2000; Roos and 
Messens, 2011; Sundaresan et al., 1995). ROS generated transiently in 
response to various stimuli impose their effect on downstream signaling by 
transiently inhibiting PTPs (Gough and Cotter, 2011; Karish and Neel, 2013; 
 35 
Rhee, 2006; Traore et al., 2008). Moreover, H2O2 added exogenously was 
shown to induce signaling cascades resembling growth factor-induced 
activation (Denu and Tanner, 1998). In addition, H2O2 is the most commonly 
utilized ROS in investigating oxidation-susceptibility of PTPs, employed also in 
a study by Denu and Tanner focused on demonstrating reversible oxidation as 
a general regulatory principle of PTPs (Denu and Tanner, 1998; Östman et al., 
2011).  
1.3.1 The Class I of PTPs 
The members of the Class I of PTPs (99) can be further subdivided into 
transmembrane receptor-like PTPs (RPTPs) (21), non-receptor-like PTPs 
(NRPTPs) (17) and Vaccinia H1 (VH1)-like phosphatases, which are also 
referred to as DUSPs (Alonso et al., 2004 and shown in Figure 4). Whereas 
NRPTPs consist of cytosolic proteins with a single catalytic domain and 
achieve diversity through domains flanking either side of the catalytic domain, 
RPTPs are transmembrane proteins. They contain various extracellular 
domains and transmembrane region, and 12 of them have a tandem of the 
cytoplasmic PTP domains (Majeti and Weiss, 2001; Tonks, 2006). Extracellular 
domains of the RPTPs display different motifs, which suggest their participation 
in intercellular communication or cell-matrix contacts (Barford, 1995; Böhmer et 
al., 2013). The PTP domains of RPTPs are referred to as D1 (membrane-
proximal) and D2 (membrane-distal) (Tonks, 2006). Catalytic activity is almost 
exclusively confined to the D1 domain. The D2 domain is important for 
stabilization of the protein and for mediating protein interactions. 
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1.3.1.1 DUSPs 
As mentioned previously, 61 DUSPs have been reported (Alonso et al., 2004). 
Excluding the conserved residues of the PTP-signature motif, they exhibit 
significant sequence divergence compared to the classical PTPs. Further 
subdivision into seven groups can be performed based on structure and 
homology between phosphatase domains. These groups include mitogen 
activated protein kinase (MAPK) phosphatases (MKPs)  (11), atypical DUSPs 
(19), PRL phosphatases (3), slingshots (3), phosphatase and tensin 
homologues (PTENs) (5), myotubularins (16) and cell division cycle 14 
homologues (Cdc14s) (4). As this thesis was focused on PRL-3 and VHR, the 
other DUSP families will not be discussed. 
DUSPs constitute a heterogeneous group of the PTP superfamily (Tonks, 
2013). Unlike classical PTPs, the more shallow and broad catalytic pocket of 
DUSPs yields more various substrate specificity (Jackson and Denu, 2001),  
rendering them capable to not only catalyze dephosphorylation of 
phosphotyrosine (pTyr), but also phosphoserine/threonine (pSer/pThr) 
residues, as well as nonpeptidic substrates, such as phosphoinositides (PIPs), 
messenger ribonucleic acid (mRNA) or glycans (Campbell et al., 2003; Gentry, 
Romá-Mateo et al., 2012; Leslie, Gray et al., 2000; Leslie et al., 2001; Li et al., 
2013; Lokareddy et al., 2013; McParland, Varsano et al., 2011; Patterson et al., 
2009; Zhang, 2003b).  
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Figure 4: Classification of PTPs. (a) PTPs are divided into four classes, and 
classes I-III are cysteine-based. The Class I is further subdivided into classical 
PTPs, comprised of RPTPs and NRPTPs, and DUSPs. (b) DUSPs are further 
divided into seven subgroups based on structure and similarity of their 
phosphatase domains (adapted from Alonso et al., 2004). 
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1.3.1.2 MKPs 
MKPs share little sequence similarity with the classical PTPs, but they have 
similar topology and employ the same catalytic mechanism (Patterson et al., 
2009).  MKPs represent a subgroup of DUSPs which can dephosphorylate 
MAPKs. The MAPKs represent a final constituent in conserved tripartite kinase 
signaling cascades, and are activated by the upstream dual-specificity kinases 
termed MAPK kinases (MAPKK, MAPKK or MEK), which, in turn, are activated 
by their upstream kinases (MAPKKK, MAPKKK or MEKK) (Caunt and Keyse, 
2013). MAPKKs activate MAPKs by dual phosphorylation of both Tyr and Thr 
residues of the -ThrXTyr-motif in the kinase activation loop of the MAPKs (Katz 
et al., 2007; Theodosiou and Ashworth, 2002; Todd et al., 1999; Zhou et al., 
2002). MAPKKK are activated by various upstream activators (Katz et al., 
2007; Lahiny et al., 2010). The ultimate targets of the activated MAPKs cover a 
diverse portfolio of substrates involved in cellular processes as diverse as 
regulation of gene expression, proliferation, differentiation, immune response, 
cell survival versus programmed cell death or cell cycle progression (Patterson 
et al., 2009; Zhou et al., 2002).  In mammals, there are four major families of 
MAPKs (Chang and Karin, 2001). These comprise extracellular signal-
regulated kinase (Erk) 1/2 (Erk1 is also known as p44 MAPK or as MAPK1 and 
Erk2 as p42 MAPK or as MAPK2), p38 MAPKs (p38α, β, γ and δ), c-jun N-
terminal kinases (JNKs; JNK 1-3) (also known as stress-activated protein 
kinase, SAPK) and Erk5, also known as Big MAP kinase (BMK) 1 (Caunt and 
Keyse, 2013; Theodosiou and Ashworth, 2002; Zhang and Liu, 2002). Distinct 
MAPK pathways are activated in response to a particular stimulus: Erk1/2 are 
commonly activated by growth or differentiation factors, Erk5 by stress cues as 
well as by growth factors, and the members of the JNK and p38 families by 
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inflammatory cytokines and various environmental stress conditions, such as 
oxidative stress, osmotic or heat shock or irradiation (Haagenson and Wu, 
2010; Katz et al., 2007; Pumiglia and Decker, 1997; Raman et al., 2007; 
Robinson and Cobb, 1997; Todd et al., 1999; Wagner and Nebreda, 2009). 
MKPs can demonstrate activity against various MAPKs in vitro. However, the 
specificity of an MKP toward a specific MAPK is more distinct in vivo (Zhang et 
al., 2011; Zhou et al., 2002). MKPs can be further subdivided into three groups, 
based on their amino acid sequence similarity, subcellular localisation and 
substrate specificities (Dickinson and Keyse, 2006). These three groups 
contain ten catalytically active phosphatases, whereas DUSP24, also known as 
MK-STYX, resembles features of the MKPs, but it has naturally occurring 
mutation of the catalytic cysteine into glycine, thus rendering it a 
pseudophosphatase (Tonks, 2013; Wishart, 1995). The three subfamilies of the 
active MKPs include: nuclear MKPs, induced in response to mitogens and 
stress signals (MKP-1/DUSP1, MKP-2/DUSP4, DUSP2/PAC-1 and DUSP5), 
cytoplasmic MKPs, with activity toward Erk1/2 (MKP-3/DUSP6, MKP-4/DUSP9 
and MKP-X/DUSP7), and MKPs with selectivity for JNK and p38 isoforms of 
MAPKs which can be localised in both nucleus or cytoplasm (DUSP8, MKP-
5/DUSP10 and DUSP16) (Caunt and Keyse, 2013; Dickinson and Keyse, 
2006). MKPs quench the activity of MAPKs by dephosphorylating the residues -
ThrXTyr- in the activation loop, either or both (Caunt and Keyse, 2013). There 
is a number of phosphatases reported to downregulate MAPKs by 
dephosphorylation (Keyse, 2000; Saxena and Mustelin, 2000). They exhibit 
distinct subcellular localisation, substrate preference and regulation. Most of 
them are nuclear and silent until a proper signal is imposed. By controlling the 
magnitude and duration of the kinase activation, downregulation of a particular 
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MAPK through dephosphorylation fine-tunes cellular response to a particular 
stimulus (Dickinson and Keyse, 2006; Keyse, 2008).  
All MKPs share common architectural features. They have a catalytic domain at 
the C-terminal end, with partial sequence similarity to the one of VH1 
(Dickinson and Keyse, 2006; Theodosiou and Ashworth, 2002; Tonks, 2013). 
On the N-terminal end, they carry a domain with two regions which bear 
sequence similarity to the catalytic domain of Cdc25. Interestingly, the Cdc25 
homology domain (CH2) is also pointing towards evolutionary link with the 
rhodanese-like enzymes (Alonso et al., 2004; Dickinson and Keyse, 2006). 
CH2 domain is not present in the atypical DUSPs, which are discussed in the 
next chapter. Further structural characteristics of the MKPs will not be 
discussed as MKPs were not the studied in this thesis. 
1.3.1.3 Atypical DUSPs 
Atypical DUSPs are a subfamily of DUSPs (Alonso et al., 2004). Although they 
have substrates amongst MAPKs, they show substrate specificity also outside 
of the family of the MAPKs (Bayón and Alonso, 2010). Compared to the 
classical MKPs, they lack the N-terminal MAPK-binding (MKB) domain and, 
almost exclusively, any other recognisable motifs and are smaller in size 
(Bayón and Alonso, 2010; Patterson et al., 2009; Wei, Ryu, et al., 2011).  
In general, the data on the atypical DUSPs is very complex and conflicting 
(Bayón and Alonso, 2010; Patterson et al., 2009). Substrate specificity in vivo 
cannot be merely extrapolated from the in vitro studies, and quite often the 
observed function is dependent on the cell type or on a particular cell stimulus. 
In addition, some atypical DUSPs can act as scaffolds, or can require a yet 
unidentified component in the signal transduction pathways to elicit a particular 
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response. To shed light on the mechanisms behind the involvement of atypical 
DUSPs in various cellular processes, in normal or pathological states, more 
efficient substrate, and interacting partners, trapping mutants would need to be 
developed to complement approaches such as knockout mice models or MS 
based techniques, to enable identification of less abundant interacting partners. 
1.4 VHR 
1.4.1 General properties of VHR  
VHR/DUSP3 is an atypical DUSP comprised of 185 amino acids organized in a 
single catalytic domain (Bayón and Alonso, 2010; Ishibashi et al., 1992; 
Yuvaniyama et al., 1996). It was identified by Ishibashi et al. by using 
expression cloning strategy (Ishibashi et al., 1992). The newly discovered 
enzyme bore resemblance to VH1, hence being named VH1-Related 
phosphatase. Apart from the residues of the PTP signature motif, it shares no 
discernible sequence homology to the classical PTPs (Schumacher et al., 
2002). VHR demonstrated the ability to dephosphorylate artificial phosphatase 
substrate pNPP, but also tyrosine-phosphorylated insulin-, platelet-derived 
growth factor-, epidermal growth factor- and keratinocyte growth factor 
receptors (IR, PDGFR, EGFR and KGFR, respectively), RTKs, as well as 
serine-phosphorylated casein, classifying as a phosphatase with dual 
specificity (Denu et al., 1995a; Ishibashi et al., 1992). When nucleophilic 
Cys124 of the P-loop was exchanged to Ser, VHR completely lost its catalytic 
ability, thus indicating that a single active site governed its activity towards both 
classes of phosphorylated substrates (Ishibashi et al., 1992; Schumacher et al., 
2002; Yuvaniyama et al., 1996; Zhou et al., 1994). 
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Being one of the smallest DUSPs, VHR emerged into a prototypic phosphatase 
used to extensively profile catalytic properties of DUSPs (Zhou et al., 1994). By 
using radioactively labeled pTyr-containing substrate, it was demonstrated that 
hydrolysis of a phosphate monoester proceeds via mechanism employed by 
the classical PTPs (Denu et al., 1995b; Zhou et al., 1994). In addition, the 
activity of VHR against pSer/pThr-containing peptides was around 300 times 
lower. VHR demonstrated up to three-fold preference for bisphosphorylated 
peptides over monophosphorylated ones (Luechapanichkul, Chen et al., 2013).  
Moreover, the subcellular localisation of endogenous VHR was investigated in 
a panel of mammalian cell lines, and also in a set of human breast cancer cells 
(Todd et al., 1999). VHR was found to be mostly localised in the nucleus, with 
occasional cytoplasmic staining, and present at high levels. The protein level of 
VHR was found to fluctuate during cell cycle progression, being barely 
detectable in G1, peaking through S phase and being highest in G2/M phase 
(Rahmouni et al., 2006). The subcellular localisation of VHR was also found to 
change with the cell cycle progression. In interphase, VHR was mostly found in 
the nucleus, while in telophase it was concentrated between the daughter 
chromatids. When levels of VHR were reduced by small interfering (si) RNA, 
the cells arrested in G1/S and G2/M phases. These cells also had increased 
levels of p21Cip/Waf1 and downregulated genes implicated in cell cycle 
regulation, deoxyribonucleic acid (DNA) replication, repair or transcription. 
Reduced level of VHR in G1 phase was linked to the growth-promoting role of 
MAPKs. It was previously recognised that in the presence of growth arresting 
stimuli, such as DNA damaging agents or phorbol esters, prolonged activation 
of Erk1/2 led to cell cycle arrest, whereas activation of JNK was reported to 
activate p53 and, subsequently, p21Cip-Waf1 (Rahmouni et al., 2006; Tang et al., 
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2002). Thus, cell cycle dependent levels of VHR would enable activation of 
MAPKs for only as long as necessary for normal cell cycle progression. 
1.4.2 Structural characteristics of VHR 
The report of the crystal structure of VHR listed several structural specificities 
of this phosphatase (Yuvaniyama et al., 1996). The overall protein fold was 
shown to be similar to the fold of the classical PTPs (Figure 5). Compared to 
the classical PTPs, the active site pocket of VHR was shallower (no more than 
6Å in depth). The depth of the active site pocket was the result of differences in 
the architecture of the N-terminal α1- β1 loop, which was shown to be shorter in 
VHR than in the classical PTPs. This region was termed the “recognition 
region” due to its recognised role for substrate recognition. Next, the region 
defined by the β3-β7 sheets was called the “variable insert” segment.  The 
corresponding region in the PTPs was shown to be almost four times longer. 
The amino acid composition of this region is diverse. The amino acid residues 
localised at the edges of the β3-β7 region were known to contribute to the 
integrity of the active site, but apart from Met69 in VHR, the functional 
significance of the other residues in this region has not been profiled. The 
carbonyl group of Met69 is forming a hydrogen bond with the conserved 
Arg130 of the P-loop.  
The preference of VHR to dephosphorylate pTyr was explained by reporting the 
crystal structure of its catalytically inactive mutant C124S in complex with a 
peptide derived from the activation loop of p38 MAPK (Schumacher et al., 
2002). The structure showed that a narrow entrance to the active site crevice in 
VHR was created by the bulky residues at the edges of the entrance, Glu126 
and Tyr128. Most of the dual-specific MKPs have smaller hydrophobic residues 
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at these positions, Ala and Ile, respectively (Tonks, 2013). Interestingly, when 
those point-mutations were simultaneously generated in VHR and the activity of 
the double mutant was assessed against a peptide derived from the activation 
loop of JNK, but with both phosphorylated residues in the peptide being pThr, 
double mutant was nine-fold better than the native enzyme (Schumacher et al., 
2002). Related to this, a recently reported crystal structure of DUSP27 revealed 
an analogous rationale for its preference for hydrolyzing pTyr over pThr/pSer 
(Lountos et al., 2011). In DUSP27, the sites of Glu126 and Tyr128 are 
occupied by Met149 and Arg151, respectively. In addition to DUSP27, DUSP13 
was identified as a close structural homologue of VHR (Kim et al., 2007). The 
regions of the most prominent structural differences between VHR and 
DUSP27 are the N-terminal segment and the loop β3-α4 (Lountos et al., 2011). 
In VHR, the N-terminal helix is a part of the substrate-binding groove, while in 
DUSP27 it projects away from the active site, whereas the region 
corresponding to the loop β3-α4 is known as the “variable insert” segment 
(Yuvaniyama et al., 1996). The reported crystal structure of DUSP27 showed 
that the protein crystallized as a dimer through swapping of the N-terminal 
helices, similar to VH1 (Koksal et al., 2009; Lountos et al., 2011). Dimerisation 
mechanism is likely to be contributed by the extended conformation of the N-
terminal helix. Similarly to VHR, DUSP27 prefers pTyr containing substrates 
(Friedberg et al., 2007; Lountos et al., 2011). It has narrow entrance to the 
active site pocket, dictated by the bulky Met149 and Arg151 (Lountos et al., 
2011). Intriguingly, the surface charge distribution in DUSP27 is reversed with 
respect to VHR (Friedberg et al., 2007; Lountos et al., 2011). All the 
aforementioned differences between VHR and DUSP27 are likely to result in 
different substrate portfolio, although the physiological substrates of DUSP27 
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are yet to be identified. Similarly, the most prominent structural differences 
between VHR and DUSP13 are in the α1-β1 loop, known as substrate 
recognition region in VHR, and in the β3-α4 loop, which is shorter in DUSP13 
with two residues, corresponding to Phe68 and Met69 in VHR, missing (Kim et 
al., 2007; Yuvaniyama et al., 1996).  
Figure 5: Comparing structure of VHR with classical PTPs PTP1B and Yersinia 
PTP. The overall fold of VHR resembles that of the classical PTPs, like 
indicated in panel A. “Recognition region” segment is pointed out in green and 
“variable insert” in orange. Panel B shows structure-based sequence 
alignment. Conserved residues are indicated in pink, helices are represented 
as cylinders, sheets as arrows and structurally equivalent regions in blue. 
Reprinted with permission from Yuvaniyama, J., Denu, J.M., Dixon, J.E. & 
Saper, M.A. Crystal structure of the dual specificity protein phosphatase VHR. 
Science 272, 1328-1331 (1996). 
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1.4.3 Physiological substrates of VHR 
Only few physiological substrates of VHR have been reported and these 
include MAPKs Erk1/2 and JNK, erythroblastic leukemia viral oncogene 
homolog 2 (ErbB2) and signal transducers and activators of transcription 
(STAT) 5 (Hoyt, Zhu, Cerignoli et al., 2007; Luechapanichkul, Chen et al.,  
2013; Todd et al., 1999; Todd et al., 2002; Wang, Yeh et al., 2011 and Figure 
6).  
Erk1/2 was identified as a physiological substrate of VHR by using its D92A 
mutant immobilized on an affinity column, which retained Erk1/2 from African 
green monkey kidney COS-1 cellular extracts enriched for tyrosine-
phosphorylated proteins (Todd et al., 1999). Hence, D92A served as a 
substrate-trapping mutant of VHR. In general, substrate-trapping mutants are 
employed in order to isolate and identify transient phosphatase-substrate 
interactions, (Zhang, 2003a). Mutants which can function as substrate traps 
have the ability to recognise and bind substrates, yet they lack functionality of 
the key catalytic residues.  
Purified recombinant VHR demonstrated the ability to dephosphorylate both 
recombinant Erk1/2 and Erk1/2 from the cellular extracts, with preference for 
Tyr185 residue from the activation motif of Erk1/2. Moreover, when the 
endogenous VHR was immunodepleted from COS-1 cell extracts, 
dephosphorylation of Erk1/2 was slowed down comparing to the mock-treated 
control, whereas immunodepletion had no effect on dephosphorylation of p38, 
confirming VHR as a regulator of Erk1/2. Under the conditions, no difference in 
the phosphorylation level of JNK was observed, whereas the level of 
phosphorylated p38 MAPK showed only small additional decrease in the 
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presence of the recombinant VHR. Unlike MKPs reported previously, the 
protein level of VHR was not fluctuating in response to different stimuli, such as 
EGF treatment or stimulation with different mitogens. Thus, VHR was 
suggested to maintain phosphorylated level of Erk1/2 at the basal level in the 
dormant state and by deactivating it after appropriate stimulation, by 
preferentially dephosphorylating Tyr185 residue of its activation loop.  
It is interesting to note that activity of VHR against Erk1/2 was shown to be 
decreased in cultured human intestinal epithelial cells and in murine epithelia in 
vivo as a result of microbiota-mediated generation of ROS (Wentworth et al., 
2011). The benefits of commensal bacteria on homeostasis of the intestine 
have been acknowledged. The aforementioned study helped elucidate a 
mechanism behind commensal bacteria-modulated manipulation of signaling in 
intestinal epithelial cells. According to it, mRNA and protein levels of VHR were 
upregulated upon stimulation with bacterial N-formyl-peptides. In addition, 
formyl peptide receptor (FPR), which recognises bacterial N-formyl-peptides, 
results in the transient generation of ROS. This enables a feedback loop 
between the Erk1/2 mediated proliferation stimulative effect and transient 
downregulation of the catalytic activity of Erk1/2-specific phosphatase VHR. 
JNK was another representative of the MAPK family shown to be 
dephosphorylated by VHR (Todd et al., 2002). NIH3T3 mouse fibroblasts, 
transiently and stably transfected with wild type (wt) VHR or its inactive C124S 
mutant and subjected to various stress stimuli to activate JNK MAPK pathway, 
were shown to contain lower levels of phosphorylated JNK when wtVHR was 
overexpressed. Interestingly, it was demonstrated that association of c-Jun with 
JNK prevented VHR-mediated dephosphorylation of JNK, but had no negative 
effect on its activity against Erk1/2. This finding explained the aforementioned 
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observations when profiling the specificity of VHR against Erk1/2 and not 
seeing the effect on JNK (Todd et al., 1999). The work of Todd et al. offered an 
intriguing hypothesis to explain low levels of Erk1/2 found to associate with 
VHR, according to which VHR could be “masked” from activated Erk1/2 in a 
way comparable to the one of c-Jun and JNK (Todd et al., 2002).  
STAT5 was identified as a VHR substrate outside of the MAPK family (Hoyt, 
Zhu, Cerignoli et al., 2007). STATs are a family of transcription factors that 
undergo phosphorylation-induced activation (Braunstein et al., 2003; Klemm et 
al., 1998; Olayioye et al., 1999). Activated STATs form homo- or heterodimers. 
Dimerisation is achieved by intermolecular association involving SH2 domain of 
one STAT monomer and pTyr residue in the C-terminal region of the second 
STAT monomer. Activated STATs translocate to the nucleus to activate 
transcription of the target genes regulating diverse cellular processes, such as 
immune response, apoptosis or growth suppression (Jardin and Sticht, 2012). 
The mechanism of STAT5 dephosphorylation by VHR was found to proceed in 
two steps (Hoyt, Zhu, Cerignoli et al., 2007). It requires phosphorylation of 
Tyr138 in VHR, which acts as a binding site for the SH2 domain in STAT5. The 
second step involves dephosphorylation of Tyr694 in the displaced C-terminal 
end of STAT5. This mechanism was also confirmed recently by Jardin and 
Sticht who applied molecular modeling and dynamics approaches to profile 
structural requirements for STATs dephosphorylation by VH1 and VHR (Jardin 
and Sticht, 2012). The overall conclusion was that the specificity for 
dephosphorylating a particular form of STATs is derived from the nature of the 
residues located at the interface of the STAT-dimers. 
ErbB2 was identified as a novel substrate of VHR by using stably transfected 
non-small cell lung cancer (NSCLC) H1299 cells (Wang, Yeh et al., 2011). VHR 
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was shown to preferentially dephosphorylate Tyr992 residue of the receptor. 
VHR-mediated dephosphorylation of Tyr992 had a suppressive effect on the 
activation of PLCγ/PKC signaling pathway, whilst not affecting the activation of 
Src.  
The first systematic profiling of combinatorial peptide libraries in order to 
illuminate substrate preferences of VHR in vivo was reported recently 
(Luechapanichkul, Chen et al., 2013). It was revealed that VHR could 
dephosphorylate two classes of pTyr containing peptides. Peptides from the 
Class I resembled the reported VHR substrates, while the members of the 
Class II constitute a potential pool of uninvestigated cellular substrates. 
Intriguingly, the latter ones exhibited distinct binding mode, with the consensus 
motif (V/A)P(I/L/M/V/F)X1-6pY at the N-terminal end. Although screening 
PhosphoSite database did not identify any human protein matching this criteria, 
it is plausible that this motif can be generated through proteolytic action on the 
proteins which do contain the aforementioned consensus sequence internally. 
 
 
Figure 6: Summary of known physiological substrates of VHR. The figure was 
partially generated in ChemBioDraw. 
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1.4.4 Regulation of VHR   
VHR expression is not triggered in response to various mitogenic stimuli (Todd 
et al., 1999). Related to this, it was reported that inactivation of Erk1/2 in EGF-
stimulated cells does not cease after treatment with cycloheximide, which 
inhibits protein synthesis. This was noted to be in accordance with the earlier 
reports pointing towards a constitutively expressed phosphatase in the Erk1/2 
pathway. According to them, downregulation of Erk1/2 occurred already 15 min 
after stimulation and independently of the de novo protein synthesis, whilst 
transcript for the inducible MKPs was present no sooner than 30 min after the 
stimulation. The aforementioned work of Todd et al. proposed a model 
according to which VHR could be kept inactive via transiently oxidised 
nucleophilic Cys124, due to the production of H2O2 as a part of “normal” 
receptor-mediated signaling events. 
Reports on the regulatory principles of VHR are scarce. Two studies indicated 
that phosphorylation of Tyr138 is important for dephosphorylation of STAT5 in 
vivo, and for downregulation of Erk2 and JNK in T-cells (Alonso et al., 2003; 
Hoyt, Zhu, Cerignoli et al., 2007).  
Phosphorylation of Tyr138, by ZAP-70 and tyrosine kinase (Tyk)-2 did not 
affect the catalytic activity of VHR in vitro, suggesting its likely regulatory role 
as a docking site for the SH2 domain of STAT5 (Hoyt, Zhu, Cerignoli et al., 
2007), as already mentioned. Interestingly, Tyr138 phosphorylation was 
detected only in the catalytically inactive form of VHR, most likely indicating 
trans- and not auto-dephosphorylation of wtVHR, due to the localisation of 
Tyr138 being opposite to the active site pocket. 
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In T-cells, VHR was found to relocalize from diffused cytoplasmic distribution to 
the sites of the T-cell and antigen-presenting cell (APC) contact, after 
stimulation (Alonso et al., 2003). The time course of relocalisation coincided 
with the time after which downregulation of Erk1/2 and JNK was observed. For 
comparison, the effects of VH1 and VHR on T-cell activation was different; VH1 
was a strong inhibitor (Koksal and Cingolani, 2011), converted to promote viral 
replication in the host cell by bypassing cellular antiviral response, and VHR 
acted like a negative regulator by decreasing the course of the MAPKs 
activation. 
It was demonstrated that the activity of VHR against Erk1/2 can be enhanced 
by Vaccinia-related kinase (VRK) 3 (Kang and Kim, 2006). VRK3 imposed a 
negative effect on the activation of Erk1/2 by interacting with VHR, but 
independently of its kinase activity. The catalytic activity of VHR against pNPP 
and purified recombinant pErk2 was increased when it was overexpressed with 
VRK3. VRK3 was shown to be negative regulator of Erk1/2 signaling, while 
JNK and p38 MAPKs were not affected.  
1.4.5 VHR in cancer 
VHR has been linked to breast cancer (Hao and ElShamy, 2007). It was shown 
that expression of VHR was decreased upon overexpression of breast cancer 1 
(BRCA1)-IRIS. BRCA1-IRIS is found overexpressed in different breast and 
ovarian cancer cell lines. It positively correlates with the expression of cyclin D1 
which is implicated in cell growth regulation. Cyclin D1 expression is induced by 
binding of a transcription factor called activating protein (AP) 1, composed of c-
Jun and Fos proteins, to the promoter region of cyclin D1. C-Jun is activated by 
JNK, which is reportedly downregulated by VHR (Todd et al., 2002). 
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Overexpression of VHR in human mammary epithelial (HME) cells reduced 
expression of cyclin D1, thus opening up possibilities for VHR inhibitors in the 
development of therapeutics targeting BRCA1-IRIS-mediated effects on cell 
proliferation (Hao and ElShamy, 2007). Next, it was demonstrated that mRNA 
levels of VHR were reduced in cancer tissues derived from NSCLC patients, 
and that nude mice injected with H1299 cells overexpressing VHR developed 
smaller tumours, thus linking VHR expression to suppression of cancer cell 
proliferation in NSCLC cells (Wang, Yeh et al., 2011).    
In contrast to the above findings, VHR was shown to be overexpressed in 
prostate cancer as opposed to the normal prostate (Arnoldussen et al., 2008). 
This effect was linked to its ability to downregulate JNK thus preventing JNK-
mediated apoptosis. 
VHR was found overexpressed in several cervix cancer cell lines (Henkens et 
al., 2008). In those cell lines VHR was found in nucleus and in cytoplasm, 
whereas in normal cervix cells, it was localised in the cytoplasm. Increased 
levels of VHR were the result of increased protein stability because mRNA 
levels of VHR in normal and cancer cervix cells were comparable. In the light of 
the previously reported demonstration that VHR loss by siRNA caused cell 
senescence (Rahmouni et al., 2006), it was postulated that increased protein 
level of VHR in cervix cancer cells would enable the cells to proliferate 
(Henkens et al., 2008).  
Development of small-molecule inhibitors of VHR is not just appealing from the 
stand of the therapeutic development, but also as a potential tool to manipulate 
physiological roles of VHR. The collaborative work of Osada and Sodeoka 
(Usui et al., 2001) resulted in the development of a potent competitive inhibitor 
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(RK-682) of VHR. The most promising aspect in VHR selective inhibitor 
development is by exploring its unique structural features. The aforementioned 
study showed that the inhibitor was binding to VHR as a dimer, potentiating 
association through extensive hydrophobic interactions. Arg158 was shown to 
be an important residue for inhibition. Although this residue is conserved in 
many PTPs (Yuvaniyama et al., 1996), its surrounding is markedly different. 
Moreover, Shi et al. docked over 80,000 compounds into the active site of VHR 
to isolate the most promising candidates (Shi et al., 2007). (Glucosamine-
aminoethoxy) triphenyltin (GATPT) was identified as a competitive inhibitor, 
which caused accumulation of the phosphorylated Erk1/2 and JNK in HeLa 
cells due to inhibiting VHR’s catalytic activity. The screening approach was 
marked as promising to increase the structural space of potential VHR 
inhibitors, and could be especially beneficial in the early phases of therapeutic 
development. The collaborative work of Mustelin and Tautz (Wu, Vossius, 
Rahmouni et al., 2009) was an extrapolation of the previous findings linking 
VHR to progression of cervical cancer (Henkens et al., 2008). The lead 
compounds were identified by chemical library screening. Docking of the most 
potent compound suggested that three hydrophobic patches proximal to the 
VHR’s active site could be used for structural optimisation of the inhibitors, also 
demonstrated by the crystal structure of VHR in complex with the inhibitor SA3. 
Importantly, these hydrophobic areas are unique for VHR and comprised in part 
of the residues of the “recognition region” and “variable insert” segments in 
VHR (Yuvaniyama et al., 1996). SA3 compound was most efficient in 
decreasing proliferation rates of cervix cell lines HeLa and CaSki, thus proving 
that VHR could be exploited as a pharmaceutical target in treating cervix 
cancer. 
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1.5 The PRLs 
The PRLs belong to a unique family of the VH1-like group of the Class I Cys-
based PTPs (Alonso et al., 2004; Tonks, 2013). The PRL family of 
phosphatases consists of only three members, namely PRL-1, PRL-2 and PRL-
3. The PRLs contain the CAAX motif (where C is cysteine, A is an aliphatic 
amino acid and X is any amino acid) at the C-terminal end, which is a unique 
feature amongst PTPs. They contain a consensus sequence for the PTPs, but 
apart from the PTP-signature motif, they lack recognisable domains which may 
partake in substrate recruitment (Bessette et al., 2007; Kozlov et al., 2004). In 
addition, as opposed to many PTPs, the PRLs carry an alanine in the position 
of the conserved serine in the signature motif. The PRLs are small 
phosphatases of about 20 kilodaltons (kDa) in size. PRL-1 and PRL-3 contain 
173 amino acids, whereas PRL-2 contains 167 amino acids (Kozlov et al., 
2004). 
Rat PRL-1 was the first member of the PRL group of phosphatases to be 
identified as an immediate-early gene induced in regenerating liver after partial 
hepatectomy, and in insulin-treated H35 rat hepatoma cell line, where it was 
found to be consistently expressed (Diamond et al., 1994). Mouse PRL-2 and 
PRL-3 were discovered by searching the Expressed Sequence Tags (ESTs) 
database for homologues of PRL-1 (Zeng et al., 1998). Human PRL-1 and 
PRL-2 were also identified in an in vitro prenylation screen (Cates et al., 1996). 
The same study pinpointed PRL-1 and PRL-2 as oncogenic PTPs, because 
injecting nude mice with PRL-1 and PRL-2 stably expressed in D27 hamster 
pancreatic ductal epithelial cells caused tumour development. 
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1.5.1 Prenylation of the PRLs 
As already mentioned, the PRLs are the only members of the PTPs to be 
modified by prenylation (Tonks, 2013). Protein prenylation is a type of PTM in 
which either farnesyl (15 carbon atoms) or geranylgeranyl (20 carbon atoms) 
isoprenoid units are covalently attached to a cysteine residue at the C-terminal 
end of proteins, aiding their localisation to the intracellular membrane 
compartments and also affecting protein-protein interactions (Gao et al., 2009; 
Si et al., 2001; Zhang and Casey, 1996). Protein prenylation proceeds via three 
distinct steps. In the first step, a lipid moiety is attached to a cysteine residue of 
the CAAX motif by prenyl-transferases (PTs). While PTs reside in the cytosol, 
the enzymes required for the following steps are membrane-associated (Choy 
et al., 1999). In the second step, prenylated CAAX motif is recognised by a 
prenyl-CAAX protease, which is localised on the endoplasmic reticulum (ER), 
releasing the -AAX residues (Gao et al., 2009). The final step involves 
methylation of the α-carboxyl group of the prenylated cysteine by a 
prenylcysteine carboxymethyltransferase. 
In general, prenylated proteins are characterised either by the presence of the 
CAAX motif (also referred to as the CAAX-box) at their C-terminal end, or by 
the CCXX, XXCC or XCXC motifs (Gao et al., 2009; Si et al., 2001). The latter 
is mainly a feature of the Rab family of small guanosine triphosphate 
hydrolases (GTPases) (Zhang and Casey, 1996). Geranylgeranyl-transferase 
(GGT) II prenylates a substrate when it is bound to a carrier protein called Rab 
escort protein (REP) (Zeng et al., 2000). The former compiles proteins 
modifiable by farnesyl-transferases (FTs) and GGTs I and II (Gao et al., 2009). 
The type of lipid modification is determined by the identity of the amino acid in 
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the “X” position of the CAAX motif (Zeng et al., 2000). FTs prefer methionine, 
serine or glutamine, while GGT I prefers leucine. 
In vitro prenylation of the purified recombinant PRLs showed that PRL-1 and 
PRL-2 could be modified by both farnesylation and geranylgeranylation, 
whereas PRL-3 was only farnesylated (Zeng et al., 2000). Interestingly, an 
earlier in vitro study of prenylated proteins showed that both PRL-1 and PRL-2 
could be modified by farnesylation, whereas the signal for geranylgeranylation 
was much weaker (Cates et al., 1996). The study also identified FTs as the 
enzymes responsible for both lipid modifications. Recently, it was reported that 
PRL-3 transiently overexpressed in human embryonic kidney (HEK) 293 cells 
could also be modified by palmitoylation, whereas the same modification was 
not detected in PRL-1 and PRL-2 (Nishimura and Linder, 2013). Interestingly, 
the same study identified that brain specific splice variant of Cdc42 (bCdc42) 
with dual lipid modification exhibits distinct subcellular localisation pattern and 
functionalities compared to the variant that was shown to be only prenylated. In 
addition, bCdc42 which contained both prenyl and palmitoyl moieties was more 
prone to localisation to the plasma membrane. Given that PRL-1 and PRL-2 
were shown to be only classically modified by prenylation, it would be 
interesting to see how this distinction with respect to PRL-3 reflects on 
functionalities. 
1.5.2 Expression of the PRLs 
Rat PRL-1 mRNA was found at high levels in muscle and brain (Diamond et al., 
1994). Expression pattern of murine PRLs is different in various tissues (Zeng 
et al., 1998; Bessette et al., 2007). Mouse PRL-1 mRNA shows ubiquitous 
distribution, but is excluded from skeletal muscle and heart, where PRL-3 is 
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abundantly expressed (Lin et al., 2013). PRL-2 mRNA in mouse and rat is more 
widely expressed compared to the other PRL-counterparts. Human PRL-1 and 
PRL-2 mRNAs are ubiquitously expressed, and PRL-3 is highly expressed in 
skeletal muscle (Dumaual et al., 2006). In addition, PRL-3 was found 
expressed in developing blood vessels and erythrocytes at the mRNA and 
protein levels, but not in the corresponding adult counterparts (Guo et al., 
2006). Furthermore, Zimmerman et al., found detectable levels of PRL-3 also in 
fetal intestine, adult heart, pancreas and a number of other organs, but not in 
the liver or kidney (Zimmerman et al., 2013). This data indicate that, in spite of 
high degree of amino acid sequence homology, PRLs could exhibit tissue-
specific expression patterns, with interspecies variability. 
Furthermore, both PRL-1 and PRL-3 were found expressed in the intestinal 
epithelial cells (Diamond et al., 1996; Zeng et al., 2000). They were found 
associated with the differentiated cells of the villus and not with the proliferating 
cells of the crypt. However, the work of Dumaual et al., that focused on the 
investigation of the expression pattern of PRL-1 and PRL-2 in normal human 
adult tissues, also detected PRL-1 mRNA in the cell of the crypt, thus 
suggesting that there might exist posttranscriptional regulatory mechanisms for 
the expression of PRL-1 mRNA (Dumaual et al., 2006). The early studies 
conducted on PRL-1 suggested that its role in the intestine might be linked to 
differentiation, and in liver to proliferation (Diamond et al., 1994). In addition, 
PRL-1 was also found expressed at the protein level in developing digestive 
tissues, where it was associated with differentiation (Kong et al., 2000). 
However, it cannot be excluded that the differential roles PRL-1 might have in 
regenerating liver and intestine were not the result either of diverse set of 
potential substrates present in different tissues, or of differences in the 
 58 
amplitude and/or duration of the stimulus leading to distinct outcomes, like 
observed for MAPKs (Diamond et al., 1996). 
1.5.3 Subcellular localisation of the PRLs 
The data on the subcellular localiztion of the PRLs is not consistent (Fiordalisi 
et al., 2006; Song et al., 2009; Wang et al., 2002; Zeng et al., 2003).  
Zeng et al. demonstrated that ectopically expressed PRL-3 localizes to the 
cytoplasmic site of the plasma membrane and to the punctate cytoplasmic 
structures resembling endosomes (Zeng et al., 2000). The protein could not be 
detected in the proliferating epithelial cells of the crypt in the small intestine but 
only in the villi, indicating possible role of PRL-3 in differentiation-linked 
processes. In addition, after the treatment with the FTase inhibitor, or by 
employing PRL-2 mutant lacking the consensus prenylation motif, the protein 
was relocalised to the nucleus thus demonstrating the importance of 
prenylation for subcellular localisation.  
PRL-1 was identified as a phosphatase with predominantly nuclear localisation 
(Diamond et al., 1994). A later study (Wang et al., 2002) reported that 
localisation of PRL-1 was cell-cycle-dependent, by investigating endogenous 
phosphatase in HeLa cells. Generating green-fluorescent protein (GFP)-fused 
variants carrying different mutations in the CAAX motif demonstrated 
prenylation-dependent localisation to the ER in non-mitotic cells. In the mitotic 
phase, PRL-1 relocated to the centrosomes and it was also found to associate 
with the microtubules of the mitotic spindle. Moreover, it was demonstrated that 
cell cycle-dependent shuttling of PRL-1 between nucleus and cytoplasm had 
role in normal progression of the cell cycle. The catalytically deficient mutant 
D72A exhibited slower progression through the cell cycle compared to the 
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native protein or to the non-farnesylation mutant C170S. The C170S mutant 
demonstrated that farnesylation was important for regulating dynamics of the 
mitotic spindle as its expression caused defects in form of lagging 
chromosomes between two daughter nuclei. Therefore, several lines of 
evidence indicated that PRL-1 is important for normal progression of the cell 
cycle, and that this function depends on its phosphatase activity. 
By using Chinese hamster ovary (CHO) cells stably transfected with enhanced 
GFP (EGFP)-fused PRL-3 variants, Zeng et al. demonstrated enrichment of the 
protein in the dynamic membrane structures, such as ruffles or protrusions 
(Zeng et al., 2003). Furthermore, the role of the constituting residues of the 
prenylation motif, which in PRL-3 has CCVM sequence, on the subcellular 
localisation, was also investigated (Song et al., 2009). The Cys170 of the 
CAAX-box proved essential for determining the localisation of PRL-3 in B16F1 
murine myeloma cells. The ectopically expressed myc-tagged wtPRL-3 was 
diffused throughout the cytoplasm and at the plasma membrane.  
The work of Fiordalisi et al. showed that in SW480 colon cancer cells 
transfected with GFP-fused PRL-1 and PRL-3 these phosphatases reside 
predominantly in the endomembranes, and that this localisation depends on the 
prenylation (Fiordalisi et al., 2006). The localisation of PRL-3 in human 
myeloma OH-2 cells was shown to be cell-cycle dependent, with the 
predominant nuclear localisation in G0/G1 phase of the cell cycle (Fagerli et al., 
2008). Although this indicated its plausible participation in cell cycle 
progression, PRL-3 knockdown failed to induce cell cycle arrest.  
 60 
Overall, the reported differences in the localisation of PRL-3 may be explained 
through the use of differentially-tagged constructs or to the cell-type or cell-
cycle-dependent variations. 
1.5.4 Structural characteristics of the PRLs 
The three members of the PRL-family in humans share 76-87% of amino acid 
sequence identity (Fagerli et al., 2007; Zeng et al., 2003 and Figure 7).  
Figure 7: Structure-based multiple sequence alignment of all three PRLs and 
the structurally most closely-related PTPs. Ci-VSP  and PTPMT1 show activity 
toward PI(4,5)P2 and PI(5)P, respectively. The PRLs are shown in full length; 
and the other PTPs in truncated versions according to relevance to THE 
sequence alignment with the PRLs. The amino acids are coloured by polarity: 
A, P, V, I, W, F, L, G, M (black); S, T, Y, N, C, Q (green); D, E (red); H, K, R 
(blue). The consensus residue and conservation rate at each position are 
shown below the sequences. An ambiguous residue is indicated as ‘X’. The 
conserved ‘CXnE’ motif, the WPD-loop and the active site P-loop are indicated 
in red squares. With permission from Rios, P., Li, X. & Köhn, M. Molecular 
mechanisms of the PRL phosphatases. FEBS J. 280, 505-524 (2013).  
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In addition, PRLs exhibit significant level of amino acid sequence homology 
between species: human and murine PRL-1 and PRL-2 are completely 
identical, while the PRL-3 phosphatases of the two species bear 96% 
sequence identity (Stephens et al., 2005). However, outside of its own family, 
the PRLs demonstrate quite low amino acid sequence homology in the regions 
excluding the residues of the PTP signature motif (Kozlov et al., 2004; Zeng et 
al., 1998). They display the highest homology to Cdc14p, a DUSP of 
Saccharomyces cerevisiae (S. cerevisiae) implicated in the regulation of cell 
cycle progression (Tonks, 2013; Zeng et al., 2000), and to PTEN, a DUSP with 
phosphoinositide phosphatase activity (Stephens et al., 2005). With Cdc14p 
and PTEN, the PRLs share around 20% and 17% sequence identity, 
respectively. The closest structural homologues of both PRL-1 and PRL-3 are 
VHR, PTEN and kinase-associated phosphatase (KAP) (Kozlov et al., 2004; 
Sun, Wang et al., 2005 and see Figure 7). A new study also recognised the 
structure-sequence-based similarity to the myotubularins, which are also 
phosphoinositide phosphatases (Li et al., 2013). 
The solution structure of PRL-3 was solved by two independent studies (Kim et 
al., 2004; Kozlov et al., 2004). Kim et al. reported solution structure of PRL-3 
solved by nuclear magnetic resonance (NMR) study (Kim et al., 2004). The 
structure was of the apo-form of the protein, comprising residues 1-162. The 
structural report showed that the loops forming the active site were significantly 
diverted from the catalytically most optimal conformation. In addition, the 
solution structure of PRL-3 solved by Kozlov et al., coupled to kinetic profiling 
of the site-specific mutants (C49A, D71A, D72A, A111S), shed light on their 
functional significance and helped to explain some structural distinctions of 
PRL-3 comparing to other DUSPs (Kozlov et al., 2004). The residues of the 
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PTP-signature motif are more hydrophobic in PRL-3 then in VHR or PTEN 
(Kozlov et al., 2004; Stephens et al., 2005). The active site pocket is broad and 
shallow due to the differences in the surrounding loops. The architecture of the 
active site pocket would suffice for binding of substrates with pSer/pThr or pTyr 
residues, or phosphoinositol headgroups (Al-Aidaroos and Zeng, 2010; 
McParland, Varsano et al., 2011). Cys104 serves as a nucleophile in the 
phospho-substrate hydrolysis (Kozlov et al., 2004). Asp72 acts as a general 
acid/base, and it is localised in the WPFDD loop. This loop is highly flexible. 
Upon binding of a substrate, it can undergo a large conformational change 
flipping over the active site entrance and optimising the relative positions of the 
key catalytic residues. Fine-tuning the arrangement of the catalytically 
important residues upon substrate binding has been acknowledged also for 
other representatives of the DUSPs, such as PTP1B, or a number of MKPs 
(Caunt and Keyse, 2013; Kozlov et al., 2004).  
Cys49 was identified as a regulatory cysteine residue (Kozlov et al., 2004). 
Under less reducing conditions, it formed a disulfide bond with the catalytic 
Cys104. Intramolecular disulfide bond formation represents a feature PRLs 
share with PTEN. It is postulated that reversible disulfide bond formation 
observed between Cys49 and Cys104 in both PRL-1 and PRL-3 under 
oxidising conditions might provide a mechanism to protect the active site 
cysteine from the excessive oxidation (Sun, Wang et al., 2005).   
Most of the conserved residues amongst PRLs are either important for 
catalysis or structural integrity. The highest conservation is around the active 
site pocket and the lowest one on the side opposite to it. For example, position 
141 contains isoleucine in PRL-3 and phenylalanine in PRL-1 and PRL-2. This 
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difference could have a role in fine-tuning substrate specificity (Kozlov et al., 
2004). 
The PTP signature motif of PRL-3 has an untypical amino acid profile because 
the conserved arginine is followed by alanine, whereas in PRL-1 this position is 
occupied by valine (Kozlov et al., 2004). As it can be seen from the sequence 
profile of the consensus signature motif, most PTPs have serine or threonine 
residing in this position. Serine or threonine in this position is important in 
catalytic reaction by facilitating the breakdown of the phosphoenzyme 
intermediate (Sun, Luo et al., 2007; Zhang, 1998). Generating the A111S 
mutant of PRL-3 and examining its activity against 3-O-methylfluorescein 
phosphate (OMFP) showed an increase in the catalytic activity (Kozlov et al., 
2004). Thus, the extremely low activity of PRL-3 observed against artificial 
phosphatase substrates or synthetic peptides could be attributed to the lack of 
residue with the hydroxyl group (Kozlov et al., 2004; McParland, Varsano et al., 
2011). It is interesting to note that the A111S mutant was not active against 
phosphoinositides, unlike the wt protein, although it could not be determined if 
this was due to the observed structural perturbation of this variant or 
differences in the catalytic mechanism (McParland, Varsano et al., 2011).    
For PRL-1, it was demonstrated that it forms trimers in two independently 
solved crystal structures, as well as in solution at higher concentrations, with 
the active site facing on the outside of the trimer (Jeong et al., 2005; Sun, 
Wang et al., 2005). The trimeric association was stabilised due to extensive 
hydrophobic and polar interactions, and almost 30% of each monomer was 
burried at the interface. Moreover, cross-linking with glutaraldehyde of the 
membrane fraction of human embryonic kidney (HEK) 293 cells transiently 
expressing wtPRL-1 confirmed the intrinsic ability of PRL-1 for trimers. 
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Prenylation of PRL-1 is important for localising the protein to the plasma 
membrane, and increase in the local concentration of PRL-1 could contribute to 
the trimer formation. Interestingly, farnesylation alone was not sufficient to keep 
the protein at the plasma membrane, because the mutant in which six positively 
charged residues were exchanged for alanine shifted to the cytoplasm (Sun, 
Wang et al., 2005). When only the first three residues of the polybasic stretch in 
PRL-1 were exchanged for alanine, only a fraction of the protein was found in 
the soluble fraction and the majority still demonstrated localisation pattern 
comparable to the wt protein, unlike to the case where all six basic residues 
were exchanged to alanine, as already mentioned (Sun, Luo et al., 2007). The 
synergism of both electrostatic and hydrophobic interactions for maintaining 
PRL-1 at the plasma membrane is not without precedence, and analogous 
requirement has already been noted for K-Ras or myristoylated alanine-rich C 
kinase substrate (MARCKS) (Murray et al., 1997; Sun, Wang et al., 2005). 
Furthermore, for PRL-1 it was demonstrated that trimerisation was necessary 
for PRL-1-mediated increase in cell proliferation and migration, alongside its 
phosphatase activity and prenylation (Sun, Luo et al., 2007). When mutations 
were introduced at the dimer interface in PRL-1 (T13F and G97R), trimerisation 
was reduced and the ability of PRL-1 to promote cell proliferation and migration 
was diminished. In addition, trimeric association of PRL-1 did not affect its 
catalytic performance against pNPP, and no cooperativity between the catalytic 
centers was observed. However, the effect might exist at the level of real 
physiological substrates. Furthermore, for PRL-3 it was also demonstrated that 
it had the ability to form trimers in vitro and in cells (Sun, Luo et al., 2007).  
The region in the PRLs adjacent to the modification site for prenylation 
(residues 136-161) could serve as a bipartite NLS (Pascaru, Tanase et al., 
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2009; Zeng et al., 2000). This polybasic region could therefore aid in the 
membrane tethering of the PRLs by interacting electrostatically with the 
negatively charged phospholipids and/or particular plasma membrane proteins 
(Sun, Wang et al., 2005; Zeng et al., 2000). Pascaru, Tanase et al. tried to 
elucidate the role of the residues in the polybasic stretch in PRL-3, with 
emphasis on their possible function as NLS (Pascaru, Tanase et al., 2009). 
They reported that removal of the first three residues, Lys-Arg-Arg, of the 
potential NLS, did not render the localisation pattern different than the one of 
the wt protein, and that only additional removal of the CAAX-box residues 
shifted the protein into the nucleus, thus doubting that polybasic region 
functions as an NLS. PRL-2 lacks three amino acid residues directly adjacent 
to the prenylation motif (Si et al., 2001; Sun, Wang et al., 2005). Drawing a 
parallel to the Rab GTPases, where divergent region at the C-terminal end 
dictates the interaction with the β-subunit of the GGT II, one could envision 
similar pattern in PRL-2. Moreover, only PRL-2 was shown to interact with the 
β-subunit of the GGT II (Si et al., 2001). Because PRL-1 and PRL-3 bear an 
insertion of three amino acids directly in front of the CAAX-box, this patch could 
play a role in determining specificity for a particular subcellular localisation. This 
case would not be without precedence, as it was already demonstrated that the 
Ras GTPases require a stretch of basic residues in addition to farnesylation in 
order to trigger localisation to the plasma membrane (Murray et al., 1997). 
Moreover, heterotrimeric guanine nucleotide-binding proteins (G-proteins) 
provide another example where multiple lipid modifications are needed for 
proper localisation to the plasma membrane in order to enable signal 
propagation to the downstream components (Takida and Wedegaertner, 2003). 
Modifications of these proteins include the attachment of a myristate (14 carbon 
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atoms) and/or a palmitate to an N-terminal glycine or cysteine residue, 
respectively, of the α-subunit, and by prenylation of the γ-subunit.  
For PRL-1 it was demonstrated that the residues of the CAAX-box and 
polybasic region have an important role not only in shaping subcellular 
localisation but also in binding affinity to different PIPs of the plasma membrane 
(Bessette et al., 2008; Sun, Luo et al., 2007). However, no catalytic activity of 
PRL-1 against phospholipids was observed (Sun, Luo et al., 2007; Yu et al., 
2007). 
The residues at the C-terminal end of the PRLs could be important not only for 
subcellular localisation of the proteins, but also as a sophisticated regulatory 
mechanism of their catalytic activity. Pascaru, Tanase et al. investigated the 
catalytic activity of various forms of PRL-3 mutated in the residues of the 
CAAX-box or the polybasic stretch (Pascaru, Tanase et al., 2009). They 
determined that deletion of the CAAX-box residues increased the catalytic 
efficiency, hypothesizing that the hydrophobic interactions between the -VM 
residues of the CAAX-box could facilitate oligomeric association between PRL-
3 monomers, with a derogative effect on the catalytic activity. This observation 
is opposite to the observation that trimerisation induced no effect on the 
catalytic efficiency of PRL-1 in vitro (Sun, Luo et al., 2007). 
In general, the investigations of the structural determinants of the PRLs could 
be grouped into two categories. One encompasses the residues of the P-loop 
and of the WPD-loop directly involved in the dephosphorylation reaction, and 
the residue Cys49 implicated in the redox-mediated regulation of the catalytic 
activity of PRL-1 and PRL-3 through transient formation of a disulfide bond with 
the catalytic cysteine (Fiordalisi et al., 2006; Ishii et al., 2013; Jeong et al., 
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2005; Kozlov et al., 2004; McParland, Varsano et al., 2011; Sun, Wang et al., 
2005; Zeng et al., 2003). The second group of research interest spans across 
the residues of the C-terminal polybasic region, which were suggested to 
potentially function as a bipartite NLS (Pascaru, Tanase et al., 2009; Sun, Luo 
et al., 2007; Zeng et al., 2000) and the CAAX-box at the C-terminal end of the 
protein, which are important for localizing the protein to the plasma membrane 
and punctuate structures resembling endosomes (Fiordalisi et al., 2006; 
Pascaru, Tanase et al., 2009; Rios et al., 2013; Skinner et al., 2009; Song et 
al., 2009). The more intense research focus on the detailed analysis of the 
various mutants for PRL-2 is still pending. 
Apart from the residues of these two categories, no other in-depth profiling of 
the other non-homologous residues amongst the PRLs has been reported. On 
exception is the recent discovery of Src-mediated phosphorylation of PRL-3 
(Fiordalisi et al., 2013). PRL-3 was shown to be phosphorylated on Tyr53 by 
Src. This modification is required for the PRL-3-mediated promotion of cell 
invasion and activation of RhoC GTPase. Figure 8 provides a summary of key 
structural features of PRL-3, with pointed out the residues important for 
catalytic mechanism, redox regulation and sub-celullar localisation. 
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Figure 8: Solution structure of PRL-3 (PDB: 1R6H). (a) Structural 
representation of PRL-3 generated in Pymol with the most important structural 
features pointed out (see panel (c) for labeling). (b) Secondary structure 
elements of PRL-3. Reproduced from Kozlov, G. et al. Structural insights into 
molecular function of the metastasis-associated phosphatase PRL-3. J. Biol. 
Chem. 279, 11882-11889 (2004) (no permission needed). (c) Sequence of 
PRL-3 with the elements of the secondary structure pointed out in the 
sequence. Highlighted are the following residues: Cys49 (yellow), general 
acid/base Asp72 (red), P-loop (blue, with catalytic Cys104 underlined), bi-
partite polybasic region (grey) and CCVM of the CAAX-box (green).  
 
 
 69 
1.5.5 The PRLs in cancer 
Saha et al. applied the serial analysis of gene expression (SAGE) technology to 
identify consistent genetic alterations contributing to liver metastasis, as the 
primal cause of mortality of colorectal cancer patients (Saha et al., 2001). The 
PRL-3 gene was identified as the only one being highly expressed in all 18 
colorectal cancer metastases. The same study demonstrated that the 
expression level of PRL-3 was not detectable in the normal epithelium, whilst 
reaching intermediate level in patients with an advanced disease state. In a 
later study, Saha et al. set another milestone by (i) demonstrating elevated 
expression levels of PRL-3 in metastases of colorectal cancer, regardless of 
the site of the metastatic lesions and by (ii) showing that levels of PRL-3 in liver 
metastases of different origins were low (Bardelli, Saha et al., 2003). Since 
then, the PRL family of phosphatases, and PRL-3 in particular, has received 
much research interest (Al-Aidaroos and Zeng, 2010; Rios et al., 2013). PRL-3 
is regarded as a promising biomarker for monitoring tumour aggressiveness 
and as a predictive marker of colorectal cancer metastases to liver or lung, 
following surgical removal of the primary tumours (Al-Aidaroos and Zeng, 2010; 
Kato et al., 2004; Molleví et al., 2008). In addition, PRL-3 was found 
overexpressed in different types of tumours, including hepatocellular, 
nasopharyngeal, breast, gastric, lung or brain (Bardelli, Saha et al., 2003; 
Matsukwa et al., 2010; Parker et al., 2004; Zhao et al., 2008; Zhou, Wang et 
al., 2008). In addition, low levels of PRL-3 were detected in lung and liver 
metastases of primary cancers of non-colorectal origin (Bardelli, Saha et al., 
2003; Stephens et al., 2005). Moreover, mRNA and protein levels of PRL-3 
were increased in multiple myeloma cells, where depletion of PRL-3 reduced 
cell migration (Fagerli et al., 2008). The differences observed in the malignant 
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effect of PRL-3 in various systems studied could be an indication of a cell-type 
dependent effect of this phosphatase. PRL-3 mRNA was not detected in any of 
the 28 samples obtained from the pancreas cancer patients, whereas PRL-1 
and PRL-2 were found upregulated in contrast to normal pancreas (Stephens 
et al., 2008). In addition, PRL-3 was shown to be upregulated in ovarian cancer 
as opposed to normal ovarian tissue, and to promote tumour development in 
mouse model, thus supporting a role of PRL-3 as an early prognostic marker in 
human ovarian cancer (Bessette et al., 2008; Liu, Al-Aidaroos et al., 2013). 
Downregulation of PRL-3 in ovarian cancer cells A2780 elevated protein and 
mRNA levels of integrin α2 via upregulation of transcription factors c-jun and c-
fos and also reduced levels of adhesion protein paxillin. No effect on integrin 
β1, which was demonstrated to interact with PRL-3 (Tian et al., 2012), was 
observed thus suggesting that in ovarian cancer PRL-3 might downregulate 
integrin α2 thus contributing to cancer progression (Varner and Cheresh, 1996).  
Furthermore, PRL-3 has been shown to have role in angiogenesis in several 
independent studies (Al-Aidaroos and Zeng, 2010; Bessette et al., 2007; 
Bessette et al., 2008; Guo et al., 2004; Guo et al., 2006). Guo et al. discovered 
that injection of CHO cells stably expressing wtPRL-3 into the tail vein of nude 
mice led to formation of vascularized tumours in the lung, whereas no 
metastases were detected for injection of C104S mutant (Guo et al., 2004). 
Moreover, sometimes the tumours were formed within the existing blood 
vessels. The authors suggested that PRL-3 expressing cancer cells might 
secrete proteases which would digest basal lamina of the surrounding blood 
vessels thus enabling invasion of the cancer cells into the circulatory system 
(Chambers et al., 2002; Folkman and Klagsbrun, 1987; Hanahan and 
Weinberg, 2000). Furthermore, additional study demonstrated that CHO cells 
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and human colon cancer DLD-1 cells expressing wtPRL-3 had the ability to 
recruit endothelial cells in an angiogenesis co-culturing assay in vitro (Guo et 
al., 2006). Moreover, when murine lung cancer cells were introduced 
subcutaneously into nude mice, only wtPRL-3 expressing cells demonstrated 
the ability to develop tumours with significant degree of vascularization. The 
mechanism that led to endothelial cells being recruited by PRL-3 expressing 
cells could involve either endothelial cells responding to specific surface factors 
on PRL-3 expressing cells, or the latter ones releasing diffusible angiogenesis-
stimulating factors. Thus, these findings suggested that phosphatase activity of 
PRL-3 is an important factor in PRL-3-mediated role in angiogenesis, and that 
therapeutics which would inhibit it might find application in antiangiogenic 
therapy. 
The role of the PRLs in promoting cell proliferation and metastases 
development was early recognised (Cates et al., 1996; Diamond et al., 1994; 
Zeng et al., 2003). Wang et al. investigated expression of PRL-1 mRNA in a 
broad panel of normal and cancer cell lines and demonstrated that PRL-1 
mRNA was increased in a subset of cancer cells (Stephens et al., 2005; Wang 
et al., 2002). Furthermore, D27 hamster pancreatic epithelial cells 
overexpressing PRL-1 and PRL-2 demonstrated altered growth rates, 
characterised by shorter doubling time comparing to the vector control, and  
were able to induce tumour formation in nude mice (Cates et al., 1996).  
In addition, nonmetastatic CHO cells stably overexpressing PRL-1 and PRL-3 
exhibited enhanced cell motility and invasiveness compared to the control cells, 
and were also able to induce liver and lung metastases when injected in nude 
mice (Zeng et al., 2003). The transforming phenotype was dependent on the 
phosphatase activity, because the inactive C104S mutant of PRL-3 showed a 
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reduction in cell motility, albeit not at the level of the control cells. This result 
indicated that overexpression of the catalytically deficient mutant C104S could 
facilitate increase in cell motility in a manner independent of the catalytic 
activity (Bessette et al., 2007; Zeng et al., 2003). Furthermore, injection of 
B16F1 murine melanoma cells, with low metastatic potential, overexpressing 
wtPRL-3 and different mutants in the CAAX-box sequence, induced severe 
lung metastases in nude mice in a farnesylation-dependent manner (Song et 
al., 2009; Stephens et al., 2005). These results clearly indicated a causative 
role of the PRLs in promoting tumourigenesis. Recently, PRL-3 knockout 
mouse model was reported (Zimmerman et al., 2013). Mice lacking PRL-3 
developed normally, although it was noticed that a number of male mice was 
little declined. Nevertheless, this was in contrast to the effect reported for PRL-
2 knockout (Dong et al., 2012). It was demonstrated that treatment with a 
procarcinogen called azoxymethane (AOM) resulted in the immediately 
increased expression of PRL-3, whereas PRL-3 knockout mice exhibited over 
50% reduction in tumour formation (Zimmerman et al., 2013). These findings 
indicated that PRL-3 could also be actively involved in the early stages of 
cancer. AOM acts as a DNA damaging agent, which induces expression of p53 
and, subsequently, PRL-3, thus accounting for the observed early increase in 
PRL-3 expression following genotoxic stress. For comparison, PRL-2 knockout 
mice suffered growth retardation in embryos, due to impaired development of 
placenta, and also in adult mice (Dong et al., 2012; Dumaual et al., 2006). In 
PRL-2 knockout mice, the effect of PRL-2 deficiency was the result of reduced 
synthesis of glycogen (Dong et al., 2012). The level of active glycogen 
synthase kinase (GSK) 3β was lower due to decreased phosphorylation level of 
the enzyme responsible for its activation, Akt kinase, and increased level of 
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PTEN, which negatively regulates phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway (Dong et al., 2012; Lee, Yang et al., 1999). 
Although the causal role of PRL-3 in promoting metastasis and its potential to 
serve as a prognostic indicator of aggressiveness and clinical outcome for 
various types of tumours has been well documented, the data for PRL-1 and 
PRL-2 was limited (Al-Aidaroos and Zeng, 2010; Bessette et al., 2008). 
Recently, an extensive investigation of PRL-1 and PRL-2 distribution in normal 
and cancer human tissues of diverse origin, by in situ hybridization, was 
reported (Dumaual et al., 2012). It was shown that PRL-1 and PRL-2 mRNAs 
were expressed in both normal and cancer tissues examined. PRL-1 transcript 
was elevated in majority of breast, ovarian and renal cancer sample, and in all 
cancer samples derived from the bladder, colon, cervix, liver, lung, pancreas, 
prostate, skin, testis and stomach. Moreover, PRL-1 mRNA was also 
associated with all examined samples of the metastatic lesions to the liver and 
uterus. While the samples for PRL-1 showed variability between tissues and 
also within a particular tissue type, the levels of PRL-2 transcript were high in 
vast majority of the samples of normal or cancer origin. When correlating the 
transcript levels of the PRLs to the protein levels, it was shown that PRL-1 
mRNA and protein levels exhibited similar relative expression level, whereas 
for PRL-2 this correlation was observed for only about half of the cases 
examined. Interestingly, Dumaual et al. showed that some cancer tissue 
samples examined had lower levels of PRL-1 and PRL-2 mRNAs comparing to 
their normal counterparts. PRL-1 was lower in all or majority of the cancer 
samples derived from the ovary, breast or lung, and PRL-2 in about half of the 
samples from kidney cancer, suggesting that in some tissues PRL-1 and PRL-2 
may not have metastasis stimulatory role. Both PRL-1 and PRL-2 exhibited 
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mostly nuclear localisation, with occasional staining in the cytoplasm, in normal 
and cancer samples examined. In addition, PRL-2 was suggested as a marker 
for predicting breast cancer metastasis (Hardy et al., 2010). Its levels were 
found increased in various mammalian mammary cell lines. Moreover, primary 
breast tumours and lymph node metastases exhibited increased levels of PRL-
2 transcript, and it was also shown that PRL-2 correlated with the course of 
breast cancer development. Furthermore, increased levels of PRL-2 were 
observed in cell lines derived from pancreatic and prostate cancers, and also in 
acute myeloid leukemia (AML) (Wang and Lazo, 2012).  
1.5.6 Regulation of the PRLs by oxidation 
Like already mentioned, the PRLs contain a regulatory cysteine residue at 
position 49 (Jeong et al., 2005; Kozlov et al., 1994). In general, the architecture 
of the active site of the PTPs renders them sensitive to inhibition due to 
susceptibility of the catalytic cysteine to oxidation (den Hertog et al., 2008; 
Funato and Miki, 2013; Tonks, 2006). Oxidation as a general regulatory 
principle of the PTPs has been addressed previously. It was demonstrated 
recently that all three PRLs can be oxidised in cells after H2O2 treatment (Ishii 
et al., 2013). Based on the crystal structure of PRL-1, generation of a disulfide 
bond between Cys49 and Cys104 would not cause significant structural 
perturbations of the protein, as the two cysteines are close in space and 
without obstructing structural elements between them (Jeong et al., 2005). 
Functional implications of the intramolecular disulfide bond formation in PRL-1 
in cells were also investigated. Skinner et al. reported that PRL-1 in cells would 
be predominantly in the oxidised and, therefore, inactive form (Skinner et al., 
2009). They determined that the reduction potential of the disulfide bond 
formed between Cys49 and the active site Cys104 was lower than the 
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reduction potential range in the normal cellular environments. In addition, the 
same study showed that the residues of the CAAX-box (which in PRL-1 has 
sequence CCIQ) influence the catalytic activity of the protein, possibly by 
causing conformational changes which would eventually affect the reduction 
potential of the disulfide bridge between the regulatory and the catalytic 
cysteines. The findings by Skinner et al. also helped to interpret earlier 
observations where cells expressing PRL-1 C170S mutant showed various 
mitotic defects (Wang et al., 2002). 
Furthermore, it was shown that PRL-1 mRNA and protein expression increased 
in retinal cells following light-induced oxidative stress (Al-Aidaroos and Zeng, 
2010; Yu et al., 2007). The activity of PRL-1 was modulated under oxidative 
conditions by disulfide bond formation between the conserved cysteines at 
positions 49 and 104. This phenomenon was observed in vitro, in cultured cells 
subjected to H2O2 and in rat retina after constant light exposure. The 
conversion into the reduced form of PRL-1 was found to be mediated 
specifically by the glutathione (GSH) system, because in the presence of the 
GSH-specific inhibitor, the extent of the oxidised PRL-1 in H2O2 treated cells 
increased. This study opened up the area of the possible involvement of PRL-1 
in oxidative stress-mediated cellular responses. 
Susceptibility of PRL-3 to oxidation was also demonstrated in an MS study 
(Orsatti et al., 2009a). Orsatti et al. showed that PRL-3 has two possible 
mechanisms of inactivation by oxidation. One included the already mentioned 
disulfide bridge formed between Cys104 and Cys 49, whereas the other one 
involved conversion of the catalytic cysteine to glycine. The latter inhibitory 
principle was not known amongst the PTPs.   
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Recently, thioredoxin-related protein (TRP) 32 was demonstrated to regulate 
reduction of PRL-3 after H2O2-induced oxidation in cultured cells (Ishii et al., 
2013). TRP32 may be the key component in the regulation of the redox status 
of PRL-3 because knockdown of the endogenous TRP32 caused prolonged 
oxidation of the endogenous PRL-3. This study implicated that TRP32 could 
promote the causative role of PRL-3 in metastasis by regulating its catalytic 
ability.  
1.5.7 Other regulatory mechanisms of the PRLs: PRL-1 and PRL-2 
It was determined that the 5’- non-coding regions of the murine PRLs mRNAs 
share no more than 30% sequence identity, indicating possible differences at 
the gene level for regulation of the individual PRLs (Zeng et al., 1998). This 
observation is supported by varieties in tissue distributions of the individual 
PRLs, like already discussed. Furthermore, Zeng et al. applied the ScanProsie 
programme which identified potential phosphorylation sites in murine PRLs. 
Interestingly, PRLs exhibited differences in the number of motifs which could be 
phosphorylated by protein kinase C (PKC), casein kinase II or PTK (Stephens 
et al., 2005; Zeng et al., 1998). PRL-2 only contains two potential sites for 
phosphorylation by PTK. For PRL-1, one site for PKC and Casein kinase II 
were identified, whereas PRL-3 contained two and four sites, respectively, for 
these kinases. Further studies investigating more deeply whether 
phosphorylation could serve as a regulatory principle of PRLs and/or if 
differences in the possible phosphorylation sites by PKs would reflect in various 
regulatory principles of the PRLs have remained fairly scarce. Recently, 
Fiordalisi et al. reported significance of Src-mediated phosphorylation of Tyr53 
for PRL-3 mediated effect in promoting enhanced invasiveness and motility in 
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SW40 colon adenocarcinoma cells, which is discussed in more detail in a later 
chapter (Fiordalisi et al., 2013). 
PRL-1 was demonstrated to be regulated at the transcriptional level by the 
PRL-1 intron enhancer complex (PIEC), a developmentally regulated factor 
which binds to the first intron in the PRL-1 gene, and by an immediate-early 
gene encoded transcription factor called early growth response (Egr) factor 1, 
which was shown to bind to the P1 promoter of the PRL-1 gene (Al-Aidaroos 
and Zeng, 2010; Bessette et al., 2008; Peng et al., 1999). The expression level 
of Egr-1 and its binding to the P1 site of PRL-1 promoter were followed by an 
increase in the level of the PRL-1 transcript immediately after partial liver 
hepatectomy or following mitogen stimulation of NIH 3T3 mouse fibroblast 
cells. As the level of PRL-1 mRNA was found increased for up to 24 hours after 
hepatectomy, it was suggested that additional regulatory mechanisms exist, 
which were likely acting on the post-transcriptional level (Bessette et al., 2008; 
Peng et al., 1999). Moreover, Egr-1 did not resolve regulation of PRL-1 
expression in tissues with normally high levels of the phosphatase nor in 
cancer cells implying the existence of tissue-specific regulatory principles 
(Peng et al., 1999). 
Furthermore, both PRL-1 and PRL-3 were identified as p53 transcriptional 
targets (Al-Aidaroos and Zeng, 2010; Min, Kim et al., 2009; Stephens et al., 
2005). p53 functions as a transcriptional regulator of many genes involved in 
various cellular functions, such as cell cycle progression, DNA repair or 
apoptosis, but it also regulates expression of ubiquitin ligases implicated in its 
own downregulation, which are encoded by RCHY1 ring finger and CHY zinc 
finger domain containing 1 (PIRH2), mouse double minute 2 homolog (MDM2) 
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and caspase recruitment domain-containing protein 16 (COP1) genes (Al-
Aidaroos and Zeng, 2010; Min, Kim et al., 2009). One of the p53 targets is 
cyclin-dependent kinase (CDK) inhibitor (CKI) p21Cip1/Waf1. Werner et al. 
identified that PRL-1 overexpressing cells had higher activity of CDK 2, higher 
level of cyclin A and reduced level of CKI p21Cip1/Waf1, resulting in higher rate of 
cell proliferation (Werner et al., 2003). CDKs contain catalytic kinase and 
regulatory cyclin subunits (Song et al., 2001). Progress through the cell cycle is 
accompanied by periodic changes in the activity of CDK governed by the 
changes in the phosphorylation status of the complex and regulated 
synthesis/degradation of the constituting subunits. The work of Min, Kim et al. 
elucidated the mechanism governing PRL-1 mediated reduction in levels of 
p21Cip1/Waf1 (Min, Kim et al., 2009). Overexpression of PRL-1 was shown to 
reduce the levels of p53 through two distinct pathways, both of which facilitated 
proteosomal degradation of p53 via ubiquitination associated with induction of 
PIRH2 and MDM2. In HeLa cells expressing PRL-1, the transcript levels of 
PIRH2 and Egr-1 transcription factor were elevated. In relation, Fiordalisi et al. 
already demonstrated that PRL-1 regulates expression of serum response 
element (SRE) transcription factor (Fiordalisi et al., 2006). Interestingly, Egr-1 
was also known to positively regulate transcription of p53. The second pathway 
implicated in the downregulation of p53 involved Akt-mediated phosphorylation 
of MDM2 (Min, Kim et al., 2009). In conclusion, PRL-1 was added to the list of 
oncogenic transcriptional targets of p53. 
1.5.8 Interacting proteins and substrates of PRL-1 and PRL-2 
Only few substrates and interacting proteins for PRL-3 have been suggested 
(Al-Aidaroos and Zeng, 2010; Rios et al., 2013), thus making the investigation 
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of PRL-3-mediated effects on signaling pathways a notoriously difficult task. 
The data is even more obscure on PRL-1 and PRL-2. 
Diamond et al. recognised that PRL-1 contains the consensus sequence motif 
for the PTPs (Diamond et al., 1994). They showed that PRL-1 can be 
phosphorylated by cellular (c)-Src in vitro and that phosphorylated PRL-1 could 
dephosphorylate itself and none of the control proteins. The link between trimer 
formation of PRL-1 and its autophosphatase activity has not been investigated 
(Jeong et al., 2005; Sun, Luo et al., 2007). 
The only reported substrate of PRL-1 is activating transcription factor (ATF)-7, 
which is also known as ATF-5 or ATF-X (Al-Aidaroos and Zeng, 2010; Peters et 
al., 2001; Stephens et al., 2005). ATF-7 belongs to the family of transcription 
factors known as basic leucine zipper (bZIP) proteins. Its homodimer binds to 
cyclic AMP (cAMP) response elements (CRE). ATF-7 was identified as a PRL-
1-interacting protein in a yeast-two hybrid (Y2H) screen (Peters et al., 2001).  
Subsequently it was demonstrated that it can be dephosphorylated by PRL-1 in 
vitro, albeit only partially. The work of Peters et al. suggested that PRL-1 and 
ATF-7 pair could represent phosphorylation-mediated activity regulation of a 
transcription factor, but also that ATF-7 could act as a scaffold for PRL-1. The 
functional significance of the ATF-7 dephosphorylation by PRL-1 has remained 
uninvestigated (Al-Aidaroos and Zeng, 2010). 
Recently, p115 Rho GTPase-activating protein (GAP) was identified as a novel 
PRL-1 binding protein (Bai, Luo et al., 2011). p115 RhoGAP was identified by 
probing a phage display peptide library with recombinant PRL-1. A peptide 
which demonstrated binding to PRL-1 corresponded to the motif in the SH3 
domain of p115 RhoGAP, and this domain was demonstrated to be 
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indispensable for its interaction with PRL-1. Furthermore, it was established 
that overexpression of p115 RhoGAP negatively correlated with PRL-1-
mediated upregulation of the activation of Erk1/2 and RhoA, and cell migration 
(Bai, Luo et al., 2011; Fiordalisi et al., 2006; Luo et al., 2009). Binding of PRL-1 
to the SH3 domain of p115 RhoGAP led to an increase in the level of active, 
GTP-bound, form of RhoA, whereas the activation of Erk1/2 was achieved by 
displacing p115 RhoGAP from association with the upstream kinase implicated 
in the activation of Erk1/2, MEKK1. These findings further corroborated the role 
of PRL-1 in promoting the acquisition of metastatic properties, such as 
enhanced cell motility and invasion. 
GGT II was identified as a PRL-2 interacting protein in a Y2H screen (Al-
Aidaroos and Zeng, 2010; Si et al., 2001; Stephens et al., 2005). Intriguingly, 
PRL-1 and PRL-3 were not found to interact with GGT II. The interaction 
between PRL-2 and GGT II was dependent on the prenylation status of PRL-2. 
In the presence of FT inhibitor or by using PRL-2 variant with deleted residues 
of the CAAX-box, the interaction was not detectable. PRL-2 did not act as a 
substrate for GGT II as no modification of PRL-2 by geranylgeranylation was 
detectable in vivo. In addition, PRL-2 was found to interact with the β-subunit of 
GGT II, which contains most of the catalytically important residues, but it 
displays activity only when in complex with the α-subunit (Si et al., 2001). Thus, 
an attractive hypothesis is that, by competing with the α-subunit for binding to 
the β-subunit of GGT II, PRL-2 could participate in the regulation of the activity 
of the GGT II. In addition, the constituting subunits of the GGT II heterodimer 
are not expressed equally in all the tissues, and the levels of PRL-2 and of the 
β-subunit of the GGT II were found to be high in muscle.  
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1.5.9 The PRLs in signaling: PRL-1 and PRL-2 
Several signaling pathways in which PRL-1 and PRL-3 are engaged have been 
described, whereas investigation of PRL-2 is somewhat lagging behind (Al-
Aidaroos and Zeng, 2010; Rios et al., 2013).  
As mentioned previously, already the early studies of the PRLs implicated the 
involvement of this family of phosphatases in promoting cell proliferation 
(Diamond et al., 1994; Cates et al., 1996). Cells stably overexpressing PRL-1 
and PRL-2 showed higher growth rates and in some cases elevated levels of 
PRL-1 resulted in multinuclear cell morphology. Diamond et al. showed that 
PRL-1 can be phosphorylated by Src in vitro. Src family kinases (SFKs) are 
involved in cell proliferation, migration or apoptosis (Achiwa and Lazo, 2007; 
Luo et al., 2009). In a recent study, Src and EGFR kinases were identified as 
the key upstream targets of H2O2-mediated increase in protein tyrosine 
phosphorylation (Chan et al., 2010). Interestingly, many of the proteins whose 
tyrosine phosphorylation level was elevated after treatment with H2O2 were 
found to be important for cell adhesion and regulation of cytoskeleton, whereas 
some were also known substrates of Src. The aforementioned study by Achiwa 
and Lazo investigated the effect of depletion of the expression of the 
endogenous PRL-1 in A549 lung cancer cell line by short hairpin RNA 
(shRNA). It demonstrated reduction in cell proliferation and increase in cell 
adhesion following reduction in the expression levels of PRL-1. The protein 
level of Src was decreased, but its phosphorylation status was not affected, 
and neither was the protein level of C-terminal Src kinase (Csk). Csk acts as a 
negative regulator of the SFKs, while the former determines if the protein is 
going to be in the active form. In relation, autophosphorylation of Tyr418 by 
SFKs leads to the activation, and phosphorylation of Tyr529 by Csk to the 
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inhibition of the Src’s enzymatic activity (Luo et al., 2009). Also, the levels of 
p130 Crk-associated substrate (p130Cas) and of the active GTP-bound forms 
of Rac1 and Cdc42 GTPases were reduced concomitant with the reduction of 
the protein level of PRL-1 (Achiwa and Lazo, 2007). The members of the Rho 
family of GTPases are known key regulators of the actin cytoskeleton dynamics 
(Fiordalisi et al., 2006). In cells with reduced levels of both PRL-1 and Src, the 
focal adhesion turnover was slowed down (Achiwa and Lazo, 2007). 
Nakashima and Lazo investigated further the molecular mechanisms of the 
PRL-1-mediated effect on promoting cell proliferation, motility and invasion in 
A549 lung cancer cells (Nakashima and Lazo, 2010). Intriguingly, they 
observed that both the wtPRL-1 and its D72A mutant decreased the levels of 
the activated forms of Rac1 and Cdc42. Thus, it is possible that PRL-1 could 
exert its effect on modulating actin cytoskeleton dynamics in part independently 
of its catalytic activity, for example by protein-interaction-dependent mode of 
action. These observations were in slight discordance with the results reported 
by Fiordalisi et al., where colon cancer SW480 cells transiently expressing 
wtPRL-1 had elevated level of GTP-bound RhoA and RhoC and decreased 
level of Rac1, whereas the level of Cdc42 was not changed with respect to the 
control (Fiordalisi et al., 2006). This discrepancy could result from 
spatiotemporal oscillations in the activities of GTPases (Al-Aidaroos and Zeng, 
2010). 
It was also demonstrated that PRL-1 could promote cell motility and 
invasiveness by increasing expression of the matrix metalloproteinases 
(MMPs) (Luo et al., 2009). MMPs are hydrolytic enzymes which have an 
important role in facilitating an escape of cancer cells from the primary sites 
and promoting cell invasion through digestion of the extracellular matrix (ECM) 
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(Andl, 2010; Chambers et al., 2002). HEK293 cells stable overexpressing PRL-
1 had elevated levels of activated Src, judged by the level of phosphorylated 
Tyr416 comparing to the control cells (Luo et al., 2009). Moreover, the levels of 
activated signaling components downstream of Src (p130Cas, focal adhesion 
kinase (FAK) and phosphorylated Erk1/2 (pErk1/2)) were found to be elevated 
upon PRL-1 expression. The increase in the active levels of the MMP2/9 was 
found to be dependent on the expression of PRL-1. Moreover, the stimulatory 
effect of PRL-1 on cell migration was diminished when activity or total protein 
levels of the MMP2/9 were reduced. In addition, the levels of the MMPs were 
increased as a result of the Src/Erk1/2 mediated upregulation of the key 
regulatory transcription factors AP1 and Sp1. Moreover, Luo et al. 
demonstrated that high levels of PRL-1 in invasive lung cancer cell lines A549 
and H1299 promote cell invasiveness by operating through the aforementioned 
mechanisms. 
Wang and Lazo profiled the role of PRL-2 in migration and invasion in lung 
cancer cells A549 and observed that knockdown of PRL-2 by shRNA 
decreased cell migration and invasion (Wang and Lazo, 2012). Analysis of the 
potential mechanism showed that there were no changes in, total or 
phosphorylated, levels of p53, Src, Csk and Akt. In addition, reduction of PRL-2 
protein level resulted in decreased levels of scaffold protein p130Cas and 
vinculin, whereas levels of pErk1/2 and ezrin phosphorylated on Tyr146 were 
upregulated, which was comparable to the effect observed after reduction of 
PRL-1 in the same cell line (Achiwa and Lazo, 2007). Intriguingly, suppression 
of PRL-2 did not affect the level of ezrin phosphorylation on Thr567 and 
knockdown of PRL-1 did not impose any changes on the phosphorylation 
status of ezrin (Wang and Lazo, 2012).  
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1.5.10 Regulation of PRL-3 
Overexpression of PRL-3 in colorectal cancer metastases to liver can in part be 
attributed to an increase in the PRL-3 gene copy number (Stephens et al., 
2005). It was noted that the PRL-3 gene copy number was elevated in liver 
metastasis compared to the primary cancer sites, and in primary colorectal 
cancer with metastatic lesions to liver as opposed to metastasis-free states, 
and also in some myeloma cells (Al-Adaroos and Zeng, 2010). However, 
increase in gene copy number does not account for the observed 
overexpression of PRL-3 in other types of cancer (Bessette et al., 2008). 
Moreover, it was observed that increase in gene copy number does not always 
correlate with the elevated levels of PRL-3 mRNA and that in myeloma cells no 
connection between gene copy number and PRL-3 mRNA expression could be 
established (Al-Aidaroos and Zeng, 2010; Fagerli et al., 2008; Saha et al., 
2001). Moreover, additional mechanisms of PRL-3 regulation have been 
discovered and involve regulation at the transcriptional and translational levels, 
as well as regulation via proteosomal degradation (Al-Aidaroos and Zeng, 
2010; Rios et al., 2013). PRL-3 was found to be a transcriptional target of p53 
in mouse and human cells, and a putative p53 binding site was identified in the 
PRL-3 gene (Basak et al., 2008; Rios et al., 2013). Interestingly, expression of 
exogenous PRL-3 in mouse embryonic fibroblasts (MEFs) caused cell cycle 
arrest in G1 phase in a manner similar to p53-induced arrest. Knockdown of 
PRL-3 by shRNA approach produced the same effect, which was additionally 
shown to depend on the intact p53 pathway. These observations were in 
contrast to the observed effect of PRL-3 overexpression on enhancing cell 
proliferation in various cancer cells and also in contrast to the observed normal 
development of the PRL-3 knockout mice (Zimmerman et al., 2013). 
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Concomitantly, Basak et al. demonstrated that PRL-3 was not able to induce 
cell cycle arrest in some human cancer cell lines, thus suggesting that the 
effect on cell cycle progression may be cell type specific (Basak et al., 2008). 
Overall, in intact MEFs, basal levels of PRL-3 could regulate progression 
through cell cycle. Increased levels of PRL-3 during cell cycle arrest, as a direct 
transcriptional target of p53, were accompanied by inactivation of PI3K/Akt 
pathway. In addition, in intact MEFs, knockdown of PRL-3 led to increase in the 
protein levels of p53. This effect was mediated by increased levels of a positive 
p53 regulator called p19Arf, which was induced by the activation of p38 MAPK. 
Additionally, PRL-3 was shown to be involved in the negative regulation of 
protein levels of p53 by ubiquitin-mediated degradation, suggesting that in 
metastatic cells with elevated levels of PRL-3 these feedback loops are 
disrupted and/or different regulatory mechanism might apply (Al-Aidaroos and 
Zeng, 2010).  
Furthermore, transcription of PRL-3 was shown to be activated by vascular 
endothelial growth factor (VEGF), involving the transcription factor called 
myocyte enhancer factor (MEF) 2C, in human umbilical vein endothelial cells 
(HUVEC), although the increase in the PRL-3 transcript was not reflected at the 
protein level (Rios et al., 2013; Xu, Cao et al., 2011). Both, VEGF and MEF2C 
have been described as important factors in angiogenesis, suggesting that the 
existence of a VEGF/MEF2C/PRL-3 pathway could exert similar angiogenesis-
stimulatory effects. 
Transforming growth factor (TGF) β suppressed expression of PRL-3 in a 
mothers against decapentaplegic homologue (Smad) 3-dependent way (Jiang, 
Liu, Rajput et al., 2011). For TGFβ, both metastasis inhibitory and stimulatory 
modes of action were reported (Wakefield and Roberts, 2002). Moreover, it 
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was demonstrated that expression of wtPRL-3 promoted survival of colon 
cancer cells by activating PI3K/Akt pathway, and either in the presence of the 
PI3K inhibitor, by using negative mutant of Akt or by knocking down expression 
of PRL-3, the PRL-3-mediated suppressive effect on apoptosis was reversed 
(Jiang, Liu, Rajput et al., 2011). This study did not disclose the mechanism 
behind the PRL-3-mediated increase in the level of activated Akt, but it 
suggested that the effect could involve stimulation of Akt-activating kinases. 
Considering that TGFβ mutations occur in up to 50% of colon cancer patients, 
this is likely to account for the increased expression of PRL-3 in colon cancer 
(Rios et al., 2013). 
Transcription factor Snail was demonstrated to be a key factor in PRL-3-
mediated progression of colorectal cancer to metastasis, albeit it is not known if 
there is a direct interaction between these two proteins (Rios et al., 2013; 
Zheng, Meng, Gao et al., 2011). Snail is a well recognised EMT-driving 
transcription factor, repressing expression of epithelial markers and promoting 
cell motility and invasiveness (Andl, 2010; Thiery and Sleeman, 2006). 
Moreover, colon cancer cells overexpressing PRL-3 showed upregulated levels 
of Snail in contrast to the controls where PRL-3 expression was knocked down 
(Liu, Zhou et al., 2009). Three potential Snail binding sites were identified in the 
promoter region of the PRL-3 gene, and after introducing mutations in these 
sites or when expression of Snail was knocked down, the transcriptional activity 
of the PRL-3 promoter and the protein levels of PRL-3 were reduced, 
respectively (Zheng, Meng, Gao et al., 2011). In addition, overexpression of 
Snail promoted cell proliferation, migration and colony formation of human 
colon cancer cells, whereas Snail knockdown had the reversed effect. In the 
context of PRL-3 knockdown, proliferation of colon cancer cells increased when 
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protein levels of Snail were upregulated. The link between PRL-3 and Snail, in 
the light of the demonstrated stimulatory effect both of them have on 
proliferation of human colon cancer cells, requires further analysis. 
Expression of PRL-3 at the protein level can be negatively regulated by polyC-
RNA-binding protein (PCBP) 1, which abrogates incorporation of PRL-3 mRNA 
into polyribosomes (Al-Aidaroos and Zeng, 2010; Wang et al., 2010a). PCBP1 
was found to inhibit expression of PRL-3 by binding to the GC-rich region at the 
5’-untranslated (UTR) of PRL-3 mRNA and it also suppressed the activity of 
Akt, without affecting PRL-3 mRNA levels. Moreover, it was shown that in 
human cancer samples of various origins the protein levels of PRL-3 and 
PCBP1 were inversely correlated. Clinical significance of the findings of Wang 
et al. was additionally validated by demonstrating that injection of human colon 
cancer cells with knockdown PCBP1 enhanced tumour development in mouse 
model (Wang et al., 2010a).   
Furthermore, FKBP38 was identified as a PRL-3 interacting protein in a Y2H 
screen, and was established as a negative regulator of PRL-3 at the protein 
level (Choi, Min et al., 2011). It was demonstrated that FKBP38 promoted 
proteosomal degradation of PRL-3 and also inhibited PRL-3-mediated 
suppression of p53 activity and led to reduction in cell proliferation. 
Regulation of PRL-3 by Src-mediated phosphorylation was reported recently 
(Fiordalisi et al., 2013). PRL-3 was found to be phosphorylated on Tyr53 in 
vitro. Moreover, phosphorylation of endogenous PRL-3 in colon cancer SW480 
cells was also shown. In addition, modification of Tyr53 by phosphorylation 
proved required for PRL-3-mediated cell motility, invasion and activation of 
RhoC. Although no difference in the subcellular localisation was observed, the 
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authors speculated that phosphorylation could induce delicate changes in 
targeting PRL-3 to distinct membrane regions, albeit implications of the 
established PRL-3-Src link warrant further investigation.  
1.5.11 Interacting proteins and substrates of PRL-3 
There are several suggested protein and non-protein interacting partners of 
PRL-3 (integrin α1, keratin 8 (KRT8), elongation factor (EF) 2, cadherin 22 
(CDH22), nucleolin, stathmin, peptidyl prolyl cis/trans isomerase FK506 binding 
protein (BP) 38 (FKBP38), phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2), 
histone deacetylase (HDAC) 4, ADP-ribosylation factor (Arf) 1, and Src), 
whereas to date only few substrates are suggested (integrin β1 and ezrin) (Al-
Aidaroos and Zeng, 2010; Choi, Min et al., 2011, Fiordalisi et al., 2013, Forte et 
al., 2008, Krndija et al., 2012, Liu, Zhou et al., 2009, McParland, Varsano et al., 
2011, Mizuuchi et al., 2009, Orsatti et al., 2009b, Peng, Jin et al., 2006, Semba, 
Mizuuchi et al., 2010, Tian et al., 2012, Zheng et al., 2010; Zhou et al., 2011). 
Most of the PRL-3 interacting partners can be linked to the PRL-3-mediated 
role in cell migration and invasion. 
Integrin α1 was identified as PRL-3 interacting protein by using Y2H approach 
and the interaction was also confirmed in vivo by co-immunoprecipitation from 
African green monkey kidney COS-7 cells transiently co-expressing both 
proteins (Al-Aidaroos and Zeng, 2010; Peng, Jin et al., 2006; Rios et al., 2013). 
Integrins are heterodimeric transmembrane receptors composed of α and β 
subunits, and containing extracellular domain, which binds to the ECM, 
transmembrane and cytoplasmic domains (Peng, Jin et al., 2006; Srichai and 
Zent, 2010). They are implicated in signaling originated by binding of the ECM 
components to the integrin receptors, which triggers recruitment of diverse 
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signaling molecules to the sites of FACs at the sites of cell-ECM contacts 
(Bessette et al., 2008). Integrins are important in regulating cell-cell and cell-
ECM contacts, thus facilitating regulation of cell adhesion or motility 
(Plantefaber and Hynes, 1989). Unsurprisingly, aberrations in integrin-mediated 
signaling are a common feature of cancer cells (Al-Adaroos and Zeng, 2010; 
Bessette et al., 2008; Tian et al., 2012; Varner and Cheresh, 1996). Integrin α1, 
unlike integrin β1, does not contain any residues in its cytoplasmic domain that 
could be dephosphorylated by PRL-3. It was demonstrated that HEK293 cells 
stably overexpressing PRL-3 had reduced level of tyrosine-phosphorylated 
integrin β1, although, at the time, no direct interaction between PRL-3 and 
integrin β1 could be detected (Peng, Jin et al., 2006). Nevertheless, Tian et al. 
demonstrated that Tyr783 of integrin β1 was dephosphorylated by PRL-3 in 
vitro and also in cells after ectopic expression of PRL-3 (Tian et al., 2012). In 
the presence of inhibitors of PRL-3, the phosphorylation of this residue was 
enhanced. In addition, integrin α1 was shown to act as a negative regulator of 
the PRL-3-integrin β1 interaction because knockdown of integrin α1 by siRNA 
resulted in a decreased amount of pTyr783 of integrin β1 detected.  
CDH22, a member of the cadherin family, was also identified in a Y2H screen 
and the interaction was further confirmed in colorectal cancer cells by co-
immunoprecipitation (Liu, Zhou et al., 2009). Liu et al. noted that stable 
overexpression of PRL-3 in human colon cancer cells SW480 caused decrease 
in the levels of CDH22, epithelial (E) cadherin, which is a key component of the 
adherens junction complexes, and cytokeratin, thus illustrating the EMT-
promoting role of PRL-3 (Bessette et al., 2008; Liu, Zhou et al., 2009). 
Moreover, PRL-3 overexpressing cells demonstrated elevated levels of Snail, a 
transcription factor already linked to downregulation of E-cadherin expression 
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(Liu et al., 2005). The PRL-3-CDH22 association was suggested to affect 
phosphorylation-dependent degradation of CDH22, and further contributed to 
strengthening the contribution of PRL-3 to EMT linked events (Liu, Zhou et al., 
2009).  
KRT8 was found to interact with PRL-3 by using proteomics approach in which 
human colon cancer SW480 cells transfected with wtPRL-3 and its C104S 
mutant were assessed for difference in the phosphorylation pattern by two-
dimensional (2D) SDS-PAGE (Mizuuchi et al., 2009). KRT8 is a member of the 
intermediate filaments network (Khapare, Kundu, Sehgal et al., 2012) which is 
important for maintaining cell shape (Garrord and Chidgey, 2007). Furthermore, 
endogenous KRT8 was also shown to interact with ectopic C104S mutant of 
PRL-3 (Mizuuchi et al., 2009). KRT8 with decreased phosphorylation level at 
residues S73 and S431 was detected in human tissue samples from primary 
colon cancer and liver metastases. It was suggested that PRL-3 could be 
involved in the regulation of phosphorylation-dependent shuttling of KRT8 
between soluble cytoplasmic population and polymerized filaments whose 
disintegration is stimulated by phosphorylation. PRL-3 could disrupt the 
balance by dephosphorylating S73 and S431 in KRT8, thus contributing to 
promotion of cell motility as a result of irregularities in the regulation of dis-
assembly of intermediate filaments. To further support that PRL-3-mediated 
progression to metastasis could be helped by reducing phosphorylation of 
KRT8, it was also reported that decreased phosphorylation of KRT8 positively 
correlated with progression of oral squamous cell carcinoma (Alam et al., 
2011). Furthermore, a recent study showed that loss of plakophilin3 was 
accompanied by an increase in the expression of PRL-3 and to the concomitant 
reduction in phosphorylated KRT8 (Khapare, Kundu, Sehgal et al., 2012). 
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Plakophilin3 is a desmosomal protein. Desmosomes represent adhesion 
complexes linked to intermediate filaments (Andl, 2010; Bass-Zubek et al., 
2009; Garrod and Chidgey, 2007). Knockdown of plakophilin3 led to a 
decrease in cell-cell adhesion and increase in cell motility due to reduced 
desmosomes, in agreement with the earlier studies (Andl, 2010; Bass-Zubek et 
al., 2009; Kundu et al., 2008).     
Stathmin/oncoprotein 18 was identified as a novel PRL-3 target in a proteomics 
study, which also reported a list of 39 proteins associated with PRL-3 (Zheng et 
al., 2009). In addition, Western blot analysis on tissue samples derived from 
colon cancer patients with or without metastasis, showed elevated levels of 
stathmin in primary tumours compared to the normal counterparts, but also 
increased stathmin expression in cases with metastasis as opposed to the 
samples of the primary cancer without metastasis. It was demonstrated that the 
interaction of stathmin and PRL-3 in colon cancer cells led to destabilization of 
microtubules. The mechanism was not clear, but a hypothesis was offered 
according to which PRL-3 could be involved in dephosphorylation of the key 
regulatory serine residues of stathmin.  
Another proteomics-based investigation of PRL-3-mediated role in 
tumourigenesis was conducted recently (Chu et al., 2011). Applying 2D-
electrophoresis based comparison of human colon cancer LoVo cells 
expressing wtPRL-3 with the control cells, it was established that 17 proteins 
were up- and ten downregulated upon PRL-3 expression. In addition, eight of 
these up- or downregulated proteins were shown to have metastasis-promoting 
functions. Translationally controlled tumour protein (TCTP) was shown to be 
elevated at the levels of mRNA and protein. TCTP is known to be upregulated 
in a number of cancers (Ma et al., 2010). Upon siRNA-mediated knockdown of 
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TCTP, proliferative, migratory and invasive abilities of LoVo cells expressing 
PRL-3 were diminished, but the mechanism of TCTP in the background of 
PRL-3 is yet to be disclosed (Chu et al., 2011). 
Nucleolin was identified as a novel PRL-3 interacting protein by applying MS 
analysis of immunoprecipitates from colon cancer SW480 cells expressing 
wtPRL-3 and its catalytically inactive mutant C104S (Semba, Mizuuchi et al., 
2010). Nucleolin is a known nucleolar protein (Mongelard and Bouvet, 2007). 
The discrepancy between the previously reported subcellular distribution of 
PRL-3 and nucleolar protein being identified as a putative interacting partner of 
PRL-3 was explained by assessing the distribution pattern of nucleolin after 
ectopic expression of PRL-3 (Semba, Mizuuchi et al., 2010). Interestingly, only 
overexpression of wtPRL-3 was able to show an increase in the nucleolar 
accumulation of nucleolin, suggesting that PRL-3 could have role in regulating 
phosphorylation status and dis-assembly of nucleolin, whereas the inactive 
C104S mutant just trapped nucleolin in the cytoplasm. Nucleolin was known to 
be phosphorylated by CK2, which promotes its degradation. The mechanism of 
the role nucleolin might have in promoting proliferation of colon cancer cells 
was hypothesized based on its previously reported functions (Erard et al., 
1988; Semba, Mizuuchi et al., 2010). Intriguingly, nucleolin was reported to 
increase stability of B-cell lymphoma (Bcl) 2 mRNA, thus promoting cancer 
development (Sengupta, Bandyopadhyay et al., 2004).   
Recently, it was demonstrated that PRL-3 could act as a phosphatidylinositol-5-
phosphatase by dephosphorylating PI(4,5)P2, and also phosphatidylinositol 
(3,4,5)-trisphosphate (PI(3,4,5)P3) to a smaller extent, in vitro (McParland, 
Varsano et al., 2011). By using HEK293 stably transfected with wtPRL-3 and its 
different variants (D72A, C104S and A111S) in a cell migration and wound 
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healing assay, it was demonstrated that not only wtPRL-3 but also its D72A 
variant exhibited migratory and invasive abilities. No in vivo activity of PRL-3 
against PI(4,5)P2, or phosphoinositides in general, has yet been demonstrated 
(Rios et al., 2013). The consequences of the PRL-3-mediated downregulation 
in the levels of PI(4,5)P2 are only hypothesised, but there is a strong body of 
literature to support that PI(4,5)P2 levels need to be under rigorous control and 
that aberrations of the regulatory mechanisms could contribute to cancer 
development (Bunney and Katan, 2010; McParland, Varsano et al., 2011; Mitra 
et al., 2005; Raucher et al., 2000; Redfern et al., 2008). 
Ezrin was suggested as a substrate for PRL-3 after it was demonstrated that 
HCT116 colon cancer cells stably expressing only wtPRL-3 and not its 
catalytically deficient mutants sported distinct phosphorylation pattern (Forte et 
al., 2008). Ezrin was shown to be dephosphorylated on Thr567 by PRL-3. Ezrin 
belongs to the ezrin/radixin/moesin (ERM) family of proteins (Neisch and 
Fehon, 2011). The members of the ERM family act as linkers between plasma 
membrane and actin cytoskeleton (Zhu et al., 2010). They bind to filamentous 
(F) actin and plasma membrane via their C- and N-terminal associated 
domains (C-ERMAD and N-ERMAD), respectively. Ezrin is maintained in an 
inactive (“closed”) conformation through the intramolecular association of the 
C- and N-termini, which prevents its association with F-actin and reduces the 
affinity for the plasma membrane. The active form of ezrin is important for 
signaling affecting cell adhesion or motility (Barret et al., 2000; Fievet et al., 
2004; Rios et al., 2013). The switch between the closed and open conformation 
of ezrin is regulated by the phosphorylation status of Thr567, with 
phosphorylation disrupting intramolecular association (Forte et al., 2008). 
Overexpression of PRL-3 would therefore increase the content of inactive 
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dephosphorylated ezrin. This, in turn, might be reflected on the signaling 
components affected by ezrin, promoting cancer development by, for example, 
modulating the activity of Src or of the small GTPases Rho and Rac, for which 
the changes in the activities in the context of the exogenous PRL-3 expression 
had been reported (Fiordalisi et al., 2006; Forte et al., 2008; Liang et al., 2008; 
Wang et al., 2007a). In the light of the recently reported ability of PRL-3 to 
dephosphorylate PI(4,5)P2 in vitro, PRL-3 would affect ezrin-mediated signaling 
by both, depleting PI(4,5)P2 from the plasma membrane and by 
dephosphorylating ezrin on Thr567, thus affecting two requirements for ezrin to 
assume active conformation at the plasma membrane (Fievet et al., 2004; Rios 
et al., 2013).  
A later study by the same group (Orsatti et al., 2009b) demonstrated, by using 
2D SDS-PAGE, that phosphorylation levels of ezrin and EF-2 were changed in 
HCT116 colon cancer cells overexpressing PRL-3. Interestingly, EF-2 was also 
identified among 39 proteins associated with PRL-3 in a proteomics-based 
study of PRL-3 knockdown in SW480 colon cancer cells (Zheng et al., 2009). 
EF-2 is involved in mediating peptide chain elongation step during protein 
synthesis (Wang and Proud, 2002) and it is in its active form when 
dephosphorylated (Orsatti et al., 2009b; Ryazanov, 2002). Moreover, its 
phosphorylation on Thr56 acts as a general regulator of protein synthesis 
because phosphorylated form diminished it from binding to the ribosome 
(Orsatti et al., 2009b). No direct interaction between PRL-3 and EF-2 has been 
demonstrated (Rios et al., 2013). 
Recently, Arf1 was identified as a novel interacting partner of PRL-3, and it was 
shown to colocalize with PRL-3 at the Golgi and endosomes (Krndija et al., 
2012). Moreover, a motif within PRL-3 (MKYE) absolutely essential for its 
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interaction with Arf1 was identified. The Arf family of proteins belongs to the 
small GTPases implicated in membrane trafficking and their unique feature 
comparing to the other representatives of the small GTPases is an N-terminal 
helix detrimental for their binding to the plasma membrane (de Curtis and 
Meldolesi, 2012). Knockdown of Arf1 and structurally and functionally related 
Arf3 diminished PRL-3-mediated promotion of cell migration (Krndija et al., 
2012). In addition, expression of wtPRL-3, but not of its catalytically inactive 
(C104S) or prenylation deficient (ΔCAAX) mutants increased the level of the 
active GTP-bound form of Arf1. Dynamic changes at the plasma membrane are 
coordinated by the activities of small GTPases (de Curtis and Meldolesi, 2012). 
PRL-3 was demonstrated to increase turnover of integrin α5 in a manner 
dependent on the activity of Arf1, thus stimulating cell migration (Krndija et al., 
2012). 
1.5.12 PRL-3 in signaling 
Signaling pathways mediated by PRL-3 promote cancer progression and 
metastasis by enhancing cell proliferation, migration and invasion, mediating 
EMT switch, potentiating angiogenesis or inhibiting apoptosis (Al-Aidaroos and 
Zeng, 2010; Bessette et al., 2007; Bessette et al., 2008). The key signaling 
effects exerted by PRL-3 will be discussed. 
In the light of the previously acknowledged expression of the PRL-3 transcript 
in skeletal and cardiac muscle (Zeng et al., 1998), one early report addressed 
its possible physiological role and reported that it mediated Angiotensin-II 
(AngII) signaling (Bessette et al., 2007; Matter et al., 2001). AngII is involved in 
hyperthrophy of cardiomyocytes (Matter et al., 2001). It was demonstrated that 
HEK293 cells overexpressing wtPRL-3 had lower levels of phosphorylated 
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p130Cas, which is phosphorylated after AngII stimulation-mediated release of 
intracellular calcium (Ca2+). p130Cas is a scaffold protein with diverse 
functional domains, important for regulating cell proliferation, motility and 
apoptosis (Bessette et al., 2007; O’Neill et al., 2000; Wei et al., 2004). It is 
phosphorylated by FAK and Src in response to various stimuli, and increase in 
the phosphorylated level of p130Cas positively correlates with cell migration 
and invasion (Bessette et al., 2007; Cabodi et al., 2006; Defilippi et al., 2006). 
The reduction in the phosphorylated level of p130Cas could not be attributed to 
the direct action of PRL-3 on p130Cas. Decrease in the phosphorylated and 
total levels of p130Cas was also observed after depletion of PRL-3 by siRNA, 
with more striking effect when all three PRLs were knockdown (Daouti et al., 
2008). Moreover, thienopyridone, a small molecule identified by chemical 
library screening, demonstrated selective inhibition of the PRLs, compared to 
11 other phosphatases belonging to different classes tested (Al-Aidaroos and 
Zeng, 2010; Daouti et al., 2008). Treatment with thienopyridone caused 
inhibition of anchorage-independent growth of tumour cells and induced 
anoikis. Anoikis is a type of apoptosis caused by disrupted cell-ECM 
interactions and is caused by proteolytic cleavage of p130Cas (Daouti et al., 
2008; Wei et al., 2004). Interestingly, this effect of PRL-3 inhibitor involved a 
novel mechanism independent of the p53 pathway. 
PRL-3 was found to stimulate EMT (Al-Aidaroos et al., 2010; Wang et al., 
2007a). The EMT is characterised by loss of adhesion of epithelial cells through 
disruption of the assembly and stability of the adherens junction complexes, 
thus leading to an increase in motility and gain of ability to extravagate into the 
surrounding tissue (Andl, 2010; Thiery and Sleeman, 2006). CHO cells stably 
expressing wtPRL-3 exhibited decreased levels of vinculin and, total and 
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phosphorylated, paxillin. Paxillin is a scaffold protein which binds to FAK, which 
is an essential component in promoting integrin and growth factor mediated 
signaling (Andl, 2010; Yano et al., 2004). Vinculin is an adapter protein 
localised to the sites of cell-matrix and cell-cell contacts and its loss reduces 
cell adhesion and increased motility (Carisey & Ballestrem, 2011). In addition, 
in colorectal cancer DLD-1 cells stably expressing wtPRL-3, the expression 
levels of epithelial markers E-cadherin, integrin β3 and γ-catenin were reduced, 
and the levels of mesenchymal markers Snail and fibronectin were increased 
(Wang et al., 2007a). E-cadherin is known to interact with a number of growth 
factor receptors preventing their prolonged activation and to suppress 
expression of the proteolytic MMPs (Andl, 2010). Moreover, the cytoplasmic 
domain of cadherins is engaged in interactions with β-catenin, which links 
components of adherens junctions to actin cytoskeleton. PRL-3 was shown to 
promote EMT transition by upregulating the PI3K/Akt pathway (Wang et al., 
2007a), which is known to be an important factor in promoting cell proliferation 
and anti-apoptosis (Cully et al., 2006). The study of Wang et al. suggested that 
PRL-3 functions upstream of PI3K, because its effect on promoting EMT was 
not observed after treatment with the inhibitor of PI3K. In addition, PRL-3 
exerted its effect by downregulating PTEN at the post-translational level. The 
mechanism could involve β-catenin and MAGI-2 dependent localisation of 
PTEN to the plasma membrane (Subauste et al., 2005). Furthermore, in CHO 
and DLD-1 cells expressing wtPRL-3, the expression of GTPases RhoA and 
Rac1 was downregulated (Wang et al., 2007a). It was suggested that this could 
decrease the stability of adherens junctions, which would agree with the 
previously reported observation of the effect of RhoA on the increase of the 
amount of vinculin in focal adhesions in Madin-Darby canine kidney (MDCK) 
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cells (Kotani et al., 1997). However, in the other study it was demonstrated that 
human colon cancer SW480 cells expressing wtPRL-3 had elevated level of 
active forms of RhoA and RhoC, reduced level of Rac1, while Cdc42 remained 
unaffected (Fiordalisi et al., 2006). Moreover, the ability of PRL-3 to promote 
cell migration and invasion was abrogated in the presence of the upstream 
kinase activator of RhoA called Rho-coiled coil kinase (ROCK), suggesting that 
PRL-3 acts upstream of RhoA in a manner dependent on the activity of ROCK. 
The opposite effect of PRL-3 expression on the activation of Rho GTPases 
observed in these two studies could reflect the involvement of PRL-3 in focal 
adhesion turnover by promoting both their disassembly and assembly 
(Bessette et al., 2008; Fiordalisi et al., 2006; Wang et al., 2007a). Interestingly, 
Fiordalisi et al. dissected features dependent on the phosphatase activity of 
PRL-3, such as invasion, motility and regulation of GTPases, from activation of 
the transcription factor called serum response element (SRE). This was only 
partially reduced in case of the catalytically inefficient mutants of PRL-3 (D72A 
and C104A). The authors speculated that the latter could be the result of the 
substrate-trapping effect of D72A and C104A mutants, which might preserve 
certain substrate-interactions sufficiently long to elicit a particular effect. In the 
light of a complex crosstalk existing between integrins and cadherins, it was 
reported that activation of integrins led to downregulation of E-cadherin and to 
activation of RhoA and Rac1 GTPases, perturbing cadherin-based cell-cell 
contacts, which is in accordance with the results obtained in the study of 
Fiordalisi et al. (Fiordalisi et al., 2006; Thiery and Sleeman, 2006).  
Recently, it was reported that expression of PRL-3 at the level of mRNA and 
protein was high in a set of lung cancer cell lines tested (Jian et al., 2012). In 
accordance with this observation, knockdown of PRL-3 by siRNA caused 
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changes in cell morphology, yielding reduction in the extent of protrusive 
membrane structures, and reduced the activity of RhoA. In addition, knockdown 
of PRL-3 and downregulation of active RhoA led to reduction in levels of the 
protein called mammalian homologue of Drosophila melanogaster diaphanous 
(mDia1). mDia1 regulates polymerisation of actin after it was released from the 
autoinhibitory conformation by binding of the active RhoA to its RhoA binding 
domain (RBD) (Brandt et al., 2007; Jian et al., 2012). This study provided 
another demonstration that PRL-3 exerts its effect on cell motility and 
invasiveness by affecting components that are important for the maintenance 
and organization of the actin cytoskeleton.  
PRL-3 was linked to integrin/Src signaling (Peng et al., 2009; Rios et al., 2013; 
Tian et al., 2012). Important downstream effectors of integrin signaling are FAK 
and Src (Bessette et al., 2008; Thiery and Sleeman, 2006). In addition, Src was 
reported to promote EMT by internalizing E-cadherin in a manner dependent on 
the phosphorylation by FAK, whereas FAK recruits scaffold proteins p130Cas 
and paxillin in focal adhesions (Andl, 2010; Thiery and Sleeman, 2006). 
Moreover, FAK-Src association is important in regulating activities of GAPs and 
GEFs, which catalyze inactivation of GTPases by hydrolyzing GTP to GDP and 
activation of GTPases by releasing bound GDP and enabling binding of GTP, 
respectively (Al-Aidaroos et al., 2010; Fiordalisi et al., 2006). It was 
demonstrated that HEK293 cells stably expressing PRL-3 had reduced levels 
of Csk, which acts as a negative regulator of Src by phosphorylating Tyr527 
residue in the tail region of Src (Bessette et al., 2008; Liang et al., 2008; Rios et 
al., 2013). Upon expression of PRL-3, the pTyr527 levels were elevated, thus 
indicating increased activity of Src (Liang et al., 2007). However, the reduction 
in the level of pTyr527 of Src was not the result of direct dephosphorylation by 
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PRL-3 (Liang et al., 2008). Instead, PRL-3 expressing cells had reduced levels 
of Csk as a result of global reduction of protein synthesis caused by increase in 
phosphorylation of eukaryotic initiation factor (eIF) 2α. The general suppression 
of translation was confirmed in colon cancer SW480 cells naturally expressing 
PRL-3. Moreover, PRL-3 was shown to lead to activation of Erk1/2 in colon 
cancer LoVo cells through integrin β1 (Peng et al., 2009). This was in 
agreement with an earlier study, where expression of PRL-3 downregulated 
phosphorylation of integrin β1 and upregulated activation of Erk1/2 (Peng, Jin 
et al., 2006). Knockdown of integrin β1 by siRNA diminished PRL-3-mediated 
increase in the level of activated Erk1/2 and also abrogated PRL-3-triggered 
motility and invasion in cells and in mouse model (Peng et al., 2009). It was 
demonstrated that PRL-3 promotes cell invasion by contributing to aberrant 
regulation of MMP2 through decreased expression of the MMP inhibitor called 
TIMP2. This could provide another link of PRL-3-mediated EMT switch, 
because it was reported that E-cadherin suppresses expression of MMP-2, 
reducing invasive ability of the cells (Andl et al., 2010). Signaling pathways 
affected by PRL-3 are shown in Figure 9. 
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Figure 9: Summary of the signaling pathways affected by the PRLs and the 
outcome in cell migration and proliferation. Arrows indicate positive regulation; 
crossed lines indicate negative regulation and question marks indicate either 
not yet understood or not studied processes. With permission from Rios, P., Li, 
X. & Köhn, M. Molecular mechanisms of the PRL phosphatases. FEBS J. 280, 
505-524 (2013).  
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1.6 Challenges in identifying PTP substrates and interacting partners  
Considering the importance of protein phosphorylation in regulating diverse 
cellular processes, identifying interacting partners of the PPs could unarguably 
contribute to establishing a link between a particular phosphatase and its 
contribution to a signaling outcome. It has been already mentioned that 
substrate-trapping mutants of the PTPs are commonly used in studying 
interactions of the PTPs (Zhang, 2003a). The most commonly applied substrate 
trapping variants of the PTPs involve mutations of the residues which are 
essential for the efficient binding and hydrolysis of a substrate, such as the 
catalytic cysteine of the P-loop or the general acid/base aspartate residue of 
the WPD-loop (Blanchetot et al., 2005; Zhang, 2003a). Cysteine of the P-loop 
is commonly substituted for a serine and aspartate of the WPD-loop for an 
alanine. Notwithstanding, the double mutant simultaneously bearing both of 
these mutations may not have enhanced substrate-trapping ability, as 
witnessed for PTP1B. In spite of resulting in catalytically deficient enzymes 
which would be expected to stabilize even transient interactions, this approach 
has not been widely efficient in elucidating substrate portfolio of the PTPs (Flint 
et al., 1997; Zhang, 2003a). In addition to the mutations of the catalytically 
essential cysteine and aspartate residues, further mutations which would 
reduce the catalytic efficiency of the PTPs, without having negative effect on 
their substrate-recognition ability, were also tried (Blanchetot et al., 2005), for 
example mutation of the conserved glutamine residue of the signature motif to 
an alanine or mutation of the catalytic cysteine to an aspartate. Substrate-
trapping mutants of the PTPs were also combined with other approaches, for 
example yeast two-hybrid (Y2H) or MS (Tiganis & Bennett, 2007). In general, 
substrate-trapping PTP mutants still have considerable caveats, for example (i) 
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they are restricted to the catalytically important residues, (ii) validating the 
interactions within the cell or (iii) difficulties in identifying less abundant 
substrates. Screening various mutants for different phosphatases can be 
regarded as laborious, so more efficient approaches in investigating the 
interactions of the PTPs are needed. 
1.7 Expanded genetic code methodology 
Expanded genetic code methodology constitutes a mighty tool for probing even 
weak and transient protein interactions by using genetically encoded photo-
cross-linkable amino acids, thus bringing advantage over more conventional 
approaches which rely on Y2H screens or chemical cross-linking reagents (Ai, 
Shen, et al., 2011). Modification of the amino acid building blocks enable 
manipulation of protein structure, which not only provide a mean to gain insight 
into functional specificities of proteins or probe for protein interactions and 
associated biological pathways, but also create proteins with novel properties 
(Wang et al., 2009; Xie and Schultz, 2005). Development of an expanded 
genetic code provides a useful and powerful toolkit for studying proteins in 
prokaryotes and eukaryotes in vitro and in vivo (Xie and Schultz, 2006). This 
method enables an unnatural amino acid to be genetically encoded into protein 
concomitantly with the course of protein translation with high fidelity and 
efficiency. Over 80 unnatural amino acids have been incorporated into proteins 
to date in prokaryotes and eukaryotes, with diverse side-chain moieties as well 
as photo-excitable, redox-reactive and photocaged amino acids, clearly 
providing a sophisticated tool for controlled manipulation of structural and 
functional properties of proteins (Chen et al., 2007; Lemke et al., 2007; Liu and 
Schultz, 2010; Strømgaard et al., 2004; Wu et al., 2004; Zheng et al., 2013). 
These include, for example, amino acids which can facilitate investigation of the 
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PTMs or which contain chemical moieties that are modifiable in vitro or in cells, 
thus expanding the range of reactive side chain groups in amino acid. 
Moreover, these amino acids can serve as a platform for selective chemical 
modifications thus giving  rise to, for example, fluorescent, photo-cleavable, 
NMR or infrared (IR) probes or redox-sensitive reagents, or they can facilitate 
investigation of structural and conformational properties of proteins by X-ray 
(Liu and Schultz, 2010; Strømgaard et al., 2004; Xie and Schultz, 2006). 
There are several methods to introduce unnatural amino acids into proteins 
(Chin et al., 2003; Hendrickson et al., 2004; Liu and Schultz, 2010; Muir, 2003; 
Sakamoto et al., 2002; Suchanek et al., 2005; Strømgaard et al., 2004; 
Thibodeaux et al., 2010; Wang et al, 2009; Xie and Schultz, 2006), but in 
general they are not as advantageous as co-translational introduction of an 
unnatural amino acid. These additional approaches include chemical 
derivatisations of the modifiable amino acid side chains in proteins (thiol 
moieties of cysteines or ε-amino groups of lysines), solid-phase peptide 
synthesis (SPPS), ligation approaches using protein semi-synthesis, residue-
specific insertion of an unnatural amino acid by using bacterial strains 
auxotrophic for this amino acid, site-specific incorporation of an unnatural 
amino acid by chemically acylating a suppressor tRNA and then adding it either 
to the cell extracts or to the Xenopus oocytes and co-translational insertion of 
an unnatural amino acid. Since exploting those altarnative approaches was not 
the subject of this thesis, they will only be refered to briefly. Obviously, 
chemical modifications of the existing reactive amino acid side chains are 
restricted by the limited choice of the modifiable side chain groups. Next, SPPS 
is limited to peptides and small proteins with up to 100 residues in size. Size-
imposed restrictions can be circumvented by protein ligation methods where at 
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least two peptide fragments are ligated to produce full-length protein, but 
plausible limitations include, for example, restrictions on selecting the ligation 
site(s) or possible necessity to denature and refold the protein. Furthermore, 
residue-specific integration of an unnatural amino acid by employing a bacterial 
strain which is auxotrophic for the desired unnatural amino acid offers the 
advantage of being able to exploit an unmodified protein synthesis machinery, 
but is restricted to the unnatural amino acids which are structurally resembling 
to the canonical amino acids and it results in global replacement of the natural 
amino acid with its close structural analogue.  Last, chemical acylation of a 
nonsense suppressor tRNA is limited by the need to continuously deliver tRNA 
with stoichiometric acylation, which can then be used in vitro or in microinjected 
cells, providing restrains on the overall protein amount which can be generated. 
It is unarguable that the ability to introduce unnatural amino acids co-
translationally at defined sites in proteins opens up plethora of opportunities for 
controlled manipulations and investigations, in vitro and in vivo, in the field of 
protein biology.  
The unnatural amino acid must be delivered in response to a unique STOP or 
extended codon, although missing or rare codons were also exploited 
(Strømgaard et al., 2004; Wang et al., 2009). Moreover, a combination of 
STOP codon and frameshift mutation was used to introduce two different 
unnatural amino acids simultaneously in the same protein in E. coli and in 
mammalian cells and Köhrer et al. combined amber and ochre (UAA) STOP 
codons to insert two different unnatural amino acid in mammalian cells 
(Anderson et al., 2004  PNAS; Köhrer et al., 2003; Rodriguez et al., 2006; Xie 
and Schultz, 2005). 
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Incorporation of an unnatural amino acid at defined position in a protein 
requires an orthogonal pair comprised of a transfer RNA (tRNA) and the 
adjacent aminoacyl tRNA synthetase (aaRS) specific for the unnatural amino 
acid (Chin, 2011; Hino et al., 2006; Liu and Schultz, 2010; Xie and Schultz, 
2006 and Figure 10). The amber STOP codon (TAG) is the most frequently 
used as codon assigned to the unnatural amino acid because (i) it is the least 
used to terminate protein synthesis of the essential genes in E. coli and in 
yeast, (ii) it was reported that amber suppression can naturally occur in 
mammalian cells and (iii) it was demonstrated that amber suppression in E. coli 
with the canonical amino acids did not considerably hinder growth rate of the 
host organism, thus allowing an assumption that similar could be expected for 
amber suppression with the unnatural amino acids (Beier and Grimm, 2001; 
Hino et al., 2006; Noren et al., 1989; Wang et al., 2009; Xie and Schultz, 2005). 
An orthogonal tRNA/aaRS pair developed for the unnatural amino acid must 
not cross-react with any of the endogenous elements of the protein synthesis 
machinery. Orthogonality means that the unnatural amino acid must be 
incorporated at defined site in response to a unique codon, which must not 
encode any of the canonical amino acids. Moreover, the tRNA specific for the 
unnatural amino acid must be optimised in such a manner that it does not 
recognise any of the 20 common amino acids, and that it is not recognised by 
any of the endogenous aaRSs. In addition, its cognate aaRS must not 
aminoacylate any of the endogenous tRNAs. Furthermore, this aaRS must 
aminoacylate only its corresponding tRNA and only with the unnatural amino 
acid. Last, the unnatural amino acid must be stable when added to the growth 
medium, must be efficiently transported into the cytoplasm and stable to the 
hydrolytic actions of the cellular proteases. Liu and Schultz investigated the 
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efficiency of cellular uptake of 138 unnatural amino acids in E. coli and 
concluded that the highest cellular toxicity was obse rved when the unnatural 
amino acids closely resembled the canonical ones or when they contained 
reactive functional groups (Liu and Schultz, 1999). 
 
Figure 10: A general principle of expanded genetic code methodology. To 
introduce unnatural amino acids in vivo, the orthogonal aaRS acylates 
orthogonal tRNA with an unnatural amino acid, which is then inserted at the 
position specified by the unique codon (reproduced from Wang and Schultz, 
2002, with permission of the Royal Society of Chemistry (RSC) on behalf of the 
European Society for Photobiology, the European Photochemistry Association 
and the RSC). 
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In general, the most challenging aspect in developing an orthogonal 
tRNA/aaRS pair, specific for the unnatural amino acid, refers to the 
orthogonality of the tRNA and its cognate aaRS (Liu and Schultz, 2010). A pair 
of tRNA/aaRS, which would be specific for an unnatural amino acid, must be 
imported from a different organism, providing there is no cross-reactivity with 
the elements of the endogenous protein synthesis machinery, thus avoiding 
cumbersome approach of generating a novel, functional and orthogonal pair of 
tRNA/aaRS (Chin et al., 2003; Liu and Schultz, 2010; Wang et al., 2000; Wang 
et al., 2001; Wang et al., 2009; Xie and Schultz, 2006).. The development of an 
orthogonal pair of tRNA/aaRS specific for the photo-cross-linkable pBPA was 
not the subject of this thesis, but the development of such an orthogonal pair is 
provided in the following chapters. The tyrosyl-tRNA/RS (Tyr-tRNA/TyrRS) pair 
from archaebacterium Methanococcus jannaschii provided an orthogonal pair 
for use in E. coli (Wang et al., 2000). It was demonstrated that M. jannaschii 
TyrRS does not aminoacylate tRNAs from E. coli, whereas M. jannaschii Tyr-
tRNA provided a poor substrate for E. coli aaRSs (Wang et al., 2000, Wang et 
al., 2001). In addition, aaRSs in M. jannaschii do not have a proofreading 
mechanism and should therefore not interfere with the delivery of the unnatural 
amino acid ligated to the tRNA specific for it when applied in E. coli. To further 
increase selectivity of the imported tRNA/aaRS pair for the unnatural amino 
acid and/or reduce reactivity of the endogenous translational elements for any 
of the imported components for protein synthesis, the imported tRNA/aaRS pair 
was subjected to mutagenesis of the nucleotides that are not directly in contact 
with the  M. jannaschii  TyrRS and to the subsequent rounds of positive and 
negative selection.  In brief, the crystal structure of the homologous TyrRS from 
Baccilus stearothermophilus provided structural rationale for introducing 
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alterations in order to increase selectivity of the novel tRNA/aaRS orthogonal 
pair. Next, a library of M. jannaschii aaRS mutants was transformed in E. coli 
cells which contained a nonsense codon introduced in the gene encoding 
chloramphenicol acetyltransferase (CAT). By allowing cells to grow in the 
media supplied with both the unnatural amino acid and the appropriate 
selection antibiotic, survived cells enabled selection of the aaRSs which can be 
charged with any amino acid thus suppressing the nonsense codon in the CAT 
gene and enabling survival. In the next round, the survived cells from the first, 
positive, selection were grown without the addition of the unnatural amino acid 
to the medium, thus eliminating aaRSs which could be charged with the 
canonical amino acids. For fine-tuning selectivity of the tRNAs, a library of the 
tRNA mutants was first subjected to the negative selection, based on the 
suppression of a nonsense codon introduced in the gene encoding toxic 
product called barnase, thus eliminating the tRNAs which can be 
aminoacylated also by the endogenous aaRSs of E. coli. The second round of 
positive selection was based on the nonsense suppression in the gene 
encoding β-lactamase, thus selecting the tRNAs which were not aminoacylated 
by the aaRSs from E. coli. In addition, more orthogonal tRNA/aaRS pairs for 
application in E. coli were developed, thus increasing diversity of the unnatural 
amino acids which could be incorporated into proteins by expanded genetic 
code methodology (Xie and Schultz, 2005). To extrapolate the application of 
the expanded genetic code to the eukaryotic cells, S. cerevisiae was selected 
as the initial organism from which a novel pair of orthogonal tRNA/aaRS could 
be developed (Chin et al., 2003; Liu and Schultz, 2010; Wang et al., 2009). The 
above described two-step selection procedure was not applicable for 
developing an orthogonal pair of tRNA/aaRS in eukaryotic host because of low 
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efficiency of transformation, thus making generation of big mutant tRNA and 
aaRS libraries impractical. Furthermore, an additional obstacle is the existence 
of the nonsense-mediated decay (NMD) in eukaryotes (Amrani et al., 2006; 
Wang et al., 2009). NMD accelerates degradation of the mRNAs containing 
premature STOP codons, and the effect is more pronounced if the premature 
STOP codons were to reside closer to the 5’-end of an mRNA.  
In addition, pairs of tRNAs/aaRSs developed in E. coli, albeit not cross-reacting 
with eukaryotic protein synthesis elements, were limited in the final protein yield 
due to differences in the mechanisms for transcription and processing of the 
tRNAs (Liu et al., 2007; Wang et al., 2009). Namely, in the eukaryotes, a tRNA 
is transcribed from the promoter, referred to as the A- and B-box, which is 
integrated within the tRNA gene, whereas E. coli contains the promoter, only 
the A-box, upstream of the tRNA encoding gene (Figure 11). In contrast, B. 
stearothermophilus Tyr-tRNA contains A- and B-boxes, it is not recognised and 
charged by the mammalian aaRSs and, together with the E. coli TyrRS, 
represents an orthogonal pair for use in yeast and mammalian cells (Chin et al., 
2003; Wang et al., 2009). In addition, expression of functional prokaryotic 
tRNAs in mammalian cells was advanced by using external mammalian 
promoters which are positioned upstream of the coding region and do not 
require any intragenic elements, such as A- and B-box, thus enabling 
unobstructed transcription and generation of functional prokaryotic tRNAs (Liu 
and Schultz, 2010; Wang, et al., 2009).  
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Figure 11: Difference in the expression of prokaryotic and eukaryotic tRNAs. 
(a) Genes encoding tRNAs in E . coli are transcribed through promoters located 
upstream of the gene. (b) In eukaryotes, promoters are within the geen (A and 
B box).  Adapted from Wang et al., 2009. 
 
The spectrum of applications of the expanded genetic code is vast, and the 
unnatural amino acids have been successfully incorporated into proteins in 
CHO and HEK293 mammalian cells, and even in primary neurons (Liu and 
Schultz, 2010; Wang et al., 2007b; Wang, et al., 2009). One of the more 
attractive aspects of this methodology involves incorporation of the unnatural 
amino acids with chemical moieties that could serve as a reactive handle for 
further derivatization. The carbonyl group represents one such moiety. Photo-
excitable amino acid para-benzoylphenylalanine (pBPA) is very appealing 
because its carbonyl group enables cross-linking of proteins through highly 
reactive diradical-based intermediate which is generated transiently after 
exposure to 350-365 nm light (Hino et al., 2005; Tanaka et al., 2008).  
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1.7.1 pBPA 
The synthesis of pBPA was reported by in 1973, but it was only in 1986 that 
Kauer et al. described its successful incorporation into peptides and 
subsequent photo-induced cross-linking of 17mer calmodulin-binding peptide 
with calmodulin upon exposure to 350 nm light (Kauer et al., 1986). Since then, 
the benzophenones became wildly attractive choice for photo-labeling reagents 
due to several distinct advantages when comparing properties of pBPA to the 
other photo-probes, such as diazirirines or aryl azides, which were also 
genetically encoded in prokaryotes and eukaryotes and used for cross-linking 
(Ai, Shen et al., 2011; Chin et al., 2002a; Chin et al., 2003; Chou et al., 2011; 
Dormán and Prestwich, 1994; Haberkant and van Meer, 2009; Liu et al., 2007; 
Tanaka et al., 2008; Tippmann, Liu et al., 2007).  
 
Figure 12: Principle of photo-induced cross-linking with pBPA. Structures were 
generated with ChemBioDraw. 
 
Benzophenones are chemically stable (Dormán and Prestwich, 1994). Upon 
exposure to 350-360 nm light, they preferentially cross-link with the proximal C-
H bonds (Tanaka et al., 2008 and Figure 12). Initially, the reactive radius of the 
benzophenone moiety was approximated as a sphere with 3.1 Å radius 
measured from the oxygen of the carbonyl group (Dormán and Prestwich, 
1994). The reactivity of the benzophenone group and, thus, the efficiency of the 
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cross-linking depend on the geometric relationship between the carbonyl group 
of the benzophenone and a proximal C-H bond, and also on their 
electrochemical environment (Dormán and Prestwich, 1994; Sato et al., 2011; 
Wittelsberger et al., 2008). Benzophenones exhibit enhanced reactivity toward 
electron rich tertiary atoms, present, for example in leucine or valine, but also 
toward methenyl (CH2) groups close to a heteroatom, such as those present in 
methionine, arginine or lysine (Dormán and Prestwich, 1994). Importantly, 
pBPA has been genetically encoded for expression in prokaryotes, yeast and 
mammalian cells and also widely used for photo-induced cross-linking, 
employing the expanded genetic code methodology or incorporation into 
peptides, proving especially beneficial for studying membrane-associated 
components and transient protein interactions or PTMs (Alexander, Gerauer, et 
al., 2009; Chen et al., 2007; Chin et al., 2002a and b; Chin and Schultz, 2002; 
Chin, 2011; Chou et al., 2011; Forné et al., 2012; Hino et al., 2005; Kage et al., 
1996; Krishnamurthy, Dugan et al., 2011; Liu et al, 2007; Majmudar et al., 
2009; Musial-Siwek et al., 2007; O’Neil et al., 1989; Ryu and Schultz, 2006; 
Sato et al., 2011; Uezu et al., 2012; Völkert et al., 2003; Wang et al., 2010b; 
Xie and Schultz, 2005; Xie and Schultz, 2006; Ye, Köhrer et al., 2008).  
1.8 Aims 
The ultimate aim of the work described in this thesis was to show if nonsense 
suppression strategy utilizing the amber STOP codon could be applied to 
develop substrate -trapping mutants of PTPs, which would be more efficient in 
trapping potential interacting partners than conventional substrate-trapping 
mutants of PTPs, which contain mutations mostly of the catalytically important 
residues. The model phosphatases with which this strategy was to be 
developed were PRL-3 and VHR. These phosphatases were selected due to (i) 
 114 
the inherent difficulties of traditional methods to identify their interacting 
partners and (ii) their link to cancer. 
To achieve this, the first aims were to show that pBPA could be selectively 
incorporated, in vivo, in the selected PTPs. For this, proper positions for the 
introduction of pBPA had to be found in PRL-3 and in VHR and the conditions 
for the over-expression in E. coli and purification had to be optimised. 
Screening for the most optimal expression conditions was to be done on a 
small-scale bacterial culture (50 ml) and then extrapolated to at least five times 
higher culture volume.  
Next, the aim was to characterize the generated pBPA-containing variants for 
their cross-linking ability in vitro, and to interpret the findings by using more 
conventional mutants as controls. Characterisation of the cross-linking abilities 
of the pBPA-containing proteins was to be done on a small scale to fit 96 well-
plate setup and to minimise the amount of the pBPA-containing proteins 
needed. 
Finally, the aim was to extrapolate if this tool could be used in profiling 
interactions of the PTPs in cell lysates. This was to be achieved by using PTP 
variants where catalytically essential residue (general acid/base aspartate)  
was replaced with pBPA (D72pBPA mutant of PRL-3). This aim will require 
substantial optimisation- for example, the amounts of the bait protein and the 
lysate used, duration of pre-incubation of the bait with the lysate prior to UV-
exposure, duration of UV-exposure and optimisation of the purification 
conditions. 
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2. Materials and methods 
 
2.1 Materials and methods for Chapters 3.1-3.3 
 
2.1.1 Reagents  
para-Benzoyl-L-Phenylalanine (pBPA) was from PepTech (Massachusetts, 
USA). p-Acethylphenylalanine hydrochloride (pACF)  was from Sinon Pharma 
(China). 4-nitrophenyl phosphate disodium salt hexahydrate (pNPP) and 
sodium orthovanadate (Na3VO4) were from Sigma (Steinheim, Germany). 3-O-
Methylfluorescein phosphate cyclohexylammonium salt (OMFP) and 
Glutaraldehyde solution Grade I, 50% in H2O were purchased from Sigma-
Aldrich. D-myo-Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) was from 
Echelon Biosciences (USA). Disuccinimidyl suberate (DSS) was from Thermo 
Scientific (Rockford, IL, USA). N-2-Hydroxyethylpiperazine-N’-2-ethane sulfonic 
acid (HEPES) was purchased from Biomol GmbH (Hamburg, Germany). 
Sodium dodecylsulfate (SDS) was purchased from SERVA Electrophoresis 
GmbH (Heidelberg, Germany). 30% Acrylamide/Bis Solution, 37.5:1 (2.6% C) 
was from BIO-RAD (Hercules, CA, USA).  
Fetal bovine serum (FBS), penicillin/streptomycin and Opti-MEM I + GlutaMAX-
I were from Gibco, Life Technologies (Paisley, UK). L-glutamine (200 mM 
stock) and Trypsin-EDTA 1 x solution were from Sigma. Fugene HD was 
purchased from Promega (Madison, USA). Complete, 
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail (PIC) 
tablets and PhosSTOP (PS) phosphatase inhibitor coctail tablets were 
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purchased from Roche (Mannheim, Germany). H2O2 was 30% solution from 
Fluka (Steinheim, Germany). Acetonitrile and formic acid (99%), used for liquid 
chromatography (LC)-MS analysis, were both Ultra LC MS (ULC MS), from 
Biosolve. 
For amplification and site-directed mutagenesis (SDM) by polymerase chain 
reaction (PCR), the following enzymes were used: Phusion DNA Polymerase 
(New England Biolabs, NEB), Phire Hot Start II DNA Polymerase, Dream Taq 
Green PCR Master Mix, Maxima Hot Start PCR Master Mix (all from Thermo 
Scientific), Ampli Taq Gold 360 DNA Polymerase (Life Technologies) and 
QuickChangeLightning (QCL) SDM kit (Agilent Technologies, USA). 
dNTP Mix 10 mM each was from Thermo Scientific. All regular or high fidelity 
(HF) restriction enzymes used were from NEB, and all fast digest (FD) ones 
were from Thermo Scientific. DpnI and Tango buffer (10 x) were from Thermo 
Scientific. 
T4 DNA Ligase was from Thermo Scientific or from Life Technologies. 
Other reagents (used for preparing different buffers and solutions listed in the 
section 2.1.5, agarose, L-(+)-Arabinose, antibiotics, reducing agents L-
Glutathione and DL-Dithiothreitol (DTT), detergents Nonidet P 40 Substitute 
(NP40) and TWEEN 20) and paraformaldehyde (PFA) were from Merck 
(Darmstadt, Germany) or from Sigma-Aldrich.  
2.1.2 Materials  
Buffers for protein purification and growth media (GM) for cultivation of 
mammalian cell lines were filtered by using Millipore Express PLUS 0.22 μm 
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filters, and for sterilization of buffers and media on a scale to 20 ml, Millex-GP 
0.22 μm filters, both from Merck Millipore (Cork, Ireland), were used. 
For small scale protein purifications, Ni-NTA Superflow and polypropylene 
columns from Qiagen (Hilden, Germany) were used. His-Select Nickel Affinity 
Gel was from Sigma. 
For purification of recombinant PRL-3 and VHR variants, HisTRAP HP (1 ml) 
and GSTrap FF (1 ml) columns from GE Healthcare (Uppsala, Sweden) were 
used. 
Protein samples were resolved by using precast Nu Polyacrylmide gel 
electrophoresis (PAGE) 4-12% Bis-Tris Gels (1.0 mm thick) from Novex by Life 
Technologies. 
Protein samples were dialysed by using Spectra/Por Dialysis Membranes with 
molecular weight cut-off (MWCO) 3,000 or 6-8,000 (3K or 6-8K) from Spectrum 
Laboratories, Inc., USA. 
Protein samples were concentrated by using Ultra Centrifugal Filters-0.5 ml, 
with 3K or 10K MWCO from Amicon (Cork, Ireland). 
PIP Strips were from Echelon Biosciences.  
The following films were used: Kodak BioMax MR (high resolution radioisotope 
and chemiluminescent) from Sigma-Aldrich, and Amersham Hyperfilm ECL 
(high performance chemiluminescence film) from GE Healthcare 
(Buckinghamshire, UK). 
The following Western blotting detection reagents were used: ECL Western 
Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK) and 
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Western Lightning Plus-ECL Enhanced Chemiluminescence Substrate (Perkin 
Elmer, USA). 
2.1.3 Instruments  
DNA amplification PCR was conducted on a MJ Research Peltier Thermal 
Cycler PTC-200 from Biozym Diagnostik GmbH (Oldendorf, Germany). 
DNA bands in agarose gels were visualized with a Dual-intensity 
transilluminator from Herolab (Wiesbaden, Germany).  
DNA and protein concentrations were measured on a NanoDrop 1,000 
Spectrophotometer from PEQLAB Biotechnologie GmbH (Erlangen, Germany). 
Optical density (OD) of growing bacterial cultures was measured by Ultrospec 
2,100 pro UV/Visible Spectrophotometer from Amersham Biosciences.  
To mechanically disrupt the cells by sonication, Branson Sonifier W-250 
Ultrasonic Disintegrator with a small microtip was used. 
To load the samples onto the HisTRAP HP and GSTrap FF columns, LKB 
Pump P-1 from Pharmacia (Sweden) was used. 
Proteins were purified with Åktapurifier 10 system (GE Healthcare). The system 
contains a P-903 pump, an M-925 mixer, an UV-900 detector and a fraction 
collector Frac 950, and is operated with the UNICORN 5.20 software. 
Activity assays with pNPP or OMFP were conducted in a 96-well plate setup in 
a microplate reader Tecan Saphire 2 (Tecan, Austria). 
Photo-induced cross-linking was conducted by using 1,000 watt (W) mercury 
lamp equipped with 20CGA-345 filter with a 345 ± 5 nm cut-on/cut-off 
wavelength, 1 mm thick and dimensions 50.8 x 50.8 mm (Newport, USA).  
 119 
For lipid-binding assay, photo-induced cross-linking was performed with 
Spectrolinker UV Crosslinker Model XL-1500 A/F from Spectroline (Westbury, 
USA), by using an optimal cross-linking mode which provides UV energy 
dosage of 120 mJ/cm2. 
The proteins were transferred from polyacrylamide gels to nitrocellulose 
membranes by using iBlot Dry Blotting System with iBlot Gel Transfer Stacks 
(both from Novex by Life Technologies). 
2.1.4 Miscellaneous 
DNA primers were purchased from Eurofins MWG GmbH (Ebersberg, 
Germany). 
DNA sequencing was done by GATC Biotech AG (Konstanz, Germany). 
Purification of DNA was done by using the following commercial kits: QIAquick 
PCR Purification Kit, QIAquick Gel Extraction Kit (both from Qiagen, Hilden, 
Germany) or PureLink PCR Purification Kit (Life Technologies).  
For isolation of DNA, the following kits were used: Quick Lyse Miniprep Kit, QIA 
prep Spin Miniprep Kit or QIA filter Plasmid Maxi Kit (all from Qiagen). 
For removal of the N-terminal His6-tag in the proteins, Glutathione S-
Transferase fused tobacco etch virus (GST-TEV) protease (stock at 1 mg/ml) 
provided from the Protein Expression and Purification Core Facility at EMBL 
Heidelberg was used. 
GeneRuler 1 kb DNA Ladder, used as DNA reference standard and 6 x 
TriTrack DNA Loading Dye were from Thermo Scientific. 
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Blue Eye Prestained Protein Marker from Jena Bioscience (Jena, Germany), 
Spectra Multicolor Broad/High Range Protein Ladder from Thermo Scientific 
and BenchMark Prestained Protein Ladder from Novex by Life Technologies 
were used as protein size references. 
EnzCheck Phosphate Assay Kit was from Molecular Probes. 
The following centrifuges were used: centrifuge 5415 R (for 1.5 and 2 ml 
tubes), with up to 13,200 rpm, from Eppendorf (Hamburg, Germany) and 
Sorvall RC6, with up to 22,000 rpm, from Thermo Scientific. 
The following film development system was used: Kodak RP X-OMAT 
Processor Model M6B, from Kodak GmbH (Stuttgart, Germany). 
2.1.5 Buffers, solutions and media 
2.1.5.1 TAE 
As running buffer for agarose gels, Tris-acetate-EDTA (TAE) buffer was used. 
It contained 40 mM Tris base, 20 mM glacial acetic acid and 1 mM EDTA; pH 
value is 8.1-8.3.  
2.1.5.2 SDS-PAGE running buffer 
As SDS-PAGE running buffer, NuPAGE MOPS SDS (20 x) from Novex by Life 
Technologies was used. 
2.1.5.3 SDS-PAGE sample buffers 
SDS-PAGE sample buffer (2 x) was prepared by mixing 2.0 ml of stacking gel 
buffer (4 x) pH 6.8, 1.6 ml of glycerol, 3.2 ml of 10% (w/v) SDS, 0.8 ml of β-
mercaptoethanol and 0.4 ml of 1% (w/v) bromphenol blue. Non-reducing SDS-
PAGE sample buffer (2 x) did not contain β-mercaptoethanol. SDS-PAGE 
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sample buffer (6 x) contained 7 ml of stacking gel buffer (4 x) pH 6.8, 2.6 ml of 
glycerol, 1 g of DTT, 400 μl of 10% (w/v) SDS and 60 μl of 1% (w/v) 
bromphenol blue. 
2.1.5.4 SDS (10%) stock solution 
SDS (10%) stock solution was prepared by dissolving 10 g of SDS in 0.8 l of 
ddH2O and than topping up the final volume to 1 l with ddH2O. 
2.1.5.5 Stacking gel buffer (4 x) 
Stacking gel buffer (4 x) was prepared by dissolving 60.5 g of Tris-base in 1 l of 
ddH2O and adjusting the pH value to 6.8. 
2.1.5.6 Resolving gel buffer (4 x) 
Resolving gel buffer (4 x) was prepared by dissolving 181.5 g of Tris base in 1 l 
of ddH2O and adjusting the pH value to 8.8. 
2.1.5.7 Ammonium persulfate (10%) 
To make 10% (w/v) solution of ammonium persulfate, 1 g of a substance was 
dissolved in 10 ml of ddH2O. 
2.1.5.8 Tris-HCl (1M, pH 7.5) 
1 M Tris-HCl pH 7.5 was prepared by EMBL’s media kitchen. Tris base (121 g) 
was dissolved in 800 ml of H20, and then the pH value was adjusted to 7.5 with 
concentrated HCl. The final volume was topped up to 1 l with H2O prior to 
autoclaving. 
 
 
 122 
2.1.5.9 Phosphate Buffer Saline (PBS)  
PBS was prepared by EMBL’s media kitchen and it contained 137 mM sodium 
chloride (NaCl), 2.7 mM potassium chloride (KCl), 2 mM potassium dihydrogen 
phosphate (KH2PO4), 10 mM disodium hydrogenphosphate (Na2HPO4), with 
the pH value adjusted to 7.2.  
2.1.5.10 EDTA (0.5 M, pH 8.0) 
0.5 M EDTA pH 8.0 was prepared by EMBL’s media kitchen. Disodium-EDTA 
dihydrate (186.1 g) was dissolved in 700 ml of H20, and then the pH value was 
adjusted to 8.0 with 10 M NaCl. The final volume was topped up to 1 l with H2O 
prior to autoclaving. 
2.1.5.11 Tris buffered saline (TBS) (10 x) 
TBS 10 x stock solution contained 0.5 M Tris-HCl (pH 7.5) and 1M NaCl. TBS 1 
x solution was prepared by diluting the stock solution in ddH2O. 
2.1.5.12 TBS-Tween20 (TBS-T) 
TBS-T buffers were prepared by adding an appropriate volume of Tween-20 to 
a 1 x solution of TBS in order to obtain 0.05% or 0.1% (both v/v). 
2.1.5.13 Staining solutions for protein gels 
Protein gels were regularly stained with an aqueous solution prepared from 
Coomassie Brilliant Blue G-250 at 0.008% (w/v) and 35 mM HCl.  
Alternatively, colloidal Coomassie Blue G-250 stain was utilized and was 
prepared according to the reported protocol (Candiano, Bruschi, et al., 2004). 
In brief, the dye was made by sequentially adding the components listed below 
to an aqueous solution: 10% (v/v) phosphoric acid, 10% (w/v) ammonium 
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sulfate, 0.12% (w/v) Coomassie Blue G-250 and 20% (v/v) anhydrous 
methanol. The solution was kept light protected at rt. The gels were incubated 
with a dye either for a couple of hours at rt or overnight, either at rt or at 4°C, 
with gentle agitation, and then destained in ddH2O. 
2.1.5.14 Staining nitrocellulose membranes 
Ponceau S staining solution was used to assess the efficiency of protein 
transfer. It contained 0.1% (w/v) Ponceau powder and 5% (v/v) acetic acid in 
aqueous solution. 
2.1.5.15 Protein transfer 
Buffer for protein transfer for Western blot analyses contained 48 mM Tris 
base, 39 mM glycine, 0.37% (v/v) SDS (from 10% stock solution) and 20% (v/v) 
methanol.  
2.1.5.16 Stripping buffer for immunoblots 
As stripping buffer for immunoblots, 0.1 M glycine pH 2.8 was used.  
2.1.5.17 Stripping buffer for His Trap HP columns 
The columns were stripped by washing with stripping buffer as recommended 
by the manufacturer, and the stripping buffer contained 20 mM sodium 
phosphate, 0.5 M NaCl, 50 mM EDTA (pH 7.4).  
2.1.5.18 Recharging buffer for His Trap HP columns 
The columns were recharged by loading 0.5 ml of 0.1 M nickel (II)- sulfate in 
ddH2O. 
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2.1.5.19 Eluting buffer for GSTrap FF columns 
GSTrap columns were eluted with at least 10 mM GSH, pH 8. 
2.1.5.20 SOC medium  
SOC medium was prepared by EMBL’s media kitchen and it contained 2% 
(w/v) of bacto tryptone, 0.5% (w/v) of yeast extract, 5 M NaCl, 1 M magnesium 
chloride (MgCl2) 1 M KCl, 1 M magnesium sulfate and 20% (v/v) glucose, with 
the pH value adjusted to 7.2.   
2.1.5.21 Media for cultivation of bacterial cultures 
For propagation, bacterial strains were incubated in autoclaved Luria-Bertani 
(LB) or Terrific Broth (TB)-FB broths, supplemented with the appropriate 
antibiotic(s), as determined by the plasmid vectors and bacterial strains used. 
Both broths were prepared by EMBL’s media kitchen. LB medium (1 l) 
contained: 10 g of bacto tryptone, 5 g of yeast extract and 5 g of NaCl, with the 
pH value adjusted to 7.2. TB-FB medium (1 l) contained phosphate stock and 
extract stock at 1:9 ratio (v/v). Phosphate stock buffer contained 0.16 M 
KH2PO4 and 0.72 M dipotassium hydrogen phosphate (K2HPO4) (both from 
Merck). Extract stock (0.9 l) contained 12 g bacto tryptone, 24 g yeast extract 
and 4 ml glycerol. The final pH value was adjusted to 7.2.  
The antibiotics were used at the concentrations indicated: ampicillin (Amp) 50 
or 100 μg/ml, kanamycin (Km) 50 μg/ml, chloramphenycol (Cm) 33 μg/ml and 
tetracycline (Tet) 2.5 μg/ml. 
LB agarose plates were prepared by EMBL’s media kitchen. They contained 
1.5% (w/v) bacto agar and the following antibiotics at the concentrations 
indicated: Amp 100 μg/ml, Km 30 μg/ml, Cm 33 μg/ml, combination of Amp and 
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Cm at 100 and 33 μg/ml, respectively, and combination of Amp and Tet at 100 
and 10 μg/ml, respectively. 
2.1.5.22 Lysis buffers for mammalian cell lines 
The buffer used to lyse COS-1 cells contained 20 mM Tris-HCl (pH 7.4), 137 
mM NaCl, 10% (v/v) glycerol, 1% (v/v) NP-40, 1 mM EDTA and PIC tablet 
prepared according to the manufacturer’s instructions and used at 1:25 dilution. 
For interactome analysis involving different variants of PRL-3, HEK293 cells 
were lysed in the HNTG buffer containing 20 mM HEPES (pH 7.5), 150 mM 
NaCl, 1% (v/v) Triton X-100, 10% (v/v) glycerol and PIC (as above). 
2.1.6 DNA amplification by PCR 
The DNA templates were commonly used at the final amount of 20 or 100 ng 
for 50 μl PCR mix, or accordingly downscaled for 25 μl PCR mix.  
For 50 μl PCR reaction mix with Phire Hot Start II DNA Polymerase or Phusion 
DNA Polymerase, 0.5 μl of the enzyme was used; when using QCL-SDM kit, 25 
μl reaction mixes were made. Where required, dNTPs were added extra from 
the stock with 10 mM concentration of each dNTP to a final concentration of 0.2 
mM. The forward and reverse primers were used at the final concentration of 
0.2 μM. When using QCL-SDM kit, the primer concentration was 0.125 μM.  
The PCR conditions were adjusted depending on the amplification enzyme and 
the set of sense and antisense primers used. The annealing temperature was 
adjusted accordingly, and in general was set to about 4°C below the melting 
temperature (Tm) of the cognate primer set; the Tm was approximately 
calculated by using the equation: (G+C) x 4 + (A+T) x 2. Amplification step was 
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generally conducted for 25-30 cycles, with the final extension step at 72°C of at 
least 10 min. 
For DpnI digestion, 1 μl of the enzyme was added directly to the PCR mixture 
and incubated for 2 h at 37°C, after which the enzyme was heat-inactivated by 
incubating at 80°C for 20 min. When using QCL-SDM kit, DpnI enzyme 
supplied with the kit was used.  
2.1.7 DNA ligation 
For ligation, 1 μL of T4 DNA Ligase was added to the digested DNA insert and 
vector mixed at 3:1 (v/v) ratio. Ligation was conducted by incubating the ligation 
mixtures at rt for up to 5 h, or by overnight incubation at 16°C, and then 
transforming into chemically competent E. coli strain. 
2.1.8 Procedure for DNA isolation 
For isolation of DNA, the colonies were inoculated into LB medium (around 3 
ml) supplemented with the appropriate antibiotics and incubated at 37°C with 
vigorous agitation. For isolation and purification of DNA, commercially available 
kits were used according to the manufacturer’s instructions.  
2.1.9 Procedure for DNA propagation 
For propagation of DNA, a single colony was inoculated into LB medium (200-
400 ml) supplemented with the appropriate antibiotics and incubated for at least 
16 h at 37°C with vigorous agitation. For isolation and purification of DNA, 
commercially available kits were used according to the manufacturer’s 
instructions.  
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2.1.10 Procedure for transformation of chemically competent strains of E. 
coli 
For propagation of DNA, chemically competent DH5α and TOP10 E. coli strains 
were used, and for expression by using chemically competent cells, BL21 DE3 
strain.  
DNA (1-5 μl) was added to the thawed cells (at least 50 μl) and incubated on 
ice for 30 min. HS was applied for approximately 90 s at 42°C, after which the 
cells were recovered on ice for 2 min. Next, 300 μl of LB medium was added, 
followed by incubation for about 45-60 min with vigorous agitation at 37°C 
before plating on LB-agar with appropriate antibiotic selection. The plates were 
incubated overnight at 37°C or for approximately 48 h at rt.  
At least 20 μl of the PCR mix was used in transforming no less than 50 μl of the 
thawed cells. For ligation mixture, 10 μl of the ligation reaction was used for 
100 μl of the cell suspension.  For propagation of DNA, 1-5 μl of DNA was used 
for 50-150 μl volume of the cell suspension.  
For BL21 DE3 strain, the same procedure was used, with 5 μl of DNA added to 
100 μl of the thawed cells. 
2.1.11 Transformation procedure for electrocompetent E. coli strains  
Electrocompetent E. coli strains BL21 AI and BL21 RIL were obtained from the 
laboratory of Dr. Edward Lemke (Structural and Computational Unit, EMBL 
Heidelberg). Plasmid encoding PRL-3 or VHR variant with a specific position 
exchanged for the amber STOP codon, and plasmid encoding tRNA/aaRS 
specific for pACP (pEVOLV-ACP) or for pBPA (pEVOLV-BzF), which were 
originally obtained from Peter Schultz (The Scripps Research Institute, 
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California), were co-transformed by electroporation into bacterial strain BL21 AI 
or BL21 RIL by using E. coli gene pulser cuvette and MicroPulser. Typically, 2-
4 ng of each plasmid was mixed with 50 μl of the thawed cells prior to 
transferring the mixture to a pulser cuvette. After a pulse, the cells were 
recovered in 200 μl of the SOC medium warmed to rt and incubated for around 
45-60 min at 37°C with horizontal agitation. 
2.1.12 Antibodies (ab) and Western blotting  
The following primary ab were used: anti-Flag mouse monoclonal ab (mAb) at 
1:10,000 (M2, Sigma), anti-c-Myc mAb at 1:500 (9E10, Santa Cruz 
Biotechnology), rabbit polyclonal ab (rAb) specific to DUSP3/VHR and pErk1/2 
(Thr202/Tyr204), and monoclonal rAb specific to total Erk1/2 (137F5) at 1,000 
(all from Cell Signaling Technology). Polyclonal rAb specific to VHR was kindly 
provided by Dr. Rafael Pulido (Centro de Investigación Principe Felipe) and 
was used at 1:5,000.  Anti-PRL-3 ab (1E7) was used at 1:400.  
The following secondary ab were used: goat anti-mouse IgG-peroxidase 
conjugate (Sigma) and donkey anti-rabbit IgG-horseradish peroxidase (HRP) 
conjugate (GE Healthcare). Dynabeads protein G was used for 
immunoprecipitation (IP) (Novex by Life Technologies). 
Anti-Flag ab was used according to the slightly modified general protocol 
enclosed in the manufacturer’s instruction sheet. In brief, the membrane was 
blocked with TBS containing 3% (w/v) nonfat milk for 60 min at rt and then 
rinsed two times for 5 min with TBS. The primary ab was diluted in blocking 
solution and was incubated with the membrane for 60 min. The membrane was 
rinsed as above before adding the secondary ab diluted 1:10,000 in blocking 
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buffer and incubating for 30-60 min. The membrane was rinsed with TBST-
0.05% about eight times for 20 min prior to detection. 
For immunoblot analysis using anti-c-Myc ab, the general protocol provided by 
the manufacturer was followed, with slight modifications. Briefly, the membrane 
was rinsed for 5 min with TBS, followed by blocking in TBST-0.05% 
supplemented with 5% (w/v) nonfat milk for 60 min. The membrane was rinsed 
with TBST-0.05% three times for 15 min. Incubation with the primary ab diluted 
1:500 in blocking buffer was conducted for 3 h at rt. After washing the 
membrane as above, the secondary ab was added at 1:2,000 in blocking buffer 
and incubated for 60 min. The membrane was washed as above prior to 
visualization.  
Western blots with ab against VHR and, total or pErk1/2 (all from Cell 
Signaling) were conducted like suggested by the manufacturer. The 
appropriate secondary ab was used at 1:5,000 in blocking buffer for 60 min. 
For Western blot analysis using polyclonal anti-VHR rAb provided by Dr. R. 
Pulido, the exact procedure described for anti-Flag ab was applied. Anti-VHR 
ab and the appropriate secondary ab were used at 1:5,000 in blocking buffer 
for 60 min at rt. 
For Western blot using ab against PRL-3 (1E7), the general procedure used for 
anti-Flag ab was used, but the primary ab was used at 1:400 dilution in TBS 
with 3% (w/v) BSA for 3 h at rt. The secondary ab was used at 1:10,000 in TBS 
with 3% (w/v) BSA for 45 min-1 h at rt. 
The membranes were stripped by incubating in 0.1 M glycine pH 2.8 for at least 
60 min at rt with mild agitation, followed by extensive rinsing with TBS prior to 
reprobing. 
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2.1.13 Maintenance of mammalian cell lines  
COS-1 cells were a generous gift from Prof. Dr. Antje Gohla (Rudolf Virchow 
Center/DFG Research Center for Experimental Biomedicine, University of 
Würzburg, Germany), and HEK293 cells were obtained from the laboratory of 
Dr. Carsten Schultz (EMBL Heidelberg). 
HEK293 and COS-1 cells were cultured at 37°C in a humidified incubator under 
an atmosphere of 5% CO2 and passaged 2-3 times a week. Heracell240i and 
240 CO2 incubators used were from Thermo Scientific. The cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM), prepared by EMBL’s media 
kitchen, containing glucose at 4.5 g/l (“high glucose”) and additionally 
supplemented with 10% (v/v) FBS, 1% (v/v) penicillin/streptomycin and 2 mM 
L-glutamine. 
The components of the starving medium were as listed above, but omitting 
FBS.  
Trypsin-EDTA solution 1 x was used for detachment of cells from the culturing 
plates. 
2.1.14 Removal of His6-tag by GST-TEV 
Removal of His6-tag in the recombinant proteins was done at least overnight at 
4°C: (i) by adding the protease to a protein sample in solution; (ii) by adding the 
protease to a protein sample during dialysis or (iii) by concentrating the protein 
sample to a volume bellow 1 ml, loading it onto HisTRAP column manually and 
then loading the protease. To remove the protease, GSTrap column was 
usually coupled directly below the HisTRAP column, and Åktapurifier was used 
to elute the sample. Alternatively, the sample was first eluted from HisTRAP 
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column, concentrated to a volume bellow 1 ml and then passed over GSTrap 
column. The amount of the protease needed was initially calculated according 
to the equation: 0.06 mg of protease per 1 mg of protein to be digested (which 
had been used in the lab previously). Regularly, the amount of the protease 
used was reduced by about 20% from the calculated one to (i) ease the 
regeneration of the columns after purification and to (ii) reduce the amount of 
the protease purchased. Reduction in the amount pf the protease had no effect 
on the efficiency of digestion.  
2.1.15 Intact protein sample analysis by LC-MS 
All sample analyses by LC-MS(/MS) were performed by the Proteomics Core 
Facility at EMBL Heidelberg, and the protocols for sections 2.1.15, 2.3.10 and 
2.4.7 were provided by Kristina Dzeyk. 
Protein samples (around 1 mg/ml) were acidified using 1% formic acid solution 
and transferred into vials prior to LC-MS analysis. Desalting and protein 
separation were carried out using an Acquity Ultra Performance Liquid 
Chromatography (UPLC) system (Waters) fitted with a C4 column (2.1 mm x 15 
cm, 5 μm particle size). The column was maintained at a constant temperature 
(40°C) throughout. The outlet of the column was coupled directly to a Q-Toff II 
mass spectrometer (Waters) using the standard electrospray ionization (ESI) in 
positive ion mode. Solvent A was water, 0.1% formic acid, and solvent B was 
acetonitrile with 0.1% formic acid. The samples (between 1-20 μl) were loaded 
onto the column and desalted for 5 min at a flow rate of 0.2 ml/min, 4% B. The 
proteins were eluted from a column with a constant flow of 0.2 ml/min. During 
the elution step, the percentage of solvent B increased in linear fashion from 5 
to 25% in 1 min, and then increased to 80% in the further 11 min. On the Q-
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Toff, a spray voltage of 3.5 kV was applied, with a cone voltage of 35 V and 
extraction cone at 10 V. Collision energy of 8 eV was used, with argon in the 
collision cell. The desolvation temperature was set to 320°C, with a source 
temperature of 120°C. Data were acquired in continuum mode, over a mass 
range 500-3500 m/z, with a scan time of 0.5 and interscan delay of 0.1 s. Data 
were externally calibrated against a reference standard of intact myoglobin, 
acquired immediately after sample data acquisition. Spectra across the protein 
chromatographic peak(s) were summed and intact mass was calculated using 
the MaxEnt1 maximum entropy algorithm (Waters/Micromass) to give the zero 
charge deconvolution molecular weight. 
2.1.16 Circular dichroism (CD) measurements 
CD measurements were done with assistance of Prof. Vladimir Rybin 
(Biophysical support, Protein Expression and Purification Core Facility, EMBL 
Heidelberg, Germany) as described in McParland, Varsano et al., 2011. In 
brief, the samples were dialysed into 20 mM Tris-HCl (pH 7.4), 50 mM NaCl 
and 1 mM DTT or β-mercaptoethanol. Protein concentration was measured on 
a NanoDrop 1000 Spectrophotometer, before and after dialysis, and 
occasionally also verified by SDS-PAGE. In general, at least 0.5 ml of the 
sample, with minimal protein concentration of 0.2 mg/ml, was needed. The 
spectra were recorded on Jasco J-715 spectropolarimeter. The instrument was 
purged with nitrogen for at least 15 min before the measurements. The spectra 
were acquired across far-UV range (200-250 nm) (value for each wavelength 
represented an average of three scans). The spectra were measured at 20°C 
with a path length of 0.1 cm. The scan speed was 10 nm/min. As a control, a 
sample without the protein (blank) was also measured to check for background 
absorption. The data were analysed by using GraphPad 5.0 software. 
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2.2 Materials and methods for Chapter 3.1 
 
2.2.1 Engineering of PRL-3: D72A, I141Y, N142Y, N142A and Q145Y 
The mutants of PRL-3 were generated by one-step SDM procedure with 
Phusion DNA Polymerase and were verified by DNA sequencing (PCR-based 
SDM is used to change the nucleotides encoding a particular amino acid in the 
native protein in such a way that this amino acid gets replaced with the amino 
acid of choice). The primers used are listed below in sense and antisense 
order. Vector pET15b/wtPRL-3 was used as a template to generate the D72A 
mutant of PRL-3 by using the following set of primers: 5’-
CGTTTGACGCTGGGGCGCC-3’ and 5’-GGCGCCCCAGCGTCAAACG-3’. To 
obtain I141Y, N142Y, N142A and Q145Y, pET15b/PRL-3 ΔCAAX was used as 
a template. The following pairs of primers were used: I141Y, 5’-
CGCGGAGCCTACAACAGCAAGC-3’ and 5’-
GCTTGCTGTTGTAGGCTCCGCG-3’; N142Y, 5’-
GGAGCCATCTACAGCAAGCAGC-3’ and 5’-
GCTGCTTGCTGTAGATGGCTCC-3’; N142A, 5’-
GGAGCCATCGCCAGCAAGCAGC-3’ and 5’-
GCTGCTTGCTGGCGATGGCTCC-3’ and Q145, 5’-
AACAGCAAGTACCTCACCTAC-3’ and 5’-GTAGGTGAGGTACTTGCTGTT-3’. 
Plasmid map for vector pET15b is shown in Figure 13 and the summary of the 
vectors used is given in Figure 19.       
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Figure 13: Plasmid map for the pET15b vector. The plasmid was originally 
from Novagen and is about 5.7 kDa in size. The plasmids encoding full length 
human PRL-3 protein and the variant with the deleted residues of the C-
terminal CAAX-box were generated previously in the lab. The proteins were 
expressed with the thrombin-cleavable 6His-tag at the N-terminal end. 
Sequence recognisable by thrombin (LeuValProArg↓GlySer, with the arrow 
indicating cleavage point) was separated by three amino acids from the 6His-
tag (SerSerGly), which was preceeded by four amino acids (MetGlySerSer). 
The sequences encoding all PRL-3 variants were inserted into NdeI-XhoI 
restriction sites of the vector and in all the cases the 6His-tag was not removed 
by thrombin cleavage.  
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2.2.2 Large-scale bacterial expression of the PRL-3 variants from 2.2.1 
All the variants of PRL-3 were cloned in pET15b plasmid, which expresses 
proteins of interest as His6-tagged fusion proteins. Typically, 0.4-1 l of LB 
medium was used for large-scale expression. The medium was supplemented 
with Amp at 100 μg/ml final concentration. After inoculating the medium with 
the overnight culture of the BL21 DE3 E. coli strain, the cultures were incubated 
at 37°C and 160-200 rpm until optical density measured at 600 nm (OD600) 
reached 0.6-0.9. Protein expression was induced with 0.1 mM IPTG for 3 h at 
37°C; the cells were harvested and the pellets stored at -20°C until purification.  
2.2.3 Large-scale purification of the PRL-3 variants from 2.2.2 
The pellet was resuspended in an appropriate volume of  lysis buffer A 
containing 50 mM Tris-HCl (pH 7.4), 500 mM NaCl, 20 mM imidazole, 4 mM 
DTT and PIC (1 x). The cells were lysed by sonication at 4°C (20 rounds of 20 
pulses). The lysate was cleared by centrifugation at 4°C and 18,000 g for at 
least 30 min. The cleared lysate was applied to a HisTrap HP column 
equilibrated in buffer A, by using a peristaltic pump at a flow-rate of around 1 
ml/min. The column was washed with buffer B (the same composition as for 
buffer A, but without PIC). The protein was eluted with gradient of imidazole 
from 20 mM to 500 mM, by using an Åktapurifier. Purified His6-tagged proteins 
were dialysed against 50 mM Tris-HCl (pH 7.4), 500 mM NaCl and 4 mM DTT.  
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2.2.4 Characterisation of the catalytic activity for PRL-3: I141Y, N142Y, 
N142A and Q145Y 
Preliminary assessments of the catalytic activity for the PRL-3 variants with 
OMFP and PI(3,4,5)P3 were done as described in McParland, Varsano et al., 
2011. The final volume of the assay reaction was 100 μl. The assays were 
performed in 96-well plate format in a microplate reader Tecan Saphire 2. The 
assays conducted without the addition of enzyme (blank) were included. A 
single triplicate set was measured for each sample. In both assays, wtPRL-3 
was used as a comparison for the activity of the mutants. In addition to the 
wtPRL-3, PTP1B was used as a positive control with I141Y, N142Y, N142A 
and Q145Y mutants of PRL-3 in OMFP assay. Absorbance (A) over time was 
plotted by using GraphPad 5.0 software. The values obtained for the triplicate 
for every sample tested were plotted with the values obtained for the 
corresponding blank. The data was shown as end-point measurement, plotting 
absorbance values at the end of the assay. 
For OMFP assay, the reaction was monitored as an increase in absorbance at 
450 nm, over time (2 hours). All PRL-3 variants were assayed at 6 μM 
concentration and the concentration of OMFP used was 600 μM. Assays were 
performed at 37°C in 40 mM Tris-HCl (pH 6.2), 150 mM NaCl and 4 mM DTT; 
assay conditions had been optimised in the lab previously (McParland, Varsano 
et al., 2011). 
For assay with PI(3,4,5)P3, commercially available EnzCheck phosphatase 
assay kit was used. The reaction was monitored by measuring absorbance at 
360 nm, over time (2 hours). All PRL-3 variants were assayed at 6 μM 
concentration and the concentration of PI(3,4,5)P3 used was 100 μM. Assays 
were performed at 37°C in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
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MgCl2 and 4 mM DTT; assay conditions had been optimised in the lab 
previously (McParland, Varsano et al., 2011). The assay kit contains 20 x buffer 
(the composition is listed above), the substrate 2-amino-6-mercapto-7-methyl-
purine riboside (MESG) and purine nucleoside phosphorylase (PNP). MESG is 
converted by PNP to ribose-1 phosphate and 2-amino-6-mercapto-7-methyl-
purine ribose in the presence of a free phosphate (released in the enzymatic 
reaction), with the accompanying change in the absorption at 360 nm (shown in 
Figure 14). 
 
 
 
Figure 14: Principle of EnzCheck phosphatase assay kit. The scheme was 
adapted from the product datasheet provided by the manufacturer and the 
structures were generated using ChemBioDraw. 
 138 
2.2.5 Generating the PRL-3 variants for small-scale optimisation of 
conditions for expression with an unnatural amino acid: wtPRL-3, 
D72TAG, I141TAG, N142TAG 
pTXB3-His6 plasmid (map shown in Figure 15) was obtained from the 
laboratory of Dr. E. Lemke. It expresses protein of interest as a C-terminal 
intein-His6-tagged fusion protein. Phusion DNA Polymerase was used for PCR 
amplifications. To generate pTXB3-His6/wtPRL-3, wtPRL-3 was cloned into 
NcoI-SapI sites of pTXB3-His6 plasmid by using pTE15b/wtPRL-3 as a 
template and the following pair of primers: 5’-
GTTGTTCCATGGCTCGGATGAACCGCC-3’ and 5’-
GGTTGGTTGCTCTTCCGCACATAACGCAGCACCGGGTC-3’. Digestion of 
the PCR product was conducted with NcoI/SapI enzymes in NEB4 buffer. For 
wtPRL-3, PCR sample (10 μl) was first digested with NcoI (1 μl) overnight at 
37°C, followed by inactivation of the enzyme for 20 min at 65°C. Next, digestion 
with SapI (2.5 μl) was conducted for at least 1 h at 37°C, followed by 
inactivation as above, prior to purification from the agarose gel using 
commercially available kits. Digestion of pTXB3-His6 was conducted as 
described above. 
D72TAG, I141TAG and N142TAG were obtained by using pTXB3-His6/wtPRL-
3 as a template and the following pairs of sense and antisense primers: 72, 5’-
GCCGTTTGACTAGGGGGCGCC-3’ and 5’-GGCGCCCCCTAGTCAAACGGC-
3’; 141, 5’-CGCGGAGCCTAGAACAGCAAGC-3’ and 5’-
GCTTGCTGTTCTAGGCTCCGCG-3’ and 142, 5’-
GGAGCCATCTAGAGCAAGCAGC-3’ and 5’-
GCTGCTTGCTCTAGATGGCTCC-3. The summary of the vectors used is 
given in Figure 19.  
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Figure 15: Plasmid map for the pTXB3 vector. The plasmid is commercially 
available from Life Technologies (former Invitrogen). The plasmid was obtained 
from the laboratory of Edward Lemke, and it had been modified so that the 
protein of interest is expressed with the 6His-tag at the C-terminal end instead 
of the chitin-binding domain. The sequences encoding all PRL-3 and VHR 
variants were inserted into NcoI-SapI restriction sites of the vector.  
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2.2.6 Optimising expression and purification conditions with wtPRL-3 on 
a small scale  
Plasmid pTXB3/His6-wtPRL-3 was transformed by electroporation into BL21 AI 
and RIL strains of E. coli and into chemically competent BL21 DE3 strain. 
For small-scale test-expression experiments, 50 ml of LB or TB medium was 
used, supplemented with the appropriate antibiotics at the following final 
concentrations: Amp 50 μg/ml, Cm 33 μg/ml and Tet 2.5 μg/ml. After 
inoculating GM with the overnight culture, the cultures were incubated at 37°C 
and 160-200 rpm until OD600 reached 0.6-0.8. Protein expression was induced 
with 1 mM IPTG and/or 0.02% (w/v) L-(+)-Arabinose (from 20% (w/v) stock) for 
4 h at 37°C and for 6 h at 25°C; the cells were harvested and the pellets stored 
at -20°C until purification. The non-induced control samples were incubated for 
4 h at 37°C. 
Purification under native and denaturing conditions was tried. 
For purification under native conditions, lysis buffer A contained 50 mM Tris-
HCl (pH 7.4), 0.5 M NaCl, 5 mM imidazole, 0.2 mM tris (2-carboxyethyl) 
phosphine (TCEP) and PIC (1 x final concentration). For purification under 
denaturing conditions, the lysis buffer contained PBS, 4 M urea, 0.25 M NaCl, 5 
mM imidazole, 0.2 mM TCEP and PIC, with pH value of 8.5. For both 
conditions, the imidazole concentration in washing and eluting buffer was 10 
and 300 mM, respectively. 
The pellet was resuspended in 1 ml of the lysis buffer A and transferred into an 
Eppendorf tube. The cells were lysed by sonication at 4°C (1 round of 30 
pulses). The lysate was cleared by centrifugation at 4°C and 13,200 rpm for 45 
min. 
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The cleared lysate was incubated with His-Select Nickel Affinity Gel; about 100-
150 μl of the beads were used for each 1 ml sample of the cleared lysate. The 
beads were prepared by transferring the appropriate volume into a 15 ml tube 
and first rinsing in ddH2O, and then in washing buffer B. The lysate was 
allowed to incubate with the beads for 1-2 h on a roller at 4°C. 
Ni-NTA Superflow and polypropylene columns were used for purification. 
Before applying the sample, they were first rinsed with one bed volume of 
ddH2O, and then with washing buffer B. After applying the lysate, the beads 
were rinsed with one bed-volume of buffer B. The bound material was eluted by 
applying 300 μl of eluting buffer C. For analysis by SDS-PAGE, 30 μl of each 
sample was withdrawn. For intein cleavage, β-mercaptoethanol was added to 
the remaining samples to reach 50 mM final concentration and left to incubate 
at 37°C for at least 16 h, with moderate agitation.  
2.2.7 Small-scale test-expression with pACF 
For small-scale test-expression experiments with the unnatural amino acids, 50 
ml of TB-FB medium was used, supplemented with the antibiotics like in 2.2.6.  
After inoculating the TB-FB medium with the overnight culture of the BL21 AI 
strain, the cultures were incubated at 37°C and 160-200 rpm until OD600 
reached about 0.4-0.5. Then, pACF (structure shown in Figure 16) was added 
from the stock prepared by dissolving an appropriate amount of the amino acid 
in ddH2O; the stock concentration was usually 10 x. pACF was added about 20 
min before induction; protein expression was induced for 5-6 h at 25°C by 
adding 1 mM IPTG and 0.02% (w/v) L-(+)-Arabinose (from 20% (w/v) stock).  
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Figure 16: Chemical structure of pACF. The strcuture was generated by using 
ChemBioDraw. 
 
2.2.8 Small-scale test-expression with pBPA 
pBPA was added either after inoculating the TB-FB medium with the overnight 
culture of the BL21 AI strain or about 20 min before induction; pBPA was 
prepared by dissolving an appropriate amount in the small volume of 2 M 
NaOH to reach the desired final concentration of the amino acid, and then 
filtering it into the medium. The pH value of the medium remained 7-8. The 
flasks were kept protected from a direct light exposure throughout. The cultures 
were incubated at 37°C and 160-200 rpm until OD600 reached 0.6-0.9. Protein 
expression was induced with 1 mM IPTG and 0.02% (w/v) L-(+)-Arabinose 
(from 20% (w/v) stock) for 6 h at 25°C and then overnight at 18°C. 
2.2.9 Generating pETM20/6His-3Flag-D72TAG, I141TAG and N142TAG 
pETM20/D72TAG was obtained by using pCMV-3Flag-1A/D72TAG as DNA 
template and Phusion DNA Polymerase to amplify PRL-3-encoding region with 
the same set of primers containing sites for NcoI/XhoI enzymes like above for 
wtPRL-3. Plasmid maps for pCMV-3Flag and pETM20 vectors are given in 
Figures 17 and 18, respectively. PCR was digested with regular NcoI/XhoI 
enzymes in 2 x Tango buffer for 3 h at rt.  
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Figure 17: Plasmid map for the pCMV-3Flag-1A vector. The plasmid was 
originally from Agilent Technologies, but was already available in the lab. The 
plasmid is about 4.2 kDa in size. It expresses a protein with a triple Flag-tag 
fused onto the N-terminal end. The plasmids encoding all full length human 
PRL-3 and VHR variants were inserted into the BamHI-EcoRI restriction sites 
of the vector.  
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Figure 18: Plasmid map for the pETM20 vector. The plasmid was originally 
from Protein Expression and Purification Core Facility (EMBL Heidelberg). The 
plasmid is about 6.1 kDa in size. The initial 123 amino acid, including 111 
residues of the Trx chaperone domain, are separated by five amino acids from 
the following His-tag. Recognition site for the Tobacco Etch Virus (TEV) 
(GluAsnLeuTyrPheGln↓Gly, with the arrow indicating the cleavage point) is 
separated by a three-residue-linker (SerSerGly) from the 6His-tag. The 
plasmids encoding all full length human PRL-3 and VHR variants were inserted 
into the NcoI-XhoI restriction sites of the vector. The proteins were expressed 
with the cleavable 6His-tag fused at the N-terminal end, and the 6His-tag was 
regularly removed by GST-TEV protease.  
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pCMV-3Flag-1A/D72TAG was generated by using pTXB3-His6/D72TAG as 
DNA template, with Phusion DNA Polymerase and the following pair of primers 
with recognition sites for BamHI/EcoRI restriction enzymes: 5’-
CGGGATCCATGGCTCGGATGAACCGCC-3’ and 5’-
CCGCCGGAATTCTCACATAACGCAGCACCGGG-3’. PCR (30 μl) was 
digested with regular BamHI/EcoRI enzymes (0.5 μl each) at 37°C overnight.  
The same set of primers was used to generate pCMV-3Flag-1A/I141 (or N142) 
TAG. 
For the I141 and N142 mutants (in pCMV-3Flag-1A vector), the second NcoI 
site (detected between the Flag3-tag and the initial amino acid) was annulled 
after two rounds of SDM. In the first round, the following pair of primers was 
used: 5’-GCGGGATCTATGGCTCGGATGAACCGCC-3’ and 5’-
GAGCCATAGATCCCGCCCGGGCTTTATC-3’. The positive constructs from 
the first round of SDM were used as DNA template in the second round, with 
QCL-SDM and the following pair of primers: 5’-
GCGGGAAGTATGGCTCGGATGAACCGCC-3’ and 5’-
GAGCCATACTTCCCGCCCGGGCTTTATC-3’. Positive samples are hereafter 
referred to as pCMV-3Flag-1A/I141 (or N142) TAG_QCL-SDM. The positive 
samples were used as a template to amplify PRL-3-encoding region by using 
the following set of primers containing sites for NcoI/XhoI enzymes: 5’- 
AATTAACCCTCACTAAAGGG-3’ and 5’- 
CCGCCGCTCGAGTCACATAACGCAGCACCGGG-3’. PCR products were 
digested with FD NcoI/XhoI and 2 x Tango buffer for 3 h at rt. The summary of 
the primers used is given in Figure 19.         
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Figure 19: Summary of the primers used for generating PRL-3 variants 
expressed in pET15b, pTXB3-intein-6His and pETM20 vectors. The list refers 
to sections 2.2.1, 2.2.5 and 2.2.9. The sequences subjected to modifications 
through SDM are indicated in red. For primers introducing recognition site for 
restriction enzymes, the recognition site is indicated by an arrow. In the 
comments column, “F.” indicates forward and “R.” reverse set of primers.  
 
2.2.10 Generating VHR variants for small-scale optimisation of conditions 
for expression with an unnatural amino acid: wtVHR, L25TAG, F68TAG, 
D92TAG, N163TAG, C124S F68TAG, C124S G161TAG 
Vectors pGEX4T1 encoding human wtVHR and its catalytically inactive mutant 
C124S as the N-terminal GST-fusion proteins were generously provided by Dr. 
R. Pulido. The pairs of primers in the sections below are listed sense and 
antisense, respectively.  
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Phusion DNA Polymerase was used to exchange Phe68 for the amber STOP 
codon, TAG, by using pTXB3-His6/wtVHR as the DNA template, and the 
following pair of primers: 5’-
CAGGTCCTAGATGCACGTCAACACCAATGCCAAC-3’ and 5’-
GTGCATCTAGGACCTGCCCTCAGCC-3’. 
The following pair of primers was used to substitute Asp92 for the amber STOP 
codon by using pTXB3-His6/wtVHR and Phusion DNA Polymerase: 5’-
GCCAACTAGACACAGGAGTTCAACCTGAGCG-3’ and 5’-
CTGTGTCTAGTTGGCCTTGATGCCCAGG-3’. 
N163TAG mutant was generated from pTXB3-His6/wtVHR as the template by 
using Phusion DNA Polymerase and the following pair of primers: 5’-
GGCCCCTAG GATGGCTTCCTGGCCCAG-3’ and 5’-
GCCATCCTAGGGGCCGATCTCACGGTTC-3’; pTXB3-His6/wtVHR was 
obtained from pTXB3-His6/L25TAG by using the following pair of primers: 5’-
GCTACAGCCTTCCGAGCCAGC-3’ and 5’-GCTGGCTCGGAAGGCTGTAGC-
3’. To generate pTXB3-His6/L25TAG, VHR L25TAG was cloned into NcoI-SapI 
sites of pTXB3-His6 vector by using the following pair of primers: 5’-
GTTGTTCCATGTCGGGCTCGTTCGAGC-3’ and 5’-
GGTTGGTTGCTCTTCCGCAGGGTTTCAACTTCCCCTCCT-3’; amplification 
was conducted using Dream Taq Green PCR Master Mix. VHR mutant with 
Leu25 exchanged for the amber STOP codon was obtained from 
pGEX4T1/wtVHR by using Phusion DNA Polymerase and the following pair of 
primers: 5’-GCTACAGCTAGCCGAGCCAGC-3’ and 5’-
GCTGGCTCGGCTAGCTGTAGC-3’.  
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The C124S G161TAG mutant was generated from pGEX4T1/C124S by using 
Ampli Taq Gold 360 DNA Polymerase and the following pair of primers: 5’-
CCGTGAGATCTAGCCCAACGATG-3’ and 5’-
CATCGTTGGGCTAGATCTCACGG-3’. Figure 15 shows the plasmid map for 
pTXB3 vector and all primers used are summarised in Figure 20.       
Cloning the VHR variants in pTXB3-His6 vector by using NcoI-SapI restriction 
sites was extremely laborious and subject to constant optimisation. Regular 
SapI and FD SapI (LguI) were tried, and also regular and HF NcoI, and FD 
NcoI. The protocols which worked are outlined: (i) Digestion of pTXB3-His6 
vector by using NcoI-SapI enzymes was conducted by incubating an 
appropriate amount of vector (4 μg) diluted in NEB4 buffer at 1 x final 
concentration and supplemented with 10% (v/v) BSA first with SapI (2 μl) for 2 
h at 37°C, followed by heat-inactivation for 20 min at 65°C; the volume of the 
digestion mix was 50 μL. The sample was purified by using PCR Purification Kit 
(Life Technologies). In the final step, 35 μL of 2.5 mM Tris pH 7.9 preheated to 
65°C was used to elute DNA. The second digestion step was conducted 
according to the outline described above, but with HF NcoI (2 μl). (ii) In a total 
volume of the digestion mix set to 20 μL, 1 μg of pTXB3-His6 vector was 
incubated with FD SapI (LguI) (1 μl) for 30 min at 37°C, then heat-inactivated 
for 5 min at 65°C before adding FD NcoI (1 μl) for 30 min at 37°C, which was 
heat-inactivated for 15 min at 65°C before purifying from the agarose gel. 
The digestion of the PCR products with introduced cleavage sites for NcoI-SapI 
was performed in a similar way; regular NcoI and SapI enzymes were used, 
and also prolonged incubation times were allowed. 
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2.2.11 Generating the VHR variants for large-scale bacterial over-
expression: wtVHR, C124S, F68TAG and D92TAG 
Plasmid vector pETM20 was used to over-express recombinant human wtVHR 
and all its variants as N-terminal Flag3-tagged fusion proteins. The mutant 
VHRs were generated by one-step SDM procedure and were verified by DNA 
sequencing.  
The following pair of primers with introduced cleavage sites for BamHI-EcoRI 
restriction enzymes was used to amplify the fragments encoding wtVHR, 
D92TAG (both from pTXB3-His6), F68TAG and C124S (both from pGEX4T1) 
by using Phusion DNA polymerase: 5’-
GTTGTTGGATCCATGTCGGGCTCGTTCGAGC-3’ and 5’-
CGGAATTCTCAGGGTTTCAACTTCCCCTC-3’. Then, the PCR fragments 
were cloned into BamHI-EcoRI sites of pCMV-3Flag-1A vector, thus generating 
VHRs with the N-terminal Flag3-tag. The following pair of primers with 
introduced cleavage sites for NcoI-XhoI enzymes was used to amplify the 
fragments encoding wtVHR, C124S, F68TAG and D92TAG with the N-terminal 
Flag3-tag by using Phire Hot Start II DNA Polymerase: 5’- 
AATTAACCCTCACTAAAGGG-3’ and 5’-
CCGCCGCTCGAGTCAGGGTTTCAACTTCCCCTC-3’. Next, the PCR 
fragments were cloned into NcoI-XhoI sites of pETM20 vector. Figure 18 shows 
the plasmid map for pETM20 vector and all primers used are summarised in 
Figure 20. Digestion of the PCR products was conducted with FD BamHI and 
EcoRI enzymes in FD Green Buffer at 1 x final concentration for at least 1 h at 
37°C. For the C124S mutant of VHR, digestion with FD BamHI-EcoRI was 
conducted with Tango Buffer at 1 x final concentration. Digestion of the PCR 
products with FD NcoI and XhoI enzymes was done in Tango Buffer at 2 x final 
 150 
concentration for about 1 h at 37°C. Plasmids pCMV-3Flag-1A and pETM20 
were digested using FD BamHI-EcoRI and NcoI-XhoI, respectively, in FD 
Green Buffer diluted to 1 x final concentration, at 37°C. Regularly, the amounts 
of the insert-free plasmid and the PCR products set for digestion were 200 ng 
and 1 μg, respectively, for which 1 μl of each of the FD enzymes was used. 
Minimal duration of digestion was 15 min at 37°C. 
Figure 20: Summary of the primers used for generating VHR variants 
expressed in pTXB3-intein-6His and pETM20 vectors. The list refers to 
sections 2.2.10 and 2.2.11. The sequencess subjected to modifications through 
SDM are indicated in red. For primers introducing recognition site for restriction 
enzymes, the recognition site is indicated by an arrow. In the comments 
column, “F.” indicates forward and “R.” reverse set of primers.  
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2.2.12 Large-scale bacterial expression of recombinant VHRs from 2.2.11 
Typically, 0.5-1 l of TB-FB medium was used for large-scale expression of VHR 
variants. The general outline was as described in section 2.2.8. Expression of 
the D92pBPA mutant was induced at 20°C, for the same total time. 
For expression of the wtVHR and its C124S variant, TB-FB medium was 
supplemented with Amp at 50 μg/ml. Protein expression was induced with 1 
mM IPTG for 4 h at 37°C. 
2.2.13 Large-scale purification of recombinant VHRs from 2.2.12 
The pellet (for wtVHR and F68pBPA) was resuspended in an appropriate 
volume of the lysis buffer A containing 50 mM Tris-HCl (pH 7.4), 500 mM NaCl, 
10 mM imidazole, 2 mM DTT and PIC (1 x). The cells were lysed by sonication 
at 4°C (20 rounds of 30 pulses). The lysate was cleared by centrifugation at 
4°C and 12,300 rpm for at least 30 min. The cleared lysate was applied to a 
HisTrap HP column equilibrated in buffer A, by using a peristaltic pump at a 
flow-rate of around 1 ml/min. The column was washed with buffer B (the same 
composition as for buffer A, but without PIC). The protein was eluted with 100% 
buffer C containing 500 mM imidazole by using an Åktapurifier. Purified His6-
TEV-Flag3-VHR proteins were dialysed against 50 mM Tris-HCl (pH 7.4), 500 
mM NaCl and 0.1% (v/v) β-mercaptoethanol. The remaining VHR variants were 
purified by using the following buffers: buffer A containing 50 mM Na2HPO4 (pH 
6.4), 200 mM NaCl, 10 mM imidazole, 2 mM DTT and PIC (1 x) and were finally 
dialysed as above. 
The N-terminal His6-tag was removed by adding GST-TEV protease as 
described in section 2.1.14 and by incubating at 4°C for at least 24 h.  
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2.3 Materials and methods for Chapter 3.2 
 
2.3.1 Generating the VHR variants for large-scale bacterial over-
expression: F68A, F68D, F68W, F68C, M69A and D92A  
Plasmid vector pETM20 was used to over-express all the VHR variants as N-
terminal Flag3-tagged fusion proteins. The mutant VHRs were generated by 
one-step SDM procedure and were verified by DNA sequencing.  
The D92A mutant was obtained by using pETM20/wtVHR as the DNA template 
and the following primers: 5’-GCCAACGCCACACAGGAGTTCAACCTCAG-3’ 
and 5’-CTGTGTGGCGTTGGCCTTGATGCCCAGG-3’, and by using Phusion 
DNA polymerase. Substitution of Phe68 with alanine, aspartate, tryptophan or 
cysteine, and substitution of Met69 with alanine was conducted by using QCL-
SDM kit, employing pETM20/3Flag-wtVHR as the DNA template and the 
following pairs of the forward and reverse oligonucleotide primers: F68A, 5’-
GCAGGTCCGCCATGCACGTCAACACCAATGC-3’ and 5’-
CGTGCATGGCGGACCTGCCCTCAGCCG-3’; F68D, 5’-
GCAGGTCCGACATGCACGTCAACACCAATGC-3’ and 5’-
CGTGCATGTCGGACCTGCCCTCAGCCG-3’; F68W, 5’-
GCAGGTCCTGGATGCACGTCAACACCAATGC-3’ and 5’-
CGTGCATCCAGGACCTGCCCTCAGCCG-3’; F68C, 5’-
GCAGGTCCTGCATGCACGTCAACACCAATGC-3’ and 5’-
CGTGCATGCAGGACCTGCCCTCAGCCG-3’; M69A, 5’-
GGTCCTTCGCGCACGTCAACACCAATGCCAAC-3’ and 5’-
GACGTGCGCGAAGGACCTGCCCTCAGC-3’. The summary of the vectors 
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used is given in Figure 20. Digestion of PCR products was conducted as 
described in section 2.2.11. 
2.3.2 Large-scale bacterial expression of recombinant VHRs from 2.3.1 
Typically, 0.5-1 l of TB-FB medium was used for large-scale expression of VHR 
variants. The general outline was as described in section 2.2.8. For expression 
of the VHR variants F68A, F68D, F68W, F68C, M69A and D92A, TB-FB 
medium was supplemented with Amp at 50 μg/ml. Protein expression was 
induced with 1 mM IPTG for 4 h at 37°C. 
2.3.3 Large-scale purification of recombinant VHRs from 2.3.2 
The general outline was as described in section 2.2.13. The following buffers 
were used: buffer A containing 50 mM Na2HPO4 (pH 6.4), 200 mM NaCl, 10 
mM imidazole, 2 mM DTT and PIC (1 x). Purified proteins were finally dialysed 
exactly as described in section 2.2.13. The N-terminal His6-tag was removed by 
adding GST-TEV protease as described in 2.1.14 and by incubating at 4°C for 
at least 24 h.  
2.3.4 Phosphatase activity measurements against pNPP 
Measurements of the catalytic activity for all the VHR variants generated were 
performed by Pablo Rios according to the procedure below. 
Catalytic activity measurements of the wtVHR and its variants were conducted 
with pNPP. The reaction was monitored as an increase in absorbance at 405 
nm, over time. All the VHR variants were assayed at 500 nM concentration and 
the concentrations of pNPP used were 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 80 and 
100 mM. Assays were performed at 37°C in 25 mM HEPES (pH 7.5), 124.5 
mM NaCl, 2.5 mM EDTA and 2 mM DTT, in a final volume of 100 μl in 96-well 
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plate format, in a microplate reader Tecan Saphire 2. The reactions were 
initiated by adding 10 μl pNPP, with a multichannel pipette, at the final 
concentrations indicated above. For every substrate concentration tested, 
assays conducted without the addition of enzyme (blank) were included. All 
assays were conducted in triplicate. The minimum of two triplicate sets were 
conducted for each sample. The mean of the triplicate was subtracted to the 
mean of its corresponding blank, for every substrate concentration tested. The 
linear range of every graph, plotted as absorbance over time, was defined in 
order to calculate the slope values, which were further transformed to picomol 
(pmol) of product per minute. The data was fitted to the Michaelis-Menten 
equation to determine the Km value by using the GraphPad 5.0 software. The 
kcat values were determined manually by dividing the Vmax value by the enzyme 
concentration.  
In the regular activity assays, pNPP was used at 10 mM final concentration and 
VHR variants at 0.5 mM. The general conditions applied were as described 
above. Absorbance over time was plotted by using GraphPad 5.0 software. The 
data was shown as end-point measurement, for the time-point indicated. 
For assessing catalytic activity of the monomeric form of F68pBPA isolated by 
size-exclusion chromatography after UV-cross-linking, 0.5 μM of the protein 
was incubated with 10 mM pNPP, as described above. wtVHR was included as 
a control. Three triplicates were conducted for each sample.  
The GraphPad 5.0 software was also used to perform the statystical analysis. A 
Student’s upaired t-test was used to calculate the statystical significance and 
the asteriscs indicate ***p<0.001. 
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2.3.5 Photo-cross-linking of recombinant VHR with 345 nm light 
Photo-cross-linking experiments with purified recombinant VHRs (in vitro) or 
with PRL-3s (with cell lysate from HEK293 cells) were performed in the 
following setups: (a) 96-well plate (Costar UV plates with UV transparent flat 
bottom from Corning), (b) multidish 24-well or (c) 35 x 10 mm cell culture dish 
(both Nunc dishes from Thermo Fisher Scientific), as specified in the 
appropraite chapters in the Results and discussion section. 
(a) For in vitro cross-linking, the proteins were diluted in a buffer containing 50 
mM Tris-HCl (pH 7.4) and 150 mM NaCl to reach an appropriate protein 
concentration. The final reaction volume was 50 μl. The samples were kept on 
ice during 30 min exposure to 345 nm light. The irradiation was conducted at a 
distance of around 40 cm from the lamp.  
PS was prepared according to the manufacturer’s instruction and was diluted to 
a final 1 x concentration. The samples were allowed to incubate with PS on ice 
for 15 min prior to starting irradiation. PS is a broad-range phosphatase 
inhibitor. Its composition is not made available, but the tablet was handled 
according to the datasheet available from the manufacturer, according to which 
one tablet dissolved in 1 ml of H2O represents 10 x stock. 
In all experiments, the non-irradiated control samples were kept on ice. 
Immediately after termination of 345 nm light exposure, the samples were 
recovered (40 μl) into a clean Eppendorf tube. An aliquot of each sample was 
withdrawn, mixed with reducing 2 x SDS-PAGE sample buffer and heated at 
95°C for 5 min. Equal amounts of proteins (250 ng) were resolved by reducing 
4-12% SDS-PAGE and analysed by Western blot (anti-VHR). 
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 (b) In an attempt to discover the identity of the cross-linked peptides (after 
photo-induced cross-linking of F68pBPA variant of VHR), a sample containing 
F68pBPA variant of VHR was concentrated to 150 μl and 2.33 mg/ml. The 
sample was then subjected to 345 nm light for 30 min, as described in (a) 
above. After irradiation, 130 μl of the sample was recovered and diluted to 0.7 
mg/ml with a buffer containing 50 mM Tris-HCl (pH 7.4), 500 mM NaCl and 
0.1% (v/v) β-mercaptoethanol. An aliquot of the sample was mixed with 
reducing 6 x SDS-PAGE sample buffer and 17.5 μg of protein was resolved by 
reducing 4-12% SDS-PAGE and allowed to stain by colloidal Coomassie Blue 
G-250 stain prior to excising the bands of interest (see section 2.3.10).  
2.3.6 Cross-linking with glutaraldehyde  
Glutaraldehyde was prepared at 0.05% (v/v) in 20 mM HEPES pH 7.4-7.5. 
Proteins were first prepared at 500 μg/ml by diluting from the stocks into 
dialysis buffer containing 50 mM Tris-HCl (pH 7.4), 500 mM NaCl and 0.1% 
(v/v) β-mercaptoethanol. Next, the appropriate protein concentrations (50-250 
μg/ml) were achieved by diluting in the buffer containing glutaraldehyde so that 
to have the final 0.025% (v/v) concentration of glutaraldehyde. The final 
reaction volume was 50 μl. Cross-linking was performed at 37°C for 30 min. 
The reaction was quenched by adding 2.5 μl of 1 M Tris-HCl pH 7.5 and by 
incubating on ice for 5 min. Next, 250 ng of proteins were resolved by SDS-
PAGE and further analysed by Western blotting (anti-VHR). The control 
samples were prepared by diluting the stocks in 20 mM HEPES pH 7.4-7.5 and 
were kept on ice for the duration of the cross-linking termination step. 
As for the choice of the chemical cross-linking reagents, glutaraldehyde is a 
dialdehyde with five carbon atoms spanning chain-length shown to have the 
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highest cross-linking reactivity, when compared to formaldehyde or other 
dialdehydes with up to six carbon atoms in the chain (Migneault et al., 2004). 
Furthermore, complexes generated by glutaraldehyde are seemingly more 
thermostable, unlike formaldehyde-generated cross-linking products, which can 
be reversed if subjected to incubation temperatures above 65°C (Klockenbusch 
and Kast, 2010). The spacer chain of a cross-linking reagent represents an 
important feature when it comes to setting distance limitations assessable by a 
specific cross-linker (Back et al., 2003; Leitner et al., 2010). 
2.3.7 Cross-linking with DSS 
DSS (structure shown in Figure 21) was stored at 4°C. The product was 
handled according to the manufacturer’s instructions. The cross-linker was 
always used fresh prepared. The vial was equilibrated to rt before use. An 
Eppendorf tube was flushed with argon prior to weighing the cross-linker. Next, 
DSS was dissolved in dry DMSO so that the final concentration of the cross-
linker was 25 mM. The protein samples were diluted in 20 mM HEPES pH 7.4-
7.5. DSS was added to the protein samples so that the final concentration of 
the cross-linker was 2.5 mM. The reactions were conducted on a 50 μl scale. 
The reaction mixtures were incubated at rt for 60 min. The reaction was 
quenched at rt for 15 min by adding Tris-HCl pH 7.5 from 1 M stock solution to 
a final 20 mM. The control samples were treated the same way, but without 
DSS. Next, a sample of the reaction mixture was mixed with a 2 x SDS-PAGE 
sample buffer and heated at 95°C for 5 min. For immunoblot analysis (anti-
VHR), the samples containing 250 ng of protein were resolved by SDS-PAGE.  
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Figure 21: Chemical structure of DSS. DSS is a water-insoluble homo-bi-
functional chemical cross-linking reagent. The structure was generated by 
using ChemBioDraw. 
 
 
2.3.8 Investigating dimerisation potential of the VHR variants with respect 
to oxidising conditions 
The samples were dialysed into a buffer containing 50 mT Tris-HCl (pH 7.4) 
and 500 mM NaCl, and with or without 0.1% (v/v) β-mercaptoethanol. The 
samples were mixed with 2 x SDS-PAGE sample buffer with or without the 
reducing agent. The samples with reducing agent were incubated at 95°C for 5 
min, and without it for 30 min at 37°C. The samples were analysed by SDS-
PAGE under standard or non-reducing conditions.  
2.3.9 Size-exclusion chromatography  
Flag3-F68pBPA variant of VHR was subjected to 345 nm light for 30 min by 
aliquoting it into a 96-well plate setup, with the protein concentration set to 
about 20 mg/ml (550 μl protein sample). The recovered sample (around 400 μl) 
was subjected to several rounds of centrifugation (5 min) at 4°C and 4,000 rpm 
in order to remove any precipitates, before diluting it about 15-fold and setting 
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dialysis into a fresh buffer containing 50 mM Tris-HCl (pH 7.4), 500 mM NaCl 
and 0.1% (v/v) β-mercaptoethanol in order to check protein concentration 
before  subjecting the sample to separation by size-exclusion chromatography. 
Purification was done at the Protein Expression and Purification Core Facility at 
EMBL Heidelberg. The sample was loaded at 0.5 ml/min on a 16/60 Superdex 
75 pg column, and the buffer used was 50 mM Tris-HCl (pH 7.4), 500 mM NaCl 
and 0.1% (v/v) β-mercaptoethanol. Collected fractions were concentrated (0.22 
μm Millex-GP filters), and the concentration was measured by NanoDrop 1000 
Spectrophotometer and additionally validated by SDS-PAGE. Fraction enriched 
for the dimer was subjected for full protein mass determination. Isolated 
fractions enriched for the monomeric of the protein were pulled and assayed for 
the catalytic activity against pNPP. 
2.3.10 LC-MS/MS analysis of the F68pBPA variant after exposure to 345 
nm light 
The analyses were done by Kistina Dzeyk from the Proteomics Core Facility 
(EMBL Heidelberg). Protein bands were manually excised from the gel and 
transferred to an Eppendorf tube (0.5 ml). In-gel tryptic digestion was 
performed as described previously (Rosenfeld et al., 1992). Briefly, gel bands 
were cut into cubes (1 mm x 1 mm), reduced with 10 mM DTT and alkylated 
with 55 mM iodoacetamide. Enzymatic digestion with trypsin (Promega) was 
then performed for 18 h at 37ºC.  After acidification to eliminate trypsin activity, 
peptides were extracted from the gel pieces and concentrated using a 
SpeedVac. Prior to analysis by LC-MS/MS, peptides were reconstituted in 10 
µL 0.1% (v/v) formic acid. 
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Peptides were separated using the nanoAcquity UPLC system (Waters) fitted 
with a trapping (nanoAcquity Symmetry C18, 5µm, 180 µm x 20 mm) and an 
analytical column (nanoAcquity BEH C18, 1.7 µm, 75 µm x 200 mm).  The outlet 
of the analytical column was coupled directly to an LTQ Orbitrap Velos (Thermo 
Fisher Scientific) using the Proxeon nanospray source. Solvent A was water, 
0.1% (v/v) formic acid and solvent B was acetonitrile, 0.1% (v/v) formic acid. 
The samples (5 µL) were loaded with a constant flow of solvent A at 15 µL/min 
onto the trapping column. Trapping time was 1 minute. Peptides were eluted 
via the analytical column at a constant flow of 0.3 µL/min. During the elution 
step, the percentage of solvent B increased in a linear fashion from 3% to 40% 
B in 30 min. The peptides were introduced into the mass spectrometer via a 
Pico-Tip Emitter 360 µm OD x 20 µm ID; 10 µm tip (New Objective) and a 
spray voltage of 2.1 kV was applied. The capillary temperature was set at 
300°C. Full scan MS spectra with mass range 300-1,700 m/z were acquired in 
profile mode in the FT with resolution of 30,000. The ion accumulation time was 
set at maximum of 500 ms with limitation of 106 ions. The 15 most intense ions 
from the full scan MS were subjected to collision induced dissociation in the 
LTQ as soon as the precursor intensity exceeded the threshold of 1,000 
counts. Normalized collision energy of 40% was used, and the fragmentation 
was performed after accumulation of 3 x 104 ions or after filling time of 50 ms 
for each precursor ion (whichever occurred first). MS/MS data were acquired in 
centroid mode. Charge state screening was enabled and only doubly and triply 
charged precursor ions were selected for MS/MS. The dynamic exclusion list 
was restricted to 500 entries with maximum retention period of 30 s and relative 
mass window of 7 ppm. For internal mass calibration, a lock mass correction 
using a background ion (m/z 445.12003) was applied. 
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Software Max Quant (version 1.0.13.13) was used for generating a peak list, 
which was converted to mgf format (Cox and Mann, 2008). The MS/MS spectra 
were searched against Uniprot Human database (86,940 entries), using 
MASCOT (version 2.2.07) (Matrix Science). Enzyme specificity was set to 
trypsin and a maximum of two missed cleavages.  Cleavage after arginine or 
lysine, if followed by proline, was allowed. Carbamidomethylation on cysteines 
was set as fixed modification, methionine oxidation and pBPA modification on 
phenylalanine were included as variable modifications. The search was 
performed with an initial mass tolerance of 10 ppm for the precursor ion and 0.5 
Da for the fragment spectra. Peptides with Mascot score above 20 were 
reported. 
For the analysis of intramolecular cross-linking (see also Figure 22 below), a 
sequence of VHR was created without methionine on the position 69 and 
imported in user specific database called UserDB. For the search, a new 
modification with a mass of 217.0561 Da was predefined in Mascot science 
server. The modification encloses methionine (131.041 Da) with pBPA 
modification of 104.026Da and without water (18.011Da). The raw-data 
spectrum shows peaks for the ion series denoted in the table. The colour of 
each mass value in the table represents whether an ion was matched (red) or 
not (black) to the theoretically calculated spectrum. 
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Figure 22: Analysis of UV-induced intramolecular cross-linking for the 
F68pBPA variant of VHR. After dissociation of the peptide at the amide bond, 
the C- and N- terminal fragments are formed. The N-terminal fragments are 
called “b” ions and the corresponding C-terminal fragments are called “y” ions. 
The nomenclature of the ions is originally described in Roepstorff & Fohlman, 
1984. For the analysis of intramolecular cross-linking, a sequence of VHR was 
created without methionine on the position 69 and imported in user specific 
database called UserDB. For the search, a new modification with a mass of 
217.0561 Da was predefined in Mascot science server. The modification 
encloses methionine (131.041 Da) with pBPA modification of 104.026Da and 
without water (18.011Da). The raw-data spectrum shows peaks for the ion 
series denoted in the table. The colour of each mass value in the table 
represents whether an ion was matched (red) or not (black) to the theoretically 
calculated spectrum. 
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2.3.11 Plasmids used for expression in mammalian COS-1 cells 
For transient transfection into COS-1 cells, pCMV plasmids encoding wtVHR, 
and PRL-3 ΔCAAX, all expressed as the N-terminal Flag3-tagged fusion 
proteins were used; the plasmids encoding PRL-3 ΔCAAX was generated 
previously in our laboratory by Giulia Varsano.  
Dr. Stephen Keyse (CR UK Stress Response Laboratory, Biomedical Research 
Centre, Dundee, UK) kindly provided modified pSG5 plasmid which expresses 
protein of interest as the C-terminal myc-tagged fusion protein. First, pSG5 
vector was digested with FD EcoRI-XhoI enzymes to remove the existing 
insert. The sequence encoding wtVHR was amplified from pETM20 vector (100 
ng) by using the following pair of primers introducing EcoRI and XhoI restriction 
sites at the 5’- and 3’-end, respectively, 5’-
GTTGTTGAATTCATGTCGGGCTCGTTCGAGC-3’ and 5’-
CCGCCGCTCGAGGGGTTTCAACTTCCCCTCC-3’, and by using Maxima Hot 
Start PCR Master Mix, like suggested in the product datasheet, and with the 
initial denaturation step conducted for 15 min at 95°C.  
Digestion of both pSG5/myc and PCR product encoding wtVHR with introduced 
cleavage sites for EcoRI-XhoI was performed with FD enzymes for 2 h at 37°C, 
after which they were purified from the agarose gel. pSG5/myc was then 
subjected to a test re-ligation reaction (10 μl) by incubating with T4 DNA ligase 
(1 μl) for 15 min at rt, followed by transformation into chemically competent 
TOP10 E. coli strain (100 μl) and gave no colonies after overnight  incubation at 
37°C. 
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Ligation reaction (10 μl) with EcoRI-XhoI digested pSG5/myc plasmid and 
insert was performed using T4 DNA Ligase, with an approximate 4:1 molar 
ratio, for 2 h at rt, and then transformed into TOP10 E. coli strain. Test 
digestion using FD EcoRI-XhoI rendered an insert of the appropriate size. The 
insertion was checked by DNA sequencing. 
2.3.12 Transient transfection of COS-1 cells 
For transient transfection, COS-1 cells were seeded in 100-mm cell culture 
dishes (Corning), so that the confluence of 50-70% would be achieved after 
incubation for 16-24 h. Fugene HD transfection reagent was used at 6:1 ratio, 
diluted in Opti-MEM I + GlutaMAX-I (325 μl per 6.5 μg DNA). A mixture was 
allowed to incubate for 10-15 min at rt and then was added to the cells 
dropwise. The cells were typically assayed 24-30 h following transfection. 
2.3.13 Immunoprecipitation after H2O2 stimulated COS-1 cells 
Transfected cells were placed in a serum-free medium (SFM) for 2 h. The cells 
were then treated with 10 mM H2O2 for 60 min at 37°C. Next, the cells were 
rinsed twice with cold PBS and lysed in 1 ml of ice-cold buffer described under 
2.1.13. The cells were incubated with the lysis buffer on ice for 10 min, after 
which the lysate was cleared by centrifugation at 13,200 rpm for 6 min at 4°C. 
To the cleared cellular extracts, anti-Flag (6 μg) ab was added and incubated 
for 15-20 h at 4°C on a roller. Next, 40 μl of Dynabeads Protein G was added to 
each sample and incubated under conditions listed above for further 6 h. After 
rinsing the beads three times with stock of the lysis buffer (no PIC), the bound 
material was first eluted by applying 25 μl of 2 x SDS-PAGE sample buffer, 
without reducing agent, and incubating at 65°C for 10 min. The second elution 
was performed at 95°C for 5 min.  
 165 
2.3.14 Cross-linking with PFA in intact COS-1 cells 
The cells (60 mm) were transfected with the plasmid pCMV/Flag3-wtVHR. After 
24 h, the growth medium was removed and the cells were rinsed twice with 
pre-warmed PBS. Next, they were incubated with 0.8% (w/v) PFA in PBS at 
37°C, after which the cells were rinsed twice with cold PBS. The control dish 
was incubated in the GM only, at 37°C. The cells were lysed in ice-cold buffer 
(178.6 μl) containing 20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 10% (v/v) 
glycerol, 1% (v/v) NP-40, 1 mM EDTA and PIC (1 x). The cells were incubated 
with the lysis buffer on ice for 10 min, after which the lysate was cleared by 
centrifugation at 13,200 rpm for 6 min at 4°C. The aliquots were withdrawn, 
mixed with 2 x SDS-PAGE sample buffer, without reducing agent, and 
incubated at 60°C for 20 min or at 95°C for 5 min. To the pellets left after lysate 
clarification, 80 μl of the 2 x SDS-PAGE sample buffer, as above, was added 
and incubated at 95°C for 5 min. 20 μl of the lysate (about 5.6% of the total 
lysate) and 10 μl of the resuspended pellets (12.5%) was resolved by 4-12% 
SDS-PAGE and probed with an anti-Flag ab. 
2.3.15 Dephosphorylation of Erk1/2 in COS-1 lysate by recombinant VHR  
COS-1 cells were seeded in 100-mm plates and grown to approximately 80-
90% confluence. Next, they were placed in SFM for 16-24 h. To inactivate 
endogenous phosphatases and activate Erk1/2, the cells were subjected to a 
30 min treatment at 37°C with 1 mM Na3VO4 and 1 mM H2O2, which were 
mixed directly into the SFM. After the treatment, the cells were rinsed twice with 
cold PBS and lysed in a buffer (500 μl) described under 2.1.13. The cells were 
scraped, transferred into an Eppendorf tube and disrupted by sonication for 3 s 
on ice. The extracts were cleared by centrifugation at 13,200 rpm for 10 min at 
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4°C. The final volume of dephosphorylation reaction was 100 μl. The wtVHR 
and its F68pBPA variant, both with or without prior subjection to 345 nm light 
for 30 min at 250 μg/ml, were added to have a final protein concentration of 500 
nM. The dephosphorylation reaction was conducted at 30°C. At appropriate 
time points (0, 30 and 90 min), the aliquots were withdrawn and the reactions 
were quenched by adding 2 x SDS-PAGE sample buffer followed by heating at 
95°C for 5 min. Next, 20 μl of each sample was resolved by SDS-PAGE and 
analysed by Western blotting (anti-VHR, total and pErk1/2). 
 
2.4 Materials and methods for Chapter 3.3 
 
2.4.1 Generating pETM20/6His-3Flag-PRL-1  
Hot Start Master Mix was used. PRL-1 was sub-cloned from pETM20 vector 
into BamHI-EcoRI sites of pCMV-3Flag-1A by using the following pair of sense 
and antisense primers, respectively: 5’-
CGGGATCCATGGCTCGGATGAACCGCC-3’ and 5’-
CCGCCGGAATTCTTATTGAATGCAACAGTTGTTTC-3’. To generate 
pETM20/Flag3-PRL-1, the following pair of primers was used: 5’-
AATTAACCCTCACTAAAGGG-3’ and 5’-
CCGCCGCTCGAGTTATTGAATGCAACAGTTGTTTC-3’. Digestion (200 ng 
DNA) with FD BamHI/EcoRI and NcoI/XhoI enzymes (1 μl each) was done in a 
FD Green buffer, for at least 30 min at 37°C.  
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2.4.2 Large-scale bacterial expression and purification of PRL-1 
Expression of PRL-1 was induced for 4 h at 37°C and then overnight at 18°C, 
in 1 l of TB-FB medium. The purification setup was as outlined in section 2.3.3, 
with the following buffers: lysis and washing buffer A contained 50 mM Tris-HCl 
(pH 7.4), 200 mM NaCl, PIC, 5% (v/v) glycerol, 1 mM TCEP and 10 mM 
imidazole and eluting buffer B had 500 mM imidazole. For removal of the His6-
tag with GST-TEV, the protein was concentrated so that 0.8 ml of the sample 
was loaded onto the HisTRAP column. The sample was finally stored in 50 mM 
Tris-HCl (pH 7.4), 200 mM NaCl and 4 mM DTT. 
2.4.3 Generating pETM20/6His-3Flag-wtPRL-3 and D72A  
To annul the second NcoI recognition site identified in pCMV-3Flag-1A/wtPRL-
3 (between the Flag3-tag and the initial amino acid), the following set of primers 
was used with QCL-DSM kit: 5’-GCGGGAAGTATGGCTCGGATGAACCGCC-
3’ and 5’-GAGCCATACTTCCCGCCCGGGCTTTATC-3’. The construct is 
hereafter referred to as pCMV-3Flag-1A/wtPRL-3_QCL-SDM. 
pCMV-3Flag-1A/wtPRL-3_QCL-SDM was used as DNA template with Phusion 
DNA Polymerase and the same set of primers containing sites for NcoI/XhoI 
listed in section  2.2.9. 
pETM20/D72A was generated by using pETM20/wtPRL-3 as DNA template 
Phusion DNA Polymerase and the following set of primers: 5’-
GTTTGACGCTGGGGCGCCCCCGCCC-3’ and 5’-
CGCCCCAGCGTCAAACGGCCAGTCCAC-3’. 
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2.4.4 Large-scale bacterial expression and purification of the Flag3-tagged 
PRL-3 variants: wtPRL-3, D72A, D72pBPA 
The general protocols for purification were as outlined in section 2.3.3. To 
purify His6-TEV-Flag3-tagged wtPRL-3 and its D72pBPA mutant, the same 
buffer conditions like for wtVHR and its F68pBPA mutant were applied. 
Occasionally, DTT (2-4 mM) was used in the final buffer. D72A mutant was 
purified with buffer conditions used for the other VHR variants and was finally 
dialysed against 20 mM Tris-HCl (pH 7.4), 200 mM NaCl and 0.1% (v/v) β-
mercaptoethanol.  
2.4.5 Assessing catalytic activity of Flag3-D72pBPA with OMFP 
The assay was performed as generally described in section 2.2.4. Protein was 
assayed at 6 μM and OMFP at 50 μM final concentration.  
2.4.6 PIP Strips assay 
For PIP strips assay, all proteins were in buffer containing 50 mM Tris-HCl (pH 
7.4), 500 mM NaCl and 0.1% (v/v) β-mercaptoethanol.  
The strips were blocked in TBST-0.1% with 3% (w/v) fatty acid-free BSA (5 ml), 
for 60 min at rt with gentle agitation. The blocking buffer was discarded and the 
membrane was rinsed tree times in TBST-0.1% (5 ml), for 5 min each. Next, 
the proteins were incubated at the final concentration of 0.5 μg/mL in blocking 
buffer (5 ml) for 30 min at rt, with gentle agitation. The proteins were discarded, 
the membrane was rinsed three times, as above, and then the appropriate 
primary ab was added. Anti-Flag or anti-PRL-3 ab were used at 1:5,000 (for 60 
min) or 1:400 (for 3 h), respectively.  Next, the membrane was rinsed three 
times, as above, and then the appropriate secondary ab was added at 1:5,000 
 169 
dilution in blocking buffer and incubated for 60 min. The membrane was rinsed 
three times, as above, prior to visualization, first with ECL Western Blotting 
Detection Reagents and then with Western Lightning Plus-ECL Enhanced 
Chemiluminescence Substrate. 
Sample containing D72pBPA variant of PRL-3 was incubated with the strip for 
10 min prior to exposure to 365 nm, which was conducted for the total time of 5 
min (two irradiation intervals of 2.5 min with a 2.5 min break). After irradiation, 
the sample continued to be incubated with the strip until total incubation time of 
30 min. The non-irradiated control sample of D72pBPA was kept light protected 
throughout the assay. 
For control without protein, after initial blocking of the membrane, 5 ml of the 
fresh blocking buffer was added to it and incubated as above.  
Purified PRL-3_3A was obtained from Irina Cornaciu and the construct was 
generated by Miriam Bru Roig, from the Köhn group. 
PRL-1 was assayed under two different conditions- in the first assay, protein at 
0.5 μg/mL was incubated for 30 min, and in the second assay, the protein was 
at 5 μg/mL and was incubated with the strip for 60 min. 
2.4.7 Incubation of the PRL-3 variants (wt, D72A, D72pBPA) with HEK293 
lysate 
All variants of PRL-3 were in the form of His6-TEV-Flag3-fusion proteins. For 
each sample, two 14 cm dishes of fully confluent HEK293 cells were set. Each 
dish was lysed in 1 ml of lysis buffer described under section 2.1.5.22, scraped 
and transferred into an Eppendorf tube and then sonicated for 3 s with 20% 
duty cycle. The lysate was cleared by centrifugation for 15 min at 4°C and 
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13,200 rpm. To 2 ml of the cleared lysate, 200 μg of the bait was added and 
incubated on a roller at 4°C for 2 h. Then, the samples were transferred into a 
35 mm dish and either exposed to 345 nm light for 30 min or incubated on ice, 
light-protected, for the same time. Next, the samples were recovered into an 
Eppendorf tube and subjected to IP using Ni-affinity gel, overnight at 4°C.  
The beads were prepared as follows: 200 μl of the beads slurry was pipetted 
for each sample and rinsed twice with the stock solution of the lysis buffer (no 
PIC). The samples were centrifuged for 1 min at 4°C and 7,300 rpm. After the 
IP, the supernatant was recovered and the beads were rinsed twice as above 
and then one last time for 5 min on a roller at 4°C.  
The bound material was eluted first (E1) by adding 100 μl of 2 x SDS PAGE 
sample buffer, incubating for 10 min at 65°C and 500 rpm and then transferring 
into a clean tube. The sample was additionally cleared off the residual beads by 
centrifuging at maximal speed at 4°C for a couple of min. The second elution 
(E2) was done for 5 min at 95°C and 500 rpm. The samples were analysed by 
Western blotting (anti-PRL-3), and also subjected for LC-MS/MS analysis, 
which was done by Kristina Dzeyk from the Proteomics Core Facility (EMBL 
Heidelberg). The samples (E1) were resolved by loading 60 μl on self-made 8% 
SDS-PAGE. To prepare 20 ml of the resolving gel, the following components 
were mixed in the order indicated: ddH2O (9.3 ml), 1.5 M Tris-HCl pH 8.8 (5.0 
ml), 30% acrylamide mix (5.3 ml), 10% SDS (0.2 ml), 10% ammonium 
persulfate (0.2 ml) and TEMED (0.012 ml). To prepare 10 ml of the stacking 
gel, the following components were mixed in the order indicated: ddH2O (6.8 
ml), 1.0 M Tris-HCl pH 6.8 (1.26 ml), 30% acrylamide mix (1.66 ml), 10% SDS 
(0.1 ml), 10% ammonium persulfate (0.1 ml) and TEMED (0.01 ml). The gel 
was run at about 100 V, stained in colloidal Coomassie overnight and 
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destained in ddH2O. For each sample (irradiated and non-irradiated samples of 
D72A and D72pBPA and non-irradiated sample of wtPRL-3), the gel-bands 
were cut out in three ranges of molecular weight (I ~41-53 kDa; II ~70-93 kDa 
and III ~130-243 kDa). The raw data obtained from Orbitrap-MS/MS were 
processed with software MaxQuant, version 1.1.13, which was used for filtering 
of the data and creating .mgf files, needed for searching in MASCOT version 
2.2.03 (Matrix Science). The data were searched against Uniprot_Human 
database with the following settings: Enzyme specificity was set to trypsin and 
a maximum of one missed cleavage was allowed. Cysteine 
carbamidomethylation was used as a fixed modification and methionine 
oxidation as a variable one. The mass error tolerance for the full scan MS 
spectra was set at 10 ppm and for the MS/MS spectra at 0.5 Da. The result 
files (.dat files) were loaded into Scaffold (version 3.00.06) and identifications 
with a minimum number of peptides per protein of two and 95% confidence in 
peptide ID were reported. The data were exported to excel. The protein IDs 
were sorted by molecular weight (biggest to smallest).   
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3. Results and discussion 
 
3.1 Optimising conditions for expression of the PRL-3 and VHR variants 
with pBPA 
 
3.1.1 Selecting PRL-3 residues to be exchanged for pBPA  
Selecting PRL-3 residues which would be considered suitable to be exchanged 
for the photo-cross-linkable amino acid pBPA was done by in-depth analysis of 
the solution structure of PRL-3 (Kozlov et al., 2004) and its comparison to the 
crystal structure of highly homologous PRL-1 (Jeong et al., 2005; Sun, Wang et 
al., 2005). 
For PRL-1, the structures of both the wt protein and its C104S mutant with the 
abrogated catalytic activity, in complex with a sulfate ion, were available. The 
sulfate ion acts as a mimic of a phosphate moiety of a substrate, thus enabling 
us to analyze what amino acid residues in a protein are important for 
association with a substrate. The solution structure of PRL-3, described by Kim 
et al., included the first 162 amino acid residues, whereas the earlier reported 
solution structure of PRL-3 by Kozlov et al., did not include only the residues of 
the C-terminal CCAX-box (Kim et al., 2004; Kozlov et al., 2004).  
Moreover, whilst PRL-1 crystallized as a trimer, PRL-3 was found to be 
monomeric. However, the intrinsic ability of PRL-3 to form trimers was 
demonstrated by performing cross-linking experiments with glutaraldehyde 
(Sun, Luo et al., 2007). Therefore, at present it can be hypothesized that the 
monomeric state of PRL-3 revealed in both of its NMR-based solution structure 
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reports (Kim et al., 2004; Kozlov et al., 2004) could be a result of employed 
experimental conditions, but also of different tendencies of various PRLs to 
form dimers or higher-order oligomers, namely the requirement of distinct 
structural regions. Even PRL-1, for which trimer formation proved essential for 
exhibiting proper membrane localisation and the stimulatory effect on cell 
proliferation and migration, showed to be monomeric in solution at 
concentrations under 3 mg/ml and to contain a mixture of different-state 
oligomers at higher protein concentrations (Jeong et al., 2005; Sun, Luo et al., 
2007). It is interesting to note that several residues of the trimer interface in 
PRL-1 (Thr13, Arg18, Glu36 and Gly97) were already investigated for their 
contribution to the trimer formation (Sun, Luo et al., 2007; Sun, Wang et al., 
2005). Thr13 in PRL-1 corresponds to serine in both, PRL-2 and PRL-3, and all 
other residues (Arg18, Glu36 and Gly97) are found conserved across all three 
PRLs. Whether PRL-2 also has the intrinsic ability to form higher-order 
oligomers, in vitro and/or in cells, has not been investigated yet.  
Therefore, it could have been postulated that exchanging analogous residues 
in PRL-3, namely Ser13/Arg18/Glu36 and/or Gly97, for photo-cross-linkable 
amino acid pBPA, might be beneficial for shedding light on the investigative 
efforts tackling oligomerization potential of the PRLs. However, when Gly97 in 
PRL-1 was substituted with Arg, and Arg18 and Glu36 with alanine, the ability 
of PRL-1 to form trimers was greatly diminished in comparison to the wt 
protein. Therefore, selecting what residues in the native protein to mutate 
requires extreme caution. All mutations at the trimer interface described 
included substitutions of the residues in the native protein with amino acids of 
considerably different properties, both structural and electrochemical. pBPA is 
hydrophobic and sterically demanding and it is reasonable to believe that 
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exchanging any of the residues which were reported to be at the trimer 
interface in PRL-1 might have a similar derogative effect in PRL-3.  
Therefore, the attention was focused on the region proximal to the entry into 
the active site crevice of PRL-3. The three members of the PRLs are highly 
homologous, showing a high level of sequence identity as well as sequence 
homology between species (Jeong et al., 2005; Kozlov et al., 2004; Rios et al., 
2013; Zeng et al., 1998; Zeng et al., 2003). The surfaces around the active site 
are highly conserved between PRL-1 and PRL-3 and the regions of the most 
prominent sequence divergence were found to be localised on the face 
opposite to the active site pocket, whereas the residues around the P-loop 
were highly conserved (Jeong et al., 2005; Kozlov et al., 2004). It was 
postulated that differences in the composition of the amino acids of the loops 
surrounding the active site pocket are likely to contribute to the distinctions in 
the portfolio of the interacting partners/substrates amongst the PRLs (Kozlov et 
al., 2004). Comparing the amino acid sequences of PRL-1 and PRL-3, there 
are only 14 non-homologous residues between the two phosphatases (Jeong 
et al., 2005). Excluding the residues of the polybasic region at the C-terminal 
end of the proteins, the other non-homologous residues are mostly found at the 
end regions of the loops connecting the secondary structural elements. As for 
the region in the immediate vicinity to the entrance into the active site pocket, 
one distinct amino acid resides at position 141, which is occupied by isoleucine 
in PRL-3 and by phenylalanine in both PRL-1 and PRL-2. In addition, as this 
residue is localised in the connecting loop between the helices α5 and α6, at 
the molecular surface, exchanging it for pBPA was not considered likely to 
generate obstructions to the access of a substrate or a PRL-3-interacting 
partner, in general, to the relevant residues of the active site pocket. The 
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second two residues, Asn142 and Gln145, were selected based on the same 
rationale. Unlike position 141, the residues Asn142 and Gln145 are conserved 
amongst all three PRLs (Sun, Wang et al., 2005). Furthermore, Asn142 and 
Gln145 offered the advantage of both being localised in the flexible loop. In 
addition, the general acid/base Asp72 was also selected to be exchanged for 
pBPA. In addition to its functional implications, Asp72 is located on the WPD-
loop, which in PRL-3 is very flexible (Kozlov et al., 2004). In contrast, in the 
structure of PRL-1 in complex  with a sulfate ion (Jeong et al., 2005), WPD loop 
resumes closed conformation, flipping over the entrance to the active site cleft. 
Therefore, introducing photo-cross-linkable amino acid at the position of the 
generally conserved aspartate residue would provide further derivatization of 
the most frequently targeted residues to generate substrate-trap variants of 
PTPs. 
Figure 23 summarises the positioning of the selected residues Ile141, Asn142 
and Gln145, first opted to be substituted for tyrosine, within the native PRL-3 
protein. The position of the catalytically essential residues, Cys104 and Asp72 
(Kozlov et al., 2004), is also pointed out, for comparison of the relative 
orientations.  
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Figure 23: Selecting residues in PRL-3 to be exchanged for pBPA. (a) Solution 
structure of PRL-3 (PDB entry: 1R6H) shown as surface representation with 
colouring based on the secondary structure (helices in blue, sheets in magenta 
and loops in light pink). Residues important for catalysis, regulation by redox 
and subcellular localisation, highlighted in the sequence of PRL-3, are pointed 
out: catalytic Cys104 (blue), regulatory Cys49 (yellow), general acid/base 
Asp72 (red), and bi-partite polybasic region (grey). The residues of the CAAX 
box are not present in the structure. (b) Chemical structure of pBPA, generated 
in ChemBioDraw. (c) Overall solution structure of PRL-3 (PDB entry: 1R6H) 
presented as a ribbon diagram, with the residues selected to be first exchanged 
for tyrosine shown as sticks. (d) Surface representation of the zoomed-in P-
loop of the native PRL-3. For (c) and (d), the residues are coloured as 
indicated: Asp72 (red), Cys104 (blue), Ile141 (orange), Asn142 (green) and 
Gln145 (purple). All structures were generated using Pymol.  
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To assess if introduction of bulky pBPA would be likely to cause structural 
perturbations, first all three residues (Ile141, Asn142 and Gln145) were decided 
to be exchanged for tyrosine. When focusing on the set of canonical amino 
acids, tryptophan is likely to best mimic pBPA in terms of hydrophobicity and 
size of the side chain residue (O’Neill et al., 1989). However, pBPA is known to 
exhibit cross-linking efficiency which is dependent on the geometric constrains, 
imposed by the distance of the carbonyl moiety of pBPA from the surrounding 
amino acid residues and the rotation angle around the Cα-Cβ bond of pBPA, 
and the electrochemical properties of a potential cross-linking partner carrying 
the proximal C-H bond to which pBPA could covalently cross-link (Dormán and 
Prestwich, 1994; Tanaka et al., 2008; Wittelsberger et al., 2008). Due to the 
rotation around the Cα-Cβ bond, pBPA has certain geometric plasticity, in 
contrast to tryptophan. Therefore, trying to mimic pBPA by generating 
tryptophan mutants first might not have rendered a desirable outcome in terms 
of generating protein variants which would be structurally non-perturbed and 
still capable to recognise and/or dephosphorylate their putative interacting 
partners. Therefore, generating PRL-3 variants with tyrosine exchanging 
residues at positions 141, 142 and 145 was marked as a more appropriate 
approach. Phenylalanine, albeit smaller and perhaps less suitable than 
tryptophan in terms of size-comparability to pBPA, could better mimic pBPA-
mediated interactions due to the aforementioned geometric flexibility of pBPA. 
For example, tryptophan might impose a barricade to the entry into the active 
site pocket due to its fused ring system. On the other hand, the accessibility 
into the active site crevice for an analogous phenylalanine mutant, carrying a 
single ring in the side chain group, might be more reflective of the pocket 
 178 
accessibility for pBPA variant, with higher geometric flexibility enabled by the 
rotation around its Cα-Cβ bond, as mentioned previously. 
Furthermore, there is a wealth of literature data to support that exchanging 
different amino acid residues for pBPA reflects in the cross-linking efficiency, 
namely that some positions are more efficient than the other (Chin and Schultz, 
2002; Krishnamurthy, Dugan et al., 2011; Majmudar et al., 2009; O’Neill et al., 
1989; Sato et al., 2011; Uezu et al., 2012; Wittelsberger et al., 2006). 
Therefore, selecting several residues in PRL-3 to be exchanged for pBPA was 
strongly advised. Moreover, it was also noted previously that different pBPA-
carrying mutants of the same protein exhibited differences in terms of 
expression efficiency and the total protein yield obtained (Krishnamurthy, 
Dugan et al., 2011; Sato et al., 2011). In addition, another advantage of 
selecting several amino acid residues across a protein to be substituted for 
photo-cross-linkable pBPA lies in the opportunity to possibly obtain high-
resolution structural information of the two interacting proteins, pinpointing 
structural regions important for the interaction to occur and amino acid 
interactions critical to maintain the assembly (Krishnamurthy, Dugan et al., 
2011; Forné et al., 2012; Musial-Siwek et al., 2007; O’Neill et al., 1989; 
Wittelsberger et al., 2006a and b; Wittelsberger et al., 2008). It is obvious that 
such interpretations of the cross-linking experimental data absolutely requires 
bioinformatics tools to help identify cross-linked peptides, alongside high 
resolution tandem MS, like elegantly demonstrated in the recent work of Forné 
et al., who, by generating a novel software tool termed “Crossfinder”, were able 
to propose a structural model of chromatin remodeling enzyme called ISWI 
(Forné et al., 2012). 
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3.1.2 Selecting VHR residues to be exchanged for pBPA  
VHR (Denu et al., 1995a; Ishibashi et al., 1992) was selected as another 
representative of the atypical DUSPs (Alonso et al., 2004) in order to 
demonstrate (i) the general applicability of the expanded genetic code toolkit in 
developing more efficient substrate traps of PTPs and (ii) to provide a possible 
quality control for the trapping efficiency of PRL-3.  
VHR was known to be one of the closest homologues of PRL-3 and PRL-1, 
considering the structural similarity (Jeong et al., 2005; Kozlov et al., 2004; 
Stephens et al., 2005). Structure-based sequence comparison showed that 
PRLs did not share more than 20% of the amino acid sequence identity with 
the other members of the classical PTPs (Kozlov et al., 2004). VHR has been 
widely exploited as a prototypic DUSP in detailed profiling of the catalytic 
principles of the DUSPs (Denu et al., 1995b; Denu et al., 1996a and b; Hengge 
et al., 1996; Peters et al., 1998; Zhou et al., 1994), but investigation of its 
physiological interacting partners or regulatory mechanisms are still sparse 
(Alonso et al., 2003; Hoyt, Zhu, Cerignoli et al., 2007; Kang and Kim, 2006; 
Rahmouni et al., 2006; Todd et al., 1999; Todd et al., 2002; Wang et al., 2011; 
Zheng et al., 2013). 
To select residues in VHR which might be suitable for introduction of pBPA, 
detailed analysis of the available structural information was conducted 
(Schumacher et al., 2002; Wu et al., 2009; Yuvaniyama et al., 1996). The 
structural data was available for the native protein in complex  with a sulfate ion 
(PDB: 1VHR), catalytically deficient C124S mutant in complex with a peptide 
derived from the activation loop of p38 MAPK (PDB: 1J4X) and the wt protein in 
complex with a small molecule inhibitor termed SA3 (PDB: 3F81). In addition, 
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being one of the structurally most similar PTPs to the members of the PRL 
family of phosphatases, some comparison with respect to the structural and 
kinetic characteristic were already made (Jeong et al., 2005; Kozlov et al., 
2004; Rios et al., 2013). 
Asp92 in VHR serves as a general acid/base (Denu et al., 1995b; Yuvaniyama 
et al., 1996), therefore representing the functional equivalent to Asp72 in PRL-
3. Next, according to the structure-based sequence alignment, Asn163 in VHR 
represents an equivalent of Asn142 in PRL-3. According to the crystal structure 
of native VHR with a small molecule inhibitor SA3 (Wu et al., 2009), Leu25 is 
positioned proximal to the inhibitor. From the perspective of “closed” protein 
conformation (substrate-bound), Leu25 was regarded as a suitable residue to 
be tried for substitution with pACF and/or pBPA. In addition, Leu25 is a 
constituent of a surface-exposed hydrophobic patch, which was shown to be a 
significant component of the substrate-binding region (Wu et al., 2009).  
Moreover, Leu25 is a constituent of the N-terminal α1-β1 loop (“recognition 
region”) which is implicated in the formation of the substrate-binding groove.  
(Yuvaniyama et al., 1996). Phe68, located on the protruding β3-β4 loop of the 
“variable insert” segment lining the entrance into the active site crevice (Wu et 
al., 2009; Yuvaniyama et al., 1996) offered an advantage of being structurally 
similar to pACF and pBPA. In addition, it is positioned in the flexible loop, thus 
minimizing the likelihood that its replacement with either of the unnatural amino 
acids of interest would cause structural perturbations. With the exception of 
Met69, the function of the other residues of the “variable insert” section is still 
elusive (Yuvaniyama et al., 1996). Given the position of Phe68 relative to the 
active site pocket, exchanging this residue for pBPA might help investigating 
potential involvement of the “variable insert” segment in protein interactions. 
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Gly161, due to its positioning with respect to the active site pocket, could be 
regarded as potential negative control when trying to filter out the VHR 
substrates from its interacting partners.  
The residues selected for further optimisation in VHR are shown in Figure 24. 
 
Figure 24: Selecting VHR residues to be exchanged for pBPA. (a) Surface 
representation of the crystal structure of VHR (PDB: 1VHR) with colouring 
based on secondary structure (helices in cyan, sheets in magenta and loops in 
light pink) and residues selected to be exchanged for the amber STOP codon 
coloured as indicated: Leu25 (brown), Phe68 (green), Asp92 (red), Cys124 
(blue) with the bound sulfate ion shown as a stick representation (yellow), 
Gly161 (purple) and Asn163 (wheet). (b)  Zoom-in of (a).  (c) Crystal structure 
of the catalytically inactive VHR mutant C124S, with peptide derived from p38 
MAPK (shown in grey) bound in the active site (PDB:1J4X). The structures 
were generated using Pymol. 
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3.1.3 Generating the I141Y, N142Y, N142A and Q145Y mutants of PRL-3 
As discussed in detail in section 3.1.1, the residues that were identified as 
potentially suitable for bearing a bulky photo-cross-linkable amino acid pBPA, 
were first substituted for tyrosine. The general acid/base Asp72 was not 
mutated to tyrosine because it is located on a flexible loop which might enable 
introduction of a bulkier residue without compromising structural integrity of the 
protein. The proteins were over-expressed in E. coli as N-terminal His6-tagged 
fusion proteins, which enabled affinity-based purification. The protein yields are 
listed in Table 1, and were calculated as mg of protein obtained from one l of a 
bacterial culture.  
The size of the employed N-terminal His6-tag is not likely to cause functional 
impairment of the tagged protein. The reasoning for the N-terminal positioning 
of the affinity tag is justified by the reported findings on the importance of the 
residues of the C-terminal end in PRL-3, and PRLs in general, on the 
subcellular localisation and catalytic activity of the proteins and also on the 
importance the subcellular localisation pattern imposes on the related signaling 
pathways (Al-Aidaroos and Zeng, 2010; Pascaru, Tanase et al., 2009; Rios et 
al., 2013; Skinner et al., 2009; Zeng et al., 2000).  
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Table 1: Verifying the integrity of the PRL-3 variants (I141Y, N142Y, N142A 
and Q145Y) by determining full protein mass. The procedure is described in 
detail in section 2.1.15. The proteins were expressed from 0.4-1 l of LB 
medium, and protein expression was induced with 0.1 mM IPTG for 3 h at 
37°C. The details of the large-scale expression and purification of the 
aforementioned variants of PRL-3 are provided in section 2.2 and 2.3, 
respectively. 
 
 
 PRL-3  
 
Protein yield 
(mg of protein/ l of 
bacterial culture)  
 
Molecular mass 
calculated (Da)  
 
Molecular mass 
obtained (Da)  
 
I141Y 
 
9.1 
 
20,024.80 
 
20,025.00 
 
N142Y 
 
18.98 
 
20,023.85 
 
20,022.43 
 
N142A 
 
25.75 
 
19,930.34 
 
19,932.33 
 
Q145Y 
 
25.85 
 
20,009.82 
 
20,008.51 
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It can be concluded that all variants of PRL-3 generated expressed at 
satisfactory and comparable yields, with the exception of I141Y. In addition, 
only the fourth attempt to purify this mutant was successful. Although the 
obstacle could in part be attributed to the technical aspect, namely the reduced 
binding efficiency of Ni HisTRAP affinity columns after a couple of consecutive 
rounds of purification without stripping and recharging the columns, it could 
also be indicative of differences in the stability and/or solubility existing 
between distinct variants of PRL-3. Like mentioned previously, the amino acid 
composition of the position 141 in PRLs is distinct, with PRL-3 on the one side, 
having isoleucine, and PRL-1 and PRL-2, on the other one, both carrying 
phenyalalanine (Jeong et al., 2005; Kim et al., 2004). Thus, exchanging one of 
only 14 of the non-homologous residues between the PRLs (Jeong et al., 2005) 
might compromise structural integrity of the protein, disrupting proper folding.  
No data is yet available to support a hypothesis that a dramatically reduced 
yield of the I141Y mutant of PRL-3 in contrast to the other mutants generated, 
could be a direct implication of the importance of this residue for structural 
integrity of the PRLs. The key structural characteristics of PRL-3 that are the 
object of more intense research focus are discussed in section 1.5.4. 
Position 142 in PRL-3 corresponds to a potentially promising residue in a more 
general concept of obtaining substrate-trapping variants of PTPs with better 
substrate-trapping efficiency (Blanchetot et al., 2005; Tiganis and Bennet, 
2007; Zhang, 2003a). The most commonly utilized substrate-trapping mutants 
of the PTPs include variants with manipulated residues which are 
acknowledged to be indispensable for efficient hydrolysis of a substrate (for 
example, exchanging the active site cysteine for a serine or exchanging the 
aspartate of the general acid loop to an alanine or a glutamine) (Blanchetot et 
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al., 2005). However, additional PTP variants which could serve as substrate 
traps were also designed (Blanchetot et al., 2005; Zhang, 2003a). For example, 
for PTP1B, the successful approach included the Q262A mutant, for which 
crystal structure of a cysteinylphosphate intermediate was obtained. By 
comparing the solution structure of PRL-3 with the crystal structure of PTP1B, 
Asn142 could be equivalent to Asn262. Moreover, like stated previously, the 
position of Asn142 is conserved amongst the PRLs (Kozlov et al., 2004). Thus, 
Asn142 in PRL-3 could be lucrative for identifying novel interacting partners of 
all PRLs as well as for investigating differences amongst them. The N142A 
mutant of PRL-3 was also generated in the context of the wt background. It was 
expressed and purified under the conditions used for the previously generated 
tyrosine-mutants of PRL-3. 
3.1.4 Characterisation of PRL-3: I141Y, N142Y, N142A and Q145Y 
The next step was to profile the newly generated mutants of PRL-3 to check if 
any of the mutations introduced disrupted catalytic performance of the variants. 
Catalytic performance was assessed in preliminary experiments against the 
artificial phosphatase substrate OMFP, and then against PI(3,4,5)P3, as our 
laboratory discovered the activity of PRL-3 against PIPs (McParland, Varsano 
et al., 2011; Rios et al., 2013). In all activity assays with OMFP, PTP1B was 
used as a positive control, because PRL-3 was known to have low catalytic 
efficiency against artificial phosphatase substrates or synthetic peptides in vitro 
(Kozlov et al., 2004; McParland, Varsano et al., 2011). PTP1B regularly 
showed about ten times higher activity against OMFP than PRL-3 (it was 
excluded from the plotting as the focus was on the PRL-3 mutants and PTP1B 
was used only as an indication that the assay in general worked). The data 
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from both activity assays was regarded as a rough indication if the mutations 
introduced affected the catalytic activity of the enzyme. However, performing 
the activity assay once makes any firm statement about the catalytic 
performance of the mutants unadvisable as well as stayistical analysis. 
Comparing all the mutants generated, the catalytic activity of the Q145Y mutant 
was the lowest in both assays (Figures 25A and 26A). Unlike positions 141 and 
142, which reside in the loop connecting the helices α5 and α6 proximal to the 
entrance into the active site pocket, Gln145 is located within the α6 helix, 
pointing inwards. Therefore, it is likely that exchanging Gln for sterically more 
demanding Tyr obstructs access of a substrate into the active site. pBPA, being 
even bulkier, was regarded as likely causing even more destructive effect on 
the accessibility into the catalytic pocket, so the Gln145 mutant was removed 
from further screen.   
Interestingly, the I141Y mutant exhibited a better catalytic performance than the 
wt protein in both activity assays (Figures 25B and 26B). As stated previously, 
this position is non-homologous amongst the PRLs, and suggested to possibly 
govern substrate specificity (Kozlov et al., 2004). The generated I141Y mutant 
could have positive effect on substrate binding through hydrogen bonding-
mediated interactions enabled via an introduced hydroxyl moiety in the side 
chain of the tyrosine. These interactions could lead to more optimal positioning 
of a substrate with respect to the key catalytic residues, thus having positive 
outcome on the enzyme turnover. 
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Figure 25: Phosphatase activity of the PRL-3 variants against OMFP. The 
protocol is described in section 2.2.4. The reaction was monitored as an 
increase in absorbance at 450 nm, over time (2 hours). All PRL-3 variants were 
assayed at 6 μM and OMFP was used at 600 μM. Assays were performed 
according to the conditions had been optimised in the lab previously 
(McParland, Varsano et al., 2011). The data was plotted using GraphPad Prism 
5.0 and shown as end-point measurement (strength of signal as absorbance at 
450 nm plotted on y-axis), with standard error of the mean (SEM). 
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Figure 26: Phosphatase activity of the PRL-3 variants against PI(3,4,5)P3. The 
protocol is described in section 2.2.4. Commercially available EnzCheck 
phosphatase assay kit was used. The reaction was monitored by measuring 
absorbance at 360 nm, over time (2 hours).  All PRL-3 variants were assayed 
at 6 μM concentration and the concentration of PI(3,4,5)P3 used was 100 μM. 
Assays were performed at 37°C in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 
mM MgCl2 and 4 mM DTT; assay conditions had been optimised in the lab 
previously (McParland, Varsano et al., 2011). The data was plotted using 
GraphPad Prism 5.0 and shown as end-point measurement (strength of signal 
as absorbance at 360 nm plotted on y-axis), with SEM. 
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Alignments of PRL-3 with its closest structural homologues, in the lack of a 
structure of PRL-3 in complex with a ligand, mostly rely on extrapolating 
observations for PRL-1 in the analogous procedures (Rios et al., 2013). For 
PRL-3, substrate-binding pocket is shallower and more hydrophobic when 
compared to its closest structural homologues VHR and PTEN (Kozlov et al., 
2004; Stephens et al., 2005). The patch containing residues Ile141 and Asn142 
in PRL-3 is not homologous with Cdc14 or PTEN (Kim et al., 2004). It is 
reasonably to hypothesize that the location of both Ile141 and Asn142 in the 
rim at the entrance into the crevice of the active site pocket would put them in 
good position to mediate governing of a substrate into the catalytic cleft. From 
the general concept of the project, this would make those two residues well 
suited for substitution with the photo-cross-linkable unnatural amino acid. 
Finally, concluding from the catalytic performance with OMFP of both PRL-3 
mutants generated for position 142, this residue, albeit suggested to be an 
equivalent of Gln262 in PTP1B, failed to match the general criteria for 
developing substrate trapping mutants of the PTPs (Blanchetot et al., 2005; 
Zhang, 2003a) as it showed a very similar catalytic activity compared to the 
wtPRL-3 (Figures 25C, 25D and 26A). N142Y mutant of PRL-3 also showed 
similar albeit somewhat reduced activity against PI(3,4,5)P3 (Figure 26A). In a 
PTP variant supposed to act as a substrate trap, catalytic activity is anticipated 
to be greatly reduced compared to the unaltered protein, trapping a substrate in 
the active site pocket for sufficiently long to be isolated and profiled. However, it 
cannot be excluded that the catalytic profile of a PRL-3 variant carrying 
mutation at position 142 would not be shifted into that direction when combined 
with the additional mutation of some of the key catalytic residues (Asp72 or 
Cys104). Therefore, position 142 in PRL-3 was still regarded as promising for 
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introduction of a photo-cross-linkable amino acid, but the trial to further profile it 
as an improved PTP substrate trap in analogy to Q262A mutant of PTP1B, 
containing only the canonical amino acids, was abandoned. 
3.1.5 Small-scale optimisation of conditions for bacterial over-expression 
with wtPRL-3 
To optimize conditions for bacterial over-expression on a small scale, selected 
PRL-3 variants were expressed as C-terminal intein-His6-tagged fusion proteins 
by using pTXB3-His6 plasmid. Opting for a plasmid which would express PRL-3 
variants with an affinity tag at the C-terminal end would enable purification of 
only the full length protein, and not of the truncated variant which is also 
produced by employing the amber suppression technology. Therefore, removal 
of the intein-coupled His6-tag fused at the C-terminal end of PRL-3 variants by 
β-mercaptoethanol provided an additional means to check for the expression 
efficiency of different variants. Potential bacterial contaminants which 
eventually co-purified with the recombinant protein would not be expected to be 
affected by β-mercaptoethanol. 
The native protein was considered the best starting point to optimize conditions 
for expression of different variants with selected residues exchanged for the 
amber STOP codon. Figure 27 summarises the efforts to find the most 
appropriate experimental conditions, namely the adequate E. coli strain and 
induction temperature. Several trial experiments where expression of pTXB3-
intein-6His/wtPRL-3 in different E. coli strains and in LB and TB-FB media was 
induced at 37°C for 4 h and/or the following purification steps under native 
conditions were not successful and no protein of the expected size was 
observed by SDS-PAGE analysis.  
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This was surprising as previous large-scale expression of different N-terminally 
tagged variants of PRL-3 (D72A, I141Y, N142Y, N142A and Q145Y) did not 
show any insurmountable difficulties in terms of protein stability, showing that 
the expression was generally feasible. Furthermore, concentration of imidazole 
in the lysis and washing buffers was not exceeding 10 mM, and therefore did 
not hinder binding of the protein to the Ni-containing affinity gel. Another 
plausible explanation of the failed trail expression and purification experiments 
could be that bacterial proteins were also present alongside protein of interest. 
This could represent a problem if the amount of co-purified bacterial proteins 
exceeded the binding capacity of the affinity gel and/or if the amount of the 
recombinant protein expressed was low, which would render detection even 
more difficult. Therefore, purification under denaturing conditions was tried to 
rule out the possibility that the negative result was the outcome of inefficient 
solubility of the fused protein.  
However, large-scale purification under denaturing conditions would require 
refolding of the protein in vitro, and examining the efficiency of the refolding by 
performing activity assay. Reductions in the catalytic performance with respect 
to the non-treated protein sample would not be straightforward to explain, 
because they could be attributed to incomplete refolding, which would still 
preserve a denatured fraction of the protein, but could also indicate that the 
protein was not folded correctly. Thus, purification of the PRL-3 variants under 
denaturing conditions would be used as the last resort, albeit it was acceptable 
for small-scale test-expression experiment to rule out the aforementioned 
obstacles.   
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Figure 27: Screening for the optimal E. coli strain and induction temperature by 
using pTXB3-intein-6His/wtPRL-3. (a) Chemically competent BL21 DE3 and 
electrocompetent BL21 AI and RIL strains were usedProtein expression was 
induced for 6 h at 25°C or for 3 h at 37°C in the TB-FB medium. The non-
induced samples were incubated for 3 h at 37°C. The samples were purified 
under denaturing conditions. An aliquot of the purified sample was resolved by 
denaturing 4-12% SDS-PAGE, stained in Coomassie and destained in ddH2O. 
(b) Cleavage with 50 mM β-mercaptoethanol was done for 48 h at 4°C after 
which the samples were resolved by SDS-PAGE, like under (a), without 
purification. The identity of the other co-purified proteins was not determined. 
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As indicated on Figure 27, when BL21 AI strain was used, and protein 
expression induced at 25°C, expression of the fusion PRL-3 protein could be 
detected by SDS-PAGE analysis. Moreover, the non-induced control sample 
and the sample of BL21 AI strain with protein expression induced at 37°C 
exhibited the same background level and lack of discernible expression of the 
fused wtPRL-3. 
In stark contrast were the results obtained with the remaining two strains, 
chemically competent BL21 DE3 and electrocompetent BL21 RIL. For both of 
them, the expression of the fused wtPRL-3 protein seemed to be even more 
efficient than in BL21 AI strain, there was considerable level of “leaky” 
expression in the non-induced control samples, especially for BL21 DE3 strain. 
In the pTXB3-His6 plasmid, the expression of the gene encoding protein of 
interest is under control of T7 RNA polymerase promoter, which is 
predominantly expressed upon induction with IPTG. It has been noted that 
even under repressive conditions some T7 RNA polymerase could be 
expressed, thus driving expression of the protein of interest (Gräslund et al., 
2008). In the BL21 AI strain, the gene encoding T7 RNA polymerase is under 
control of arabinose-inducible promoter. From the results presented in Figure 
27, it can be concluded that the basal expression of T7 RNA polymerase was 
low in BL21 AI cells.  
BL21 AI electrocompetent strain of E. coli was selected as the most optimal for 
further experiments. TB-FB was selected as the preferred GM. 
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3.1.6 Small-scale optimisation of conditions for bacterial over-expression 
of the D72-, I141- and N142TAG variants of PRL-3 with pACF 
After having established the basic experimental conditions, namely the strain of 
E. coli, the choice of GM for culturing of bacteria and the induction temperature, 
by using wtPRL-3, the next step was to translate the setup into optimisation of 
conditions for expression of PRL-3 variants with the selected positions 
exchanged for the amber STOP codon.  
pACF was considered an excellent way to fine-tune the conditions for the 
expression of PRL-3 variants with the unnatural amino acid before transferring 
to pBPA. pACF was genetically encoded for expression in E. coli, S. cerevisiae 
and mammalian cells (Chin et al., 2003; Liu et al., 2007; Ryu and Schultz, 
2006; Ye, Köhrer et al., 2008) and is inexpensive. It contains a carbonyl moiety 
which acts as a reactive handle to allow additional chemical modifications (Liu 
and Schultz, 2010). Both pACF and pBPA are phenyalalanine derivatives, with 
pBPA having additional phenyl ring comparing to pACF. A critical thing to be 
optimised was the concentration of the unnatural amino acid which would allow 
for the significant protein expression level. 
In addition to PRL-3 variants with positions 141 and 142 exchanged for the 
amber codon, additional variant carrying TAG codon at the position of the 
general acid/base Asp72 was generated. For PRL-3, it was demonstrated that 
D72A mutant still displayed some catalytic activity in an in vitro assay with PIPs 
PI(3,4,5)P3 and PI(4,5)P2, while showing no activity against robust artificial 
substrate OMFP (McParland, Varsano et al., 2011). The residual phosphatase 
activity of PTPs with D→A mutation has been acknowledged (Blanchetot et al., 
2005). The similar effect of a mutation of the conserved aspartate was also 
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reported for PTEN. Although PTEN contains conserved signature motif 
characteristic for the PTPs, it was shown that it does not employ exactly the 
same mechanism (Xiao et al., 2007). Generating D92A mutant of PTEN did not 
significantly affect the phosphoenzyme intermediate formation with PI(3,4,5)P3. 
Whether lipid and protein phosphatase activities in PRL-3 might occur via 
distinct mechanistic principles has not been addressed further. The D72pACF 
variant of PRL-3 expressed with 1 mM final concentration of pACF (Figure 28). 
The expression of N142 mutant was taken as satisfactory, although the level of 
the full length protein, after cleavage with β-mercaptoethanol, was not as good 
as for the D72 mutant. I141 mutant was expressed at the very low level. In 
addition, the expression with 2 mM pACF was also tried. In this case, I141 
mutant of PRL-3 showed an increase in the expression compared to the 
expression with 1 mM pACF, but the total level of the protein detected 
remained lower than for the remaining two PRL-3 variants screened, D72- and 
N142TAG. Therefore, at that stage, all the mutants were carried out onto the 
next stage of experiments with pBPA.  
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Figure 28: Small-scale expression of the D72-, I141- and N142TAG variants of 
PRL-3, in pTXB3-intein-6His plasmid, with 1 mM pACF. (a) Chemical structure 
of pACF generated in ChemBioDraw. (b) Plasmid pTXB3-intein-6His expresses 
proteins with intein-6His-fused to the C-terminal protein end. (c) Protein 
expression of wtPRL-3 and of its pACF-containing variants was induced for 6 h 
at 25°C. The non-induced sample of the wt protein and the sample of BL21 AI 
cells were incubated for 4 h at 37°C. The samples were purified under native 
conditions. Cleavage with 50 mM β-mercaptoethanol was done overnight at 
37°C. An aliquot of the purified sample was resolved by denaturing 4-12% 
SDS-PAGE. The gel was placed in Coomassie dye, put in a microwave for 
about 10 s and then left to stain at rt, followed by destaining in ddH2O. The 
band at approximately 20 kDa (*) corresponds to the full length protein and at 
about 45-50 kDa (**) to the intein fused form; the identity of the other co-
purified proteins was not determined. 
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3.1.7 Small-scale optimisation of conditions for bacterial over-expression 
of D72-, I141- and N142TAG variants of PRL-3 with pBPA 
pBPA is known to be chemically stable (Chin et al., 2002a) and, like most of the 
unnatural amino acids, is readily taken up by prokaryotic or eukaryotic cells (Liu 
and Schultz, 2010).  
In order to try to maximize the yield of the full length protein with selectively 
introduced unnatural amino acid, conditions for induction of protein expression 
were varied, as described for Figure 29. The I141TAG mutant demonstrated 
poor suppression efficiency with pBPA, like in the case of pACF, thus ruling out 
that the low yield of the full length protein detected was the effect of the nature 
of the unnatural amino acid (Hino et al., 2012). The N142TAG mutant showed a 
good expression level, like marked with a red circle mark in Figure 29, albeit 
the concentration of pBPA in the medium had to be increased to 2.5 mM. In 
case of Asn142 mutant, likely additional advantage was allowing prolonged 
induction time. Lowering temperature to 18°C for the overnight incubation 
reduced the speed of protein production and allowed proper protein folding 
(Gräslund et al., 2008) and showed to be beneficial for the expression of the 
N142TAG variant. 
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Figure 29: Small-scale test-expression of the PRL-3 variants, in pTXB3-intein-
6His plasmid (see Figure 28b), with pBPA. BL21 AI cells were used as a 
background control. The D72pBPA mutant was expressed with 1 mM final 
concentration of pBPA, filtered into the TB-FB GM at the beginning of the 
experiment. For the I141- and N142pBPA mutants, pBPA was added to the GM 
about 20 min before induction at the final concentration of 2.5 mM. For the 
D72- and I141pBPA mutants, expression was induced for 6 h at 25°C; for the 
N142pBPA mutant, it was induced for 6 h at 25°C and then overnight at 18°C. 
Expression of the wtPRL-3 was induced for 4 h at 37°C. The samples were 
purified under native conditions. An aliquot of each sample was taken for SDS-
PAGE analysis and to the rest of the purified sample β-mercaptoethanol was 
added. Intein-6His cleavage was conducted for 36 h at 37°C, after which 20 μl 
of the final mixture, without additional purification, was resolved by denaturing 
4-12% SDS-PAGE. The band at about 20 kDa (*) corresponds to the full length 
protein and at about 45-50 kDa (**) to the intein fused form. The identity of the 
other co-purified proteins was not determined. 
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The D72TAG variant of PRL-3 was further subjected to a trial where protein 
expression was further allowed to proceed by overnight incubation at 18°C to 
assess if prolonged incubation time would negatively affect protein stability or, 
like in case of the N142 mutant, improve the overall yield of the full length 
protein produced.  
Like indicated in Figure 30, the mutant exhibited excellent expression 
efficiency, without observable readthrough of the STOP codon in the control 
sample in the absence of the addition of pBPA into the GM. In addition, the 
amount of the full length protein detected after prolonged induction time was 
higher (Figure 30) than after only 6 h incubation at 25°C (Figure 29). No 
observable effect on the overall purity of the sample was detected. 
The D72 mutant was the only variant of PRL-3 for which excellent yield of 
pBPA-containing protein was detected already at low level of pBPA in the 
medium (1 mM). It was noted previously that different unnatural amino acids 
have different optimal concentration ranges for successful protein expression 
and that higher concentrations of the unnatural amino acid in the GM could 
negatively affect cell growth (Hino et al., 2012). Moreover, the extensive study 
for the unnatural amino acid uptake from the medium, which profiled a total of 
138 amino acids, showed that the highest toxicity was linked to amino acids 
with reactive functional groups and to those which were structurally similar to 
the canonical ones (Liu and Schultz, 1999). pBPA was not in that screen and 
for pACF no toxicity was reported. 
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Figure 30: Small-scale expression of the PRL-3 D72pBPA mutant, in pTXB3-
intein-6His plasmid, under optimised conditions. pBPA was filtered into the TB-
FB GM at the beginning of the experiment, to reach the final concentration of 1 
mM. Protein expression was induced for 6 h at 25°C and then overnight at 
18°C. Intein cleavage was done with final concentration of 50 mM β-
mercaptoethanol overnight at 37°C. 20 μl of the final mixture, without additional 
purification, was resolved by denaturing 4-12% SDS-PAGE, stained in 
Coomassie and destained in ddH2O. The band at about 20 kDa (*) corresponds 
to the full length protein and at about 45-50 kDa (**) to the intein fused form. 
The identity of the other co-purified proteins was not determined. 
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3.1.8 Small-scale expression of VHR variants with pACF and pBPA  
For small-scale expression and purification experiments with different variants 
of VHR, the protocols developed with PRL-3 were successfully translated. A 
trial experiment with 1 mM pACF and the L25 mutant of VHR was not clearly 
indicative of the successful expression of the full-length protein, so the 
concentration of the amino acid was increased to 2 mM, and all the variants 
were subjected to these conditions. As shown in Figure 31, the F68 and N163 
mutants exhibited the highest expression level. According to the previously 
elaborated observations for PRL-3, it can be hypothesized that introducing a 
bulky and hydrophobic amino acid at positions 25 and 161 does not act in 
favour of proper protein folding, although both amino acids are located in the 
loop regions, which was anticipated to allow for some flexibility in 
accommodating a sterically more demanding unnatural amino acids. This 
seems to be even more likely cause in case of the L25 mutant, which is, as 
already mentioned, part of a surface-exposed hydrophobic patch, so 
introduction of pACF is not expected to negatively affect electrostatic charge 
distribution in the region.  
Nevertheless, all variants were also tried in the trial experiment with pBPA 
(Figure 32). Based on the results obtained with pACF, no lower concentrations 
than 2.5 mM of pBPA were screened. Unlike the generally satisfactory results 
obtained with pACF for all the mutants of VHR screened, only the F68 mutant, 
and to a lesser extent the L25 and G161 mutants, exhibited good expression 
level with pBPA. Taking into consideration the position of these residues, F68 
was selected for the large-scale expression in E. coli. In addition, the D92 
mutant also demonstrated expression level comparable to F68 mutant, under 
the same conditions, and was selected for up-scaled expression.  
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Figure 31: Small-scale expression of the VHR variants with pACF at 2 mM final 
concentration in pTXB3-intein-6His plasmid. pACF was added to the medium 
about 20 min before induction. Protein expression was induced for 6 h at 25°C. 
The samples were purified under native conditions. An aliquot of each sample 
was taken for SDS-PAGE analysis and to the rest of the purified sample β-
mercaptoethanol was added.  Intein cleavage was done with final concentration 
of 50 mM β-mercaptoethanol for 48 h at 37°C. 20 μl of the final mixture, without 
additional purification, was resolved by denaturing 4-12% SDS-PAGE. The 
band at approximately 50 kDa (**) corresponds to the full length fusion protein 
and at about 20 kDa to the full length protein after β-mercaptoethanol-induced 
intein cleavage (*).The identity of the other co-purified proteins was not 
determined. 
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Figure 32: Small-scale expression of the VHR variants with pBPA at the final 
concentration of 2.5 mM in pTXB3-intein-6His plasmid. pBPA was filtered into 
the into the TB-FB GM at the beginning of the experiment. Protein expression 
was induced for 6 h at 25°C and then overnight at 18°C. The samples were 
purified under native conditions. An aliquot of each sample was taken for SDS-
PAGE analysis and to the rest of the purified sample β-mercaptoethanol was 
added. Intein cleavage was done with final concentration of 50 mM β-
mercaptoethanol for 48 h at 37°C. 20 μl of the final mixture was resolved by 
denaturing 4-12% SDS-PAGE. The band at approximately 20 kDa corresponds 
to the full length protein and at about 50 kDa to the intein fused form- the areas 
are marked with red circles for the wtVHR. The identity of the other co-purified 
proteins was not determined. 
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3.1.9 Creating the final pBPA-containing PRL-3 construct for biological 
exploration 
The final construct for large-scale bacterial expression in E. coli needed to 
carry a tag for pull-down experiments. The available ab against PRL-3 are not 
suited for this, particularly when PRL-3 is cross-linked to another protein, which 
might potentially obscure ab recognition site. Whereas the pTXB3 construct 
has the advantage of removal of the truncated protein from the full length form, 
carrying the C-terminal intein-His6 tag, its use for pull-downs faced several 
problems, such as (i) instability of intein and its potential cleavage when used 
for pull-downs with the cell lysate, (ii) importance of the C-terminal region in the 
PRLs, which was already addressed in detail (Pascaru, Tanase et al., 2009; 
Rios et al., 2013; Skinner et al., 2009; Song et al., 2009) or (iii) plethora of 
literature evidence for studying the PRLs, in vitro and in cells, by utilizing the N-
terminal tagging approach (Daouty et al., 2008; Fiordalisi et al., 2006; Hardy et 
al., 2010; Liu, Al-Aidaroos et al., 2013; Song et al., 2009; Wang and Lazo, 
2012; Zeng et al., 2000). 
The pETM20 plasmid was compared with pTXB3-intein-6His, with the D72 
pBPA variant of PRL-3. The result is shown in Figure 33. In pETM20, the D72 
mutant of PRL-3 was expressed with an N-terminal Flag3-tag. Generating an 
analogous construct in the pTXB3/His6 plasmid was not successful because 
adding N-terminal tag to the protein generated a second recognition site for the 
NcoI restriction enzyme, after the nucleotide sequence encoding the affinity tag 
and immediately preceding the sequence for the starting amino acid of the 
protein. Because the PRL-3-encoding sequence was cloned into the NcoI/SapI 
sites in the pTXB3/His6 plasmid, only the final construct without the Flag3-tag 
was detected. Nevertheless, the trial experiment was conducted.  
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Like indicated previously, the yield obtained for D72pBPA, by using pTXB3/His6 
plasmid, was very satisfactory, and the level of the full length protein obtained 
was comparable to the level detected for the wt protein (Figures 30 and 33). It 
could not be excluded that, by placing the affinity tag at the C-terminal end of 
PRL-3, would not have negative effect on its proper functioning. In addition, 
considering the possible downstream applications of the unnatural amino acid-
containing variants of the recombinant PRL-3, such as microinjection into the 
cells or incubation with the cell lysate followed by photo-induced cross-linking, 
the N-terminal Flag3-tag was ultimately regarded as the most desirable, 
rendering the pETM20 plasmid of choice. Furthermore, like shown in Figure 33, 
the amount of the truncated form of the protein expressed when using the 
pETM20 plasmid was much less compared to the full length protein, so 
pETM20 plasmid was selected for further experiments. 
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Figure 33: Comparing plasmids pTXB3-His6 and pETM20 for the efficiency of 
expression of the pBPA variants of PRL-3 in E. coli. Protein expression was 
induced for 6 h at 25°C and then overnight at 18°C. In the pETM20 vector, 
D72pBPA mutant was expressed with an N-terminal Flag3-tag. wtPRL-3 was 
expressed  in the pTXB3-His6 vector. The samples were purified under native 
conditions. An aliquot of each sample was taken for SDS-PAGE analysis. The 
rest of the purified sample was subjected to intein cleavage by adding β-
mercaptoethanol to a final concentration of 50 mM. The band at about 45 kDa 
corresponds to the intein-fused form (***). When pETM20 vector was used, the 
band at about 40 kDa corresponds to the full length protein (**). The band at 
about 20 kDa corresponds to the full length protein (*). The identity of the other 
co-purified proteins was not determined. 
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3.1.10 Optimising concentration of pACF for the I141- and N142TAG 
variants of PRL-3 
Unlike fine-tuning the conditions for expression of PRL-3 variants with 
unnatural amino acid introduced at position 72, optimisation with the remaining 
two mutants proved to be much more cumbersome. For both, I141- and 
Asn142TAG, plasmids encoding both variants as N-terminal His6-TEV-Flag3-
tagged fusion proteins were generated and were subjected to another round of 
small-scale expression with pACF. The concentration of up to 5 mM pACF was 
screened. As shown in Figure 34, for I141pACF, the predominantly prematurely 
truncated form, where the amber STOP codon resulted in the termination of 
protein synthesis, was detected by SDS-PAGE analysis. For the N142pACF 
variant, the yield of the full length protein increased concomitantly with the 
increase of the concentration of pACF in the medium.  
It has been reported that the efficiency of the amber STOP codon suppression 
depends on the sequence context (Miller and Albertini, 1983). Efficiency of 
suppression of a nonsense codon was shown to depend on the composition of 
the nucleotides surrounding the STOP codon, and mainly on the first codon 
following a nonsense codon. Extensive investigation of the efficiency of the 
suppression of the amber STOP codon concluded that the codons followed on 
their 3’-side by uracil (U) or by cytosine (C) were poorly suppressed, unlike the 
codons followed by adenine (A) or guanine (G) which showed good 
suppression. However, there were also some exceptions noted, because STOP 
codons that were prior to CUG or CUC proved to be well suppressed. It is 
possible that the suppression efficiency could be affected by the secondary 
structure of the mRNA containing a nonsense codon, namely that the structure 
could be such that translation termination factors would not find it accessible 
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easily. In the case of PRL-3 variants, the most optimal sequence context 
existed. 
Next, not all positions in the protein are equally amenable to substitution with 
an unnatural amino acid (Farrell et al., 2005; Krishnamurthy, Dugan et al., 
2011; Sato et al., 2011; Uezu et al., 2012). Predicting which amino acid 
residues in the native protein would be well suited to accommodate pACF 
and/or pBPA can be helped by the available structural information, wicht was 
also the strategy applied here. It has been acknowledged that the efficiency of 
incorporation of an unnatural amino acid in response to the amber codon varies 
with the identity of the unnatural amino acid and with the position of the amino 
acid to be substituted in the gene (Hino et al., 2012). Moreover, the efficiency of 
the amber suppression with pACF was reported to be better than with pBPA 
because of the higher activity of its adjacent aaRS. 
Since we observed that the yield of the full length protein obtained with 
I141pACF variant was low, the mutant was abandoned at this stage. The 
N142TAG variant of PRL-3 was selected to be subjected to further trial 
experiments with pBPA. However, large-scale expression of N142pBPA, with 
2.5 mM concentration of pBPA, was extremely laborious and not efficient- the 
yield after the first purification step was about ten times lower. An additional 
drawback was the necessity to finally purify the sample by size-exclusion 
chromatography, to try to separate the prematurely truncated variant from the 
full length protein, and the pending optimisation of the conditions to obtain the 
separation. Therefore, the attention for biological exploration was focused on 
the D72pBPA variant of PRL-3.  
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Figure 34: Optimising concentration of pACF for expression with the I141- and 
N142TAG variants of PRL-3. Protein expression on a small scale was induced 
for 5 h at 25°C. pACF was used at 2.5 or 5 mM final concentration. The 
samples were purified under native conditions. An aliquot of each sample was 
resolved by 4-12% SDS-PAGE gel, stained in Coomassie dye and destained in 
ddH2O. The band at approximately 41 kDa corresponds to the expected size of 
the full length protein and at about 35 kDa to the variant where the amber 
STOP codon terminated protein synthesis. The identity of the other co-purified 
proteins was not determined. Blue Eye was used as the MW Protein Ladder. 
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3.2: Applicability of the photo-cross-linkable VHR variants in investigating 
dimerisation of VHR as a potential novel regulatory principle 
3.2.1. Large-scale bacterial over-expression of wtVHR and all its variants 
generated 
For large-scale bacterial expression of VHR, the pETM20 plasmid was 
selected. For VHR, the positioning of the affinity tag, which would be used in 
the pull-down experiments, at the N- or at the C-end of the protein was not at 
the level of importance discussed previously for PRL-3 (Chapter 3.1.9), as no 
sequence or structural determinants contributing to the specific subcellular 
localisation of VHR are known. The expression conditions initially applied for 
PRL-3 were taken and basically no modifications in the protocol were required.  
As indicated in Figure 35, all the variants were purified to a high purity. Like 
indicated previously, all the VHR variants were expressed as N-terminal Flag3-
tag fusion proteins and purified to a high purity. Typically 0.5-1 l scale of GM 
was prepared. Verification of all the variants generated by determining full 
mass of protein samples in solution and summary of the protein yields are 
provided in Tables 2 and 3, respectively. By using the pETM20 vector, a form 
of the protein where protein synthesis terminated at the position of the amber 
STOP codon, was also generated. Considering that for both of the pBPA-
containing variants of VHR the truncated form does not encompass the 
residues important for catalysis, it was not regarded necessary to try to 
separate the truncated form from the full-length protein by size-exclusion 
chromatography. 
The following variants of VHR were selected for large-scale bacterial over-
expression: native VHR, its photo-cross-linkable variants F68pBPA and 
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D92pBPA, catalytically inactive C124S, catalytically deficient D92A (Denu et 
al., 1995b; Ishibashi et al., 1992; Schumacher et al., 2002; Zhou et al., 1994) 
and a set of variants with systematically mutagenised position 68 (F68A, F68D, 
F68W and F68C) and the M69A mutant. The last set of mutants (F68A, F68D, 
F68W, F68C and M69A) was generated with the aim of intensive investigation 
of one of the most distinct structural features of VHR phosphatase, namely the 
“variable insert” segment.   
Considering that the F68pBPA variant of VHR showed promising results in 
expression and purification experiments conducted on a large-scale (see 
Figure 40), the advantages of utilizing an expanded genetic code approach 
were diverted from the initial attempt to identify (novel) interacting partners 
and/or substrates of VHR to providing the first in-depth investigation of the 
“variable insert” region in this phosphatase.  
In general, all the variants were expressed and purified with extremely 
satisfactory yields, which are summarised in Table 3. For simplification, the 
reported yields, calculated as mg of protein obtained from 1 l of bacterial 
culture, were calculated for the first purification step (HisTRAP)- regularly, not 
the whole batch obtained after the first HisTRAP was set for removal of the 
His6-tag by GST-TEV and the sample-to-sample variations in the efficiency of 
the recovery of the final protein sample, after the second HisTRAP and 
GSTrap, were to be expected. Nevertheless, although for large-scale 
purification of the VHR variants the conditions initially applied for PRL-3 were 
taken, basically no modifications in the protocol were required.  
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Figure 35: Coomassie stained SDS-PAGE gel of the wtVHR and all its variants 
generated. Plasmid pETM20 was used to over-express all the VHR variants as 
N-terminal Flag3-tagged fusion proteins, according to the detailed protocol 
described in sections 2.2.12 and 2.2.13. The variants of VHR with the amino 
acids at the indicated positions exchanged for the amber STOP codon, TAG, 
were expressed by growing bacterial cultures in the presence of 2.5 mM pBPA. 
2 μg of each protein was resolved by 4-12% SDS-PAGE gel, stained in 
Coomassie and destained in ddH2O. The band at approximately 23 kDa 
corresponds to the expected size of the full length protein. The band at 
approximately 14 kDa corresponds to the truncated version where the amber 
STOP codon resulted in the termination of protein synthesis. Sometimes the 
faint band at about 70 kDa was visible in some samples, the identity of which 
has not been determined. Blue Eye was used as the MW Protein Ladder. 
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Table 2: Analysis of the intact protein samples by LC-MS. The protocol is 
described in section 2.1.15.  The analysis was done by using an Acquity UPLC 
system (Waters) fitted with a C4 column coupled to a Q-Toff II mass 
spectrometer (Waters) using the ESI source in positive ion mode. Data were 
acquired over a mass range 500-3,500 m/z, with a scan time of 0.5 s. Data 
were calibrated externally against intact myoglobin as a reference standard, 
acquired immediately after sample data acquisition. Intact mass was calculated 
using the MaxEnt1 maximum entropy algorithm (Waters/Micromass).  
 
 
VHR 
Molecular  
mass 
expected (kDa) 
Molecular 
mass 
obtained (kDa) 
[Molecular mass expected 
(kDa) +H+]+xβ-mercaptoethanol  
 
Wild type 24.16 24.47 4 units of β-mercaptoethanol 
M69A 24.10 24.10  
F68A 24.09 24.17 1 unit of β-mercaptoethanol 
F68C 24.12 24.12  
F68D 24.13 24.13  
F68W 24.20 24.20  
F68pBPA 24.27 24.5 2 units of β-mercaptoethanol 
D92pBPA 24.30 24.46 2 units of β-mercaptoethanol 
D92A 24.12 24.20 1 unit of β-mercaptoethanol 
C124S 24.15 24.23 1 unit of β-mercaptoethanol 
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Table 3: Protein yields for the generated VHR variants. The yields were 
calculated as mg of protein obtained from 1 l of bacterial culture. The 
calculations were done for the protein samples after the first purification step by 
using HisTRAP. The calculations for the yield after the following purification 
steps (removal of the His6-tag by GST-TEV and the subsequent removal of the 
protease by the second HisTRAP and GSTrap columns), for which only a 
limited amount of the protein after the first purification step was used, were 
done by extrapolating the cleaving and recovery efficiencies to the whole batch, 
and checking protein concentration by measuring absorbance at 280 nm and 
resolving the samples by SDS-PAGE. 
 
 
VHR 
Protein yield 
(mg of protein/  
l of bacterial culture) 
Protein yield 
(after 2nd HisTRAP and GSTrap/ 
l of bacterial culture)  
Wild type 81.8 14.4 
M69A 40.4 11.2 
F68A 22.5 5.6 
F68C 46.5 13.1 
F68D 36.1 9.4 
F68W 34.7 10.2 
F68pBPA 73.6 8.3 
D92pBPA 50.4 4.4 
D92A 47.7 9.6 
C124S 32 1.8 
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3.2.2 Investigating cross-linking abilities of VHR variants containing 
pBPA in vitro  
In the set of preliminary experiments, which involved incubation of the 
F68pBPA variant of VHR with the cell lysate from HEK293 cells followed by 
exposure to 365 nm UV light, Western blot analysis (anti-Flag) of the 
immunoprecipitates (performed by using anti-Flag affinity gel) detected the 
bands which in size corresponded to the dimeric complexes of VHR. Analogous 
experiments without UV exposure showed no dimer formation (not shown 
because these preliminary experiments were not followed upon, as the focus of 
the project shifted into investigating dimerisation of VHR in vitro; they are 
accordingly not described in the methods, but was found necessary to mention 
them to explain how investigation of VHR homodimers started in the first 
place). VHR dimerisation has not been previously reported. In the light of these 
surprising results, an extensive investigation was designed to address 
apossibility of dimerisation as a novel feature linked to VHR. Therefore, to 
further characterize the potential of VHR to self-associate, a series of in vitro 
experiments was conducted. 
First, the dependence of the dimeric complex formation on the concentration of 
the protein was evaluated. For this purpose, the native protein and its F68pBPA 
variant were exposed to 345 nm light for 30 minutes, on ice, spanning protein 
concentration from 50 to 500 μg/mL. The subsequent Western blot analysis 
(anti-VHR) of the recovered samples detected the bands corresponding to the 
cross-linked complexes of VHR already at 50 μg/mL, as indicated in Figure 37 
(the band at about 53 kDa). There was proportional increase of the covalently 
cross-linked complexes detected following the increase of the protein 
concentration. Based on the results shown in Figure 37, the protein 
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concentration range between 50 and 250 μg/mL was selected as the range of 
interest. In addition, this range enabled keeping the reaction scale at 50 μL, 
thus minimizing the amount of the protein samples required.  
Intriguingly, the F68pBPA variant of VHR was found to also covalently cross-
link to the truncated product formed when the amber STOP codon resulted in 
the termination of protein translation instead of pBPA incorporation (Figure 37) 
(the band at about 40 kDa). This enthralling observation led to the indication 
that the region of the protein corresponding to the truncated product might bear 
sufficient structural requirements to drive intermolecular association between 
two monomeric units of VHR.  
As indicated already in Figure 35, in the purified samples of both of the pBPA-
containing variants of VHR the truncated products, with the protein translation 
aborted at the position of the amber STOP codon, were also generated, 
notwithstanding at a different extent. For the D92pBPA variant, the proportion 
of the prematurely truncated form was regularly lower than for F68pBPA. These 
truncated products were stable in the cells and, due to the N-terminal tagging, 
detected in the purified samples. At that point no further separation by size-
exclusion chromatography was rendered necessary because this fragment was 
not anticipated to impose interference with phosphatase activity assessments. 
This is due to neither of the truncated products generated for both pBPA-
containing variants included the residues of the canonical PTP signature motif 
or the residues detrimental for hydrolytic activity of the enzyme. 
It was regarded as reasonable not to perform exposures to 345 nm light for 
longer than 30 minutes to (i) prevent possible damage of the protein and/or 
cross-linked complexes which might result in yield reduction and to (ii) avoid 
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the formation of larger complexes with ambiguous solubility/stability properties 
that may generate even more artefacts, for example by modifying recognition 
by the specific antibody. Moreover, in the preliminary time-screen experiment, 
employing 365 nm light, the complex corresponding in size to the dimer was 
visible already after 5 min of UV exposure (not shown). In all the experiments, 
the samples were kept on ice for the duration of exposure to 345 nm light and 
the box was at about 40 cm distance from the UV lamp, to try to minimize the 
destructive effect such exposure might have on the protein samples. To control 
for the potential damaging effect of the UV light, wtVHR was constantly utilised 
as a control. As indicated in Figure 37, no bands in the lower molecular weight 
range were detected, indicating that under this setup no damaging effect of UV 
light on the proteins was exerted. In addition, another set of controls regularly 
used included the non-irradiated set of F68pBPA-containing samples. Lack of 
appearance of the bands in the higher molecular weight range for these 
samples indicated that the formation of the observed intermolecular complexes 
dependent on (i) the presence of pBPA in the protein and (ii) on the exposure 
of only pBPA-containing protein variants to 345 nm UV light. 
From the results presented in Figure 37, it can be seen that increasing protein 
concentration from 250 to 500 μg/mL had no significant effect on improving the 
yield of the covalently cross-linked dimers formed. Based on this observation, it 
would be reasonable to assume that the likely cause might be intramolecular 
cross-linking. Like already mentioned, the reactivity of the photo-excitable 
pBPA is affected by the geometrical constraints (Tanaka et al., 2008). This 
refers to not just the distance from the proximal C-H bonds to which pBPA 
could covalently cross-link, but also to the relative orientation the amino acid 
assumes within the peptide (Wittelsberger et al., 2008 and see Figure 36). To 
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account for negligible increase in the dimers formed after photo-induced cross-
linking, it could be hypothesized that pBPA incorporated at position 68 
assumes such an orientation that intramolecular reaction is more favoured then 
intermolecular, under the experimental conditions applied. 
 
Figure 36: Reactive radius of benzophenones. Initially, reactive radius of pBPA 
was considered a sphere about 3Å in radius, but rotation about Cα -Cβ bond 
increases reactive space. 
 
Therefore, in order to investigate if dimerisation was mediated by the cysteine 
residue of the catalytic site, an analogous experiment was performed after pre-
incubating the samples with the cocktail of the general inhibitors of the 
phosphatases known for its broad spectrum phosphatase inhibition, PS (Figure 
38). PS was used with the F68pBPA variant of VHR, but also with the wt 
protein as a control. Moreover, the C124S mutant, which has diminished 
catalytic activity, was used as additional control. All negative controls were 
clean, as expected- there were no bands in the higher molecular weight range 
detected for the non-irradiated control samples, and also no bands at the lower 
molecular weight range in case of the irradiated samples (Figure 38). 
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 A possible mechanism through which the intermolecular association in VHR 
could be mediated might involve dimeric association through disulfide bond 
formation. Cys124 is placed at the base of the active site crevice and, from 
merely structural considerations, the intermolecular association through 
Cys124-mediated disulfide bond formation was not regarded as likely. There 
was a work reported previously which investigated the mechanism commensal 
bacteria use to activate Erk1/2 pathway of the host (Wentworth et al., 2011). In 
this study it was shown that treatment of cells expressing wtVHR or its C124S 
mutant with H2O2 led to the formation of higher molecular weight complexes 
only in case of the native protein. These complexes were assigned to be 
disulfide-bond mediated complexes formed through the active site cysteine. 
The cross-linking pattern (Figure 38) obtained for the F68pBPA variant of VHR, 
with or without treatment with PS, indicated that the observed self-association 
was not significantly impacted by the availability of the active site cysteine. 
 
 
 
 
 
s 
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Figure 37: Examining the ability of the F68pBPA variant of VHR to form UV-
induced dimers after 30 min exposure to 345 nm. Non-irradiated F68pBPA and 
wtVHR, with or without UV-exposure, were used as  controls. The protocol is 
described in section 2.3.5.The band at about 53 kDa corresponds to a 
covalently cross-linked dimer and at about 40 kDa to a cross-link of the 
monomer to a product with protein synthesis terminated at position of the 
amber codon. Monomers run as a band at about 25 kDa. The band at about 70 
kDa was occasionally observed after purification of the recombinant protein 
(see Figure 35). The analysis was done by Western blot (anti-VHR). The 
results are representative of two experiments. 
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Figure 38: Assessing the effect of the active site Cys124 on the ability of VHR 
to form UV-induced dimers. This was investigated by (i) using robust 
phosphatase inhibitor PS and (ii) by employing the catalytically inactive mutant 
C124S. The protocol is described in section 2.3.5. Reactions were done in a 
96-well plate setup and the final volume was 50 μl. Recovered samples were 
mixed with 2 x SDS-PAGE sample buffer prior to resolving 250 ng of protein by 
reducing 4-12% SDS-PAGE. The analysis was done by Western blot (anti-
VHR). The band at about 53 kDa corresponds to a covalently cross-linked 
dimer, at about 40 kDa to a cross-link of the monomer to a truncated product 
and at about 25 kDa to a monomer. The band at about 70 kDa was 
occasionally observed after purification of the recombinant protein. The results 
are representative of at least two experiments.  
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It was acknowledged before that for a photo-cross-linkable amino acid 
incorporated at different positions within the same protein, different efficiencies 
in the UV-induced cross-linking were observed (Hino et al., 2005; 
Krishnamurthy, Dugan et al., 2011; Sato et al., 2011). Therefore, the D92pBPA 
variant of VHR was subjected to an analogous set of experiments to check if 
there would be any differences in the generated cross-linking pattern. The 
result is presented in Figure 39. Exposure of the D92pBPA variant of VHR to 
345 nm light resulted in the formation of a band corresponding in size to a 
dimeric complex, just like previously shown for the F68pBPA variant. Moreover, 
for the D92pBPA variant there was no band, at least at a detectable level, 
corresponding in size to a cross-link formed between the full length protein and 
the product terminated at the position of the amber codon. Like shown in Figure 
15, the amount of the truncated product present in the purified sample of the 
D92pBPA variant was less than in the case of the F68pBPA variant, which 
could be a contributing factor to the lack of covalently cross-linked complexes 
formed and/or detected with this fragment. Another plausible explanation could 
be the orientation of pBPA at position 92, which could be such that cross-
linking to the full length protein might be preferred.  
In summary, the variants of VHR with pBPA selectively introduced at positions 
68 and 92 showed the ability to form dimers after exposure to 345 nm light, in 
vitro, thus underscoring the importance of evaluating diverse positions for 
replacement with pBPA. 
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Figure 39: Examining the ability of the D92pBPA mutant of VHR to form photo-
induced dimers. Shown are the dimer-forming yields of the purified recombinant 
Flag3-tagged F68pBPA and D92pBPA variants upon 30 min exposure to 345 
nm light and across protein concentration range of 50-250 μg/ml. Irradiation 
was performed according to the protocol described in detail in section 2.3.5. 
Reactions were done in a 96-well plate setup and the final volume was 50 μl. 
Recovered samples were mixed with 2 x SDS-PAGE sample buffer prior to 
resolving 250 ng of protein by reducing 4-12% SDS-PAGE. The analysis was 
done by Western blot (anti-VHR). The band at about 53 kDa corresponds to a 
covalently cross-linked dimer, at about 40 kDa to a cross-link of the monomer 
to a truncated product and at about 25 kDa to a monomer. The band at about 
70 kDa was occasionally observed after purification of the recombinant protein. 
Proteins were detected by Western blotting using anti-VHR antibody. The 
results are representative of two experiments.  
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3.2.3 Catalytic activity of the VHR variants against pNPP 
To assess if, and how, the introduced mutations affected the catalytic 
performance of the recombinant VHR variants, an extensive kinetic profiling 
was conducted, according to the specifications described in section 2.3.4. The 
hydrolytic activity was assessed against the robust non-specific phosphatase 
substrate pNPP. All the variants were at the concentration of 500 nM, whereas 
the concentration of the substrate spanned across 0.5 to 100 mM. The pH 
value of the reaction buffer was set to 7.5. The calculated kinetic parameters 
kcat and Km are summarised in Table 4.  
The D92A and C124S mutants of VHR was omitted from the kinetic profiling 
because it had already been reported that substitution at this position entirely 
abolishes phosphatase activity (Denu et al., 1995b; Ishibashi et al., 1992; Zhou 
et al., 1994). These early studies addressing catalytic specificities of VHR as 
well as the dephosphorylation mechanism employed helped to establish that (i) 
VHR has only one catalytic centre governing dephosphorylation of both pTyr 
and pSer/pThr-containing substrates and that (ii) VHR employs the same 
catalytic principle applied by the Tyr-specific PTPs (Denu et al., 1995a and b; 
Denu et al., 1996a; Ishibashi et al., 1992; Zhou et al., 1994). 
For VHR, it was acknowledged that the enzyme displays the most efficient 
catalytic performance at the pH value 6 of the reaction buffer (Denu et al., 
1995a; Hengge et al., 1996). The activity was found to decrease at the elevated 
levels of the pH value (Denu et al., 1995a). The pH value for the data 
presented in Tables 4 and 5 was 7.5, which could contribute in accounting 
generally lower catalytic activity demonstrated by the wtVHR in contrast to the 
previously reported values (Denu et al., 1995a; Denu et al., 1996b). Other 
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differing factors were different composition of the reaction buffers used and 
also different ways of analyzing the data. 
Drawing conclusions from the data presented in Table 4, it can be generally 
stated that replacing Phe68 in the native VHR with alanine, aspartate, cysteine, 
tryptophan or photo-cross-linking pBPA resulted in no drastic alterations in the 
catalytic efficiency. The Km values of all the aforementioned variants were 
within 1-1.2 fold of the value obtained for the wtVHR.  
On the other hand, when Met69 of the native VHR was replaced with alanine, 
the Km value approximately doubled. Based on the known role of Met69 in 
contributing to the maintenance of the proper orientation of the P-loop by 
anchoring the conserved Arg130 through hydrogen bonding (Yuvaniyama et 
al., 1996), it might be that generating the M69A substituent dislocates the most 
optimal relative position of the residues of the P-loop. Moreover, the value of 
the second order rate constant kcat/Km obtained for the M69A mutant was 
about 3.2 times lower comparing to the wtVHR. Its lower value with respect to 
the values obtained for the other VHR variants subjected to the screen could be 
attributed by the already mentioned effect the substitution exerted on the Km 
value because the catalytic efficiency, as indicated by the catalytic turnover kcat 
value, was only about 1.6 times lower. 
As for the variants generated for position 68, the values of the kinetic 
parameters kcat and kcat/Km exhibited only low reductions with respect to the 
wtVHR. 
In the native protein, Asp92 acts as a general acid/base catalyst in the 
hydrolytic reaction leading to the formation of a phosphoenzyme intermediate 
and the following intermediate hydrolysis (Denu et al., 1996b). Substituting 
 226 
Asp92 with Asn, which mimics it in size but is robbed off the ability to act as an 
acid/base catalyst in the dephosphorylation reaction, significantly lowered the 
values of the kinetic parameters kcat, Km and the kcat/Km (Denu et al., 1996b; 
Kim et al., 2001). In contrast, the derogative effect of the D92pBPA substitution 
on the catalytic performance of this VHR variant was not as striking as for the 
mentioned D92N substituent. For the D92pBPA variant, the catalytic efficiency 
(indicated by kcat value) was only around 25 times lower, whereas the values 
reported previously for the D92N mutant were up to almost 120 times lower 
(Denu et al., 1996b; Kim et al., 2001). The less drastic effect of the D92pBPA 
substitution is also reflected in the value of the second order rate constant 
which is only slightly lower (about 1.4 times) than for the wtVHR. Therefore, 
based on the results presented in Table 4 for the D92pBPA variant of VHR, it 
could be postulated that the carbonyl moiety in the side chain of pBPA could in 
part rescue the lack of the putative general acid/base aspartate. 
In summary, the current study provides the first extensive kinetic investigation 
of the generally nonconserved residues in VHR, Phe68 and Met69, located in 
spatial proximity to the phosphosubstrate-binding cradle. As shown in Table 4, 
for all VHR variants generated by site-directed replacement of Phe68 in the 
native protein with alanine, aspartate, tryptophan, cysteine or photo-activatable 
pBPA, the values of the kinetic parameters were not substantially affected. 
Therefore, it could be concluded that the overall catalytic performance of the 
enzymes was virtually not altered.  
In slight contrast was catalytic efficiency of M69A variant, which exhibited a 
more pronounced shift in the values of kinetic parameters Km and kcat/Km 
when compared to the wtVHR and also the other variants generated for the 
position 68. Hence, it could be reasoned that substituting methionine for a 
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residue that lacks hydrogen bonding capacity disrupts maintenance of the 
proper geometry of the active site cleft via dislocation of the concise hydrogen 
bonding array required to fine tune relative positions and optimal distance of 
the key catalytic residues thus indirectly engaging in promoting efficient 
turnover. 
Table 4: Characterisation of the catalytic activity of the VHR variants. The 
general protocol is outlined in section 2.3.4. Kinetic parameters for the wtVHR 
and its variants were determined by using pNPP as a substrate. The proteins 
were assayed at 500 nM and concentrations of pNPP used were 0.5, 1, 5, 10, 
20, 30, 40, 50, 60, 80 and 100 mM. The assays were conducted at 37°C in a 
buffer containing 25 mM HEPES (pH 7.5), 124.5 mM NaCl, 2.5 mM EDTA and 
2 mM DTT, in 96-well plate format, in a microplate reader Tecan Saphire 2. The 
minimum of two triplicate sets of experiments was conducted for each sample. 
The Km was determined using the GraphPad 5.0 software.  
 
VHR kcat Km kcat/Km 
 s-1 mM M-1s-1 
Wild type 43.85 ± 5.16 21.38 ± 6.42 2.14 ± 0.40 
M69A 26.44 ± 3.35 43.35 ± 13.92 656.3 ± 0.29 
F68A 28.21 ± 5.56 20.66 ± 7.52 1.41 ± 0.24 
F68C 39.71 ± 1.83 25.47 ± 0.87 1.56 ± 0.12 
F68D 26.82 ± 0.62 22.49 ± 6.35 1.24 ± 0.32 
F68W 36.15 ± 24.42 21.60 ± 5.72 1.58 ± 0.71 
F68pBPA 40.04 ± 5.43 21.84 ± 8.54 2.09 ± 0.99 
D92pBPA 1.74 ± 0.01 10.48 ± 1.11 1.56 ± 0.12 
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Earlier studies also showed that the entire phosphatase activity of the wtVHR 
was utterly abrogated in the presence of a competitive inhibitor such as 
arsenate or vanadate (Zhou et al., 1994), consistent with a model of a single 
catalytic site accounting for the dual-specificity profile. The phosphatase 
inhibitor employed for the data presented in Table 5 was a broad-range 
inhibitor called PhosSTOP. According to the product specifications, PS 
demonstrated various efficiencies in inactivating diverse set of PPs screened. 
To examine the effects it imposes on the catalytic activity of VHR, a set of 
experiments was done where the native protein was pre-incubated with PS 
prior to adding pNPP (Table 5) and then compared to the performance of the 
untreated control.  
By comparing with the values of the kinetic parameters obtained for the wtVHR, 
it can be seen that the wtVHR treated with PS demonstrated only about 1.2 
times reduction in the catalytic turnover. The exhibited approximately 2.1 lower 
value of the second-order rate constant kcat/Km is the result of about 2.2 times 
higher value of the Km parameter, reflecting binding of a substrate. Whether 
further increase in the blocking of the catalytic activity of the native VHR could 
be achieved by prolonging incubation times of the enzyme with the inhibitor 
was not tested. 
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Table 5: Assessing the effect of the general phosphatase inhibitor PS on the 
catalytic activity of the wtVHR. The general protocol is outlined in section 2.3.4. 
The samples were pre-incubated with PS for 15 min prior to measurements. PS 
is a broad range phosphatase inhibitor, the composition of which is not 
speciifed, so the concentartions of its components are also not known. It was 
prepared according to the instructions from the manufacturer and was used at 
1 x final concentration (from 10 x stock). The activity was examined with pNPP 
as a substrate. The protein concentration was 500 nM and the concentrations 
of pNPP used were 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 80 and 100 mM. The 
assays were conducted at 37°C in a buffer containing 25 mM HEPES (pH 7.5), 
124.5 mM NaCl, 2.5 mM EDTA and 2 mM DTT, in 96-well plate format, in a 
microplate reader Tecan Saphire 2. Two triplicate sets of experiments were 
conducted for each sample. The Km was determined using the GraphPad 5.0 
software.  
 
 
VHR kcat Km kcat/Km 
 s-1 mM M-1s-1 
Wild type 47.80 ± 0.84 14.96 ± 1.54 2.87 ± 0.10 
Wild type + PhosSTOP 39.90 ± 4.11 32.37 ± 11.29 1.34 ± 0.25 
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3.2.4 Structural characterisation of the VHR variants by far-UV CD 
measurements  
Structural integrity of the VHR variants was investigated by obtaining fa-UV CD 
spectra (Ranjbar and Gill, 2009). Prior to CD measurements, the protein 
concentration was determined by measuring A280 with a NanoDrop 
Spectrophotometer. However, sometimes there was a discrepancy between the 
measured concentration value and the corresponding spectra obtained, 
possibly due to dilution effect when preparing the measuring cuvette for various 
samples. This concern was also noted when acquiring the CD spectra for PRL-
3 variants (D72A, I141Y, N142Y, N142A and Q145Y; data not shown). In 
addition, the CD spectra presented earlier for PRL-3 (McParland, Varsano et 
al., 2011) support the above stated difficulties in obtaining the correct protein 
concentration value by using NanoDrop. Therefore, plotting the raw data was a 
more favourable option then normalizing them to a fixed value, whereas it still 
provided a good qualitative indication of the proper protein folding.  
When comparing the spectra acquired for all the VHR variants with the CD 
measurements obtained for the native protein, only minor modifications of the 
CD spectra were observed (Figures 41-43). All the variants were in good 
agreement with the spectra acquired for the native protein. In addition, the 
spectrum for D92pBPA compared well to the one for D92A (Figure 41), as 
expected due to the positioning of this residue in the general acid/base loop. 
Acquiring far-UV CD spectra (190-250 nm) can give information about 
secondary structure of proteins because every element of the secondary 
structure (alpha-helices, beta-sheets or random coils) give characteristic shape 
and magnitude in the spectra (Ranjbar and Gill, 2009), and, like shown in 
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Figures 41-43, for all VHR variants the obtained CD spectra showed 
comparable secondary structures. 
Moreover, the variants generated for position 68 all aligned well when mutually 
compared (Figure 42). In the native protein, Phe68 is located on the surface-
exposed hydrophobic patch (Wu et al., 2009; Yuvaniyama et al., 1996), which 
prompted a hypothesis that certain plasticity to accomodate residues of diverse 
structural and electrochemical properties might be reasonable to expect. In 
additional support of this hypothesis, even the F68pBPA variant of VHR 
exhibited excellent alignment with the spectra acquired for the native protein 
(Figure 43). Furthermore, when substituting Met69, known to form hydrogen 
bond with a conserved Arg130 of the P-loop (Yuvaniyama et al., 1996), for 
alanine did not seem to cause structural perturbations (Figures 42 and 44). 
Therefore, it can be overall concluded that none of the introduced mutations 
disrupted proper folding of the mutant forms of the phosphatase, as judged by 
comparing the profile of the spectra with the results obtained for the wtVHR.  
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Figure 41: Analysis of the secondary structure for the wtVHR and its variants 
by obtaining far-UV CD measurements. The detailed protocol is outlined in 
section 2.1.16. The proteins were dialysed against 20 mM Tris-HCl (pH 7.4), 50 
mM NaCl and 1 mM β-mercaptoethanol and the concentration was measured 
by NanoDrop Spectrophotometer. The CD spectra were acquired across 200-
250 nm range. The spectra obtained for all the mutant forms were compared 
with the one for the native protein.  The spectrum for D92pBPA was also 
assessed with respect to a conventional substrate-trap D92A. The raw data 
was plotted using GraphPad Prism 5.0 software. 
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Figure 42: Analysis of the secondary structure for M69A and for a series of the 
F68-mutants of VHR by obtaining far-UV CD measurements. The detailed 
protocol is outlined in section 2.1.16. The proteins were dialysed against 20 
mM Tris-HCl (pH 7.4), 50 mM NaCl and 1 mM β-mercaptoethanol and the 
concentration was measured by a NanoDrop Spectrophotometer. The CD 
spectra were acquired across 200-250 nm range. The raw data was normalized 
to the highest concentration value amongst the samples measured (0.47) and 
the normalized values were plotted using GraphPad Prism 5.0 software. 
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Figure 43: Comparing the secondary structure of the F68pBPA variant of VHR 
to the native protein by obtaining far-UV CD measurements. The detailed 
protocol is outlined in section 2.1.16. The proteins were dialysed against 20 
mM Tris-HCl (pH 7.4), 50 mM NaCl and 1 mM β-mercaptoethanol and the 
concentration was measured by a NanoDrop Spectrophotometer. The CD 
spectra were acquired across 200-250 nm range. The spectra for wtVHR and 
for its F68pBPA mutant were acquired in two independent measurements so 
the raw data was normalized to 1 and the normalized values were plotted using 
GraphPad Prism 5.0 software. 
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Figure 44: Met69 of the variable insert segment forms hydrogen bond with 
Arg130 of the P-loop in VHR. (a) Zoom-in into the active site pocket of VHR. 
The structure of VHR (PDB: 1VHR) is shown as surface representation with 
colouring based on the secondary structure elements (helices in cyan, sheets 
in magenta and loops in light pink). Sulfate ion bound in the active site is shown 
as stick (yellow). The residues of the P-loop (from His123 to Arg130) are shown 
as sticks (Cys124 is blue and other residues from 123-129 red). Met69 and 
Arg130 are coloured based on atoms (carbon-green, hydrogen-grey, nitrogen-
blue, oxygen-red and sulfur-orange). Distance between Met69 and Arg130 was 
measured to be about 5 Å. Arg130 is at the end of the P-loop and hydrogen 
bond with Met69 helps to keep it in the optimal position (Yuvaniyama et al., 
1996). (b) Representation like under (a), but the surface spanning residues of 
the P-loop (from His123 to Arg130) is rendered transparent. All structures were 
generated using Pymol. 
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3.2.5 Investigating the self-association of the VHR variants with 
alternative cross-linking methods  
The next task was to further inspect if VHR has an intrinsic ability to form 
dimers and/or higher order oligomers. To probe the propensity of VHR for 
dimerisation without using genetically encoded site-specific incorporation of 
photo-cross-linkable amino acid, more conventional cross-linking approaches 
were employed. Despite the vastly recognised attraction of this benzophenone-
based derivative in probing stably or transiently associated interacting partners 
via photo-induced cross-linking (Hino et al., 2005; Kage et al., 1996; 
Krishnamurthy, Dugan et al., 2011; Majmudar et al., 2009; Musial-Siwek et al., 
2007; Sato et al., 2011; Uezu et al., 2012; Ye, Köhrer et al., 2008), there are 
several issues to be considered: (i) It has been demonstrated that placing 
pBPA at the protein-protein binding interface hindered cross-linking, although 
meeting predicted geometric requirements for detection of the interaction (for 
example, sufficient distance between the carbonyl group of pBPA and 
preferentially reactive proximal C-H bonds (Sato et al., 2011). (ii) Photoaffinity 
scanning experiments provided evidence that pBPA exhibits more reactivity 
towards methionine residue in the target domain than for any other amino acid 
(Tanaka et al., 2008; Wittelsberger et al., 2006a and b; Wittelsberger et al., 
2008). Moreover, introduction of single methionine mutations into the N-
terminal extracellular domain of the parathyroid hormone receptor (PTHR1) 
revealed that pBPA, which was introduced selectively at two positions in the 
docking region of the PT hormone (PTH), previously implied in the receptor 
activation, cross-linked to methionine residues spanning a range of up to 11 
amino acids in the receptor (Wittelsberger et al., 2006b). The subsequent work 
(Wittelsberger et al., 2008) strongly suggested to relax the distance constraint 
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between the carbonyl moiety of pBPA and the proximal C-H bond to at least 10 
Å when conducting computer simulations aiming at obtaining the structure of 
the interacting interface. This opposed a postulation deduced from a detailed 
mechanism describing the photochemical reactivity of the benzophenone-
based photo-cross-linkers (Dormán and Prestwich, 1994), according to which 
the mentioned distance is not to exceed 3.1 Å if abstraction of hydrogen in the 
initial reaction step is to take place. Hence, opting for a more traditional 
approach of probing the oligomerization state of proteins by using the cross-
linking reagents glutaraldehyde and DSS to investigate VHR dimerisation was 
a necessary complementary approach.  
First, wtVHR and its F68pBPA variant were subjected to cross-linking with 
glutaraldehyde. The range of the protein concentrations screened was the 
same like in the photo-induced cross-linking. As indicated in Figure 45a, the 
monomeric form of the proteins runs as a band at apparent molecular weight of 
approximately 20 kDa. A second population at about 40 kDa clearly 
corresponds to the size of a dimer. Incubation with glutaraldehyde also led to 
the detection of bands corresponding in size to higher-order oligomers. 
Moreover, in case of the F68pBPA variant of VHR, a smear of aggregated 
proteins was detected at larger molecular masses. Consistent with the results 
obtained when exposing pBPA-variants of VHR to 345 nm light, the bands 
which size could be attributed to the cross-linking with the truncated product 
terminated at the position of the amber STOP codon were also detected. 
Therefore, the results for the F68pBPA variant of VHR obtained through two 
different cross-linking approaches correlated nicely. The control samples, 
incubated without glutaraldehyde, exhibited no bands in the higher molecular 
weight range (Figure 45b). To ensure that the protein concentration was proper 
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and that the equal protein amounts were employed in the reactions, the 
aliquots of the samples were resolved by SDS-PAGE and stained with colloidal 
Coomassie (Figure 45c). 
Finding the most optimal experimental conditions to boost cross-linking 
efficiency without accompanying increase in the heterogeneity of the generated 
conjugates is still largely based on the “trial-and-error” principle (Klockenbusch 
and Kast, 2010; Leitner et al., 2010). Glutaraldehyde, although wildly applicable 
as an effective cross-linking reagent, bears somewhat controversial chemistry- 
up to 13 different forms of this reagent have been identified, depending on the 
plethora of the reaction conditions, such as pH, temperature or concentration, 
and even eight different reaction mechanisms in which these diverse forms 
could engage (Migneault et al., 2004). Unlike genetically encoded photo-
activatable amino acids, glutaraldehyde exhibits non-selective reactivity, thus 
generating a number of intra- and intermolecular connections. Considering 
debatable features of glutaraldehyde, cross-confirmation of the intrinsic ability 
of VHR to dimerize was sought by using another type of chemical cross-linking 
reagent, DSS, which has six carbon atoms in the spacer chain spanning 
residues over 11 Å. In general, succinimidyl esters classify amongst frequently 
used conventional chemical cross-linkers targeting primary amino group of 
lysine residues, and the N-terminal end of the protein (Leitner et al., 2010; 
Trakselis et al., 2005). wtVHR was used at the concentrations of 50 and 500 
μg/mL and was incubated with or without the presence of DSS in the reaction 
buffer. The subsequent analysis of the reaction mixture by Western blotting 
(Figure 45d) demonstrated that only when incubation was conducted with DSS, 
VHR monomers crooss-linked into homodimers, with enhancement in the 
cross-linking yield being concomitant with the abundance of the protein in the 
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sample. This result was consistent with the combined results obtained in the 
previous cross-linking reactions.  
Collectively with the results obtained for profiling of the F68pBPA mutant of 
VHR, it could be postulated that regulated variations in the amino acid 
composition with respect to the native protein might trigger discrete 
conformational changes with derogative effect on the dimer assembly and/or 
stabilization. As a result, two reactive moieties may not be optimally positioned 
to each other what might be reflected in different efficiency of the covalent 
capture via cross-linking.  
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Figure 45: Investigating the potential of VHR to self-associate by chemical 
cross-linking. (a) Cross-linking was done with glutaraldehyde, which was used 
at 0.025% (v/v). The monomeric forms run as a band at apparent MW of 
approximately 20 kDa. A second population at about 40 kDa corresponds to the 
size of the dimer. The faint band at about 30 kDa, present only in the 
glutaraldehyde-treated sample of the Flag3-tagged F68pBPA variant, matched 
the MW of the crosslinked complex between the full length and the truncated 
form. Bands at higher MW (in the range 53-130 kDa) correspond to the higher 
order oligomers and are the result of the non-specific cross-linking by GA. (b) 
The control samples were incubated without glutaraldehyde. (c) Estimating that 
equal protein amounts were used for cross-linking by resolving 1 μg of the 
protein samples (without glutaraldehyde) by 4-12% SDS-PAGE and staining 
with colloidal Coomassie. (d) Cross-linking of wtVHR with DSS showed dimer 
formation. The cross-linked species were detected by Western blotting (anti-
VHR). The results reflect the minimum of two independent experiments.  
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Figure 46: Investigating if the potential of VHR to self-associate depends on 
the catalytic cysteine by chemical cross-linking. (a) Glutaraldehyde was used 
from 0.05% (v/v) stock to top up to 50 μl reaction volume.  The monomeric 
forms run as a band at apparent MW of approximately 20 kDa. A second 
population at about 40 kDa corresponds to the size of the dimer. Band at about 
80 kDa correspond to the size of the trimer and are the result of the non-
specific cross-linking by GA. The control samples were incubated without 
glutaraldehyde. The cross-linked species were detected by Western blotting 
(anti-VHR). The results reflect the minimum of two independent experiments.  
 (b) Estimating that equal protein amounts were used for cross-linking by 
resolving 1 μg of the protein samples (without glutaraldehyde) by 4-12% SDS-
PAGE and staining with colloidal Coomassie.  
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3.2.6 Profiling the structural effect of position 68 on the self-association 
of VHR by chemical cross-linking with glutaraldehyde 
 
The next major focus was to systematically profile a series of mutants 
generated for the position of Phe68 in order to rigorously investigate the impact 
of steric and/or electrostatic features of this patch on the establishment of VHR 
homodimers. The variants of VHR with Phe at position 68 replaced by alanine, 
aspartate, tryptophan or cysteine, in addition to the previously obtained photo-
crosslinkable pBPA-variant, were used. Next, by subjecting the samples to the 
cross-linking with glutaraldehyde across a broad protein concentration range, it 
was assessed if any discernible effect on the dimer formation could be 
detected. All newly generated Phe68-variants of VHR were able to form dimers, 
and higher order oligomers, upon incubation with glutaraldehyde (Figure 47). 
Exchanging a hydrophobic aromatic residue in the native protein 
(phenylalanine) for a small one (alanine) or a polar, non-charged one (cysteine) 
led to a more pronounced effect on the self-association of the protein than 
exchanging it for an aliphatic charged residue (aspartate) possibly by enabling 
closer association of the monomeric units, whereas the cross-linking profile for 
the wtVHR and its F68D and F68W variants was comparable (Figures 45 and 
47). One could envision several mechanisms through which the latter could 
disrupt intermolecular association, for example by exerting electrostatic 
repulsion or by favouring the formation of salt bridges and/or polar interactions 
with the proximal residues that would obliterate fixing of the most optimal 
orientation of the monomeric units of VHR. In addition, the M69A variant also 
exhibited cross-linking pattern similar to the one obtained for the wtVHR. 
Hence, its predominant role seems to be the stabilization of the active site 
(Yuvaniyama et al., 1996).  
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Figure 47: Profiling the effect of the structural and electrostatic properties of 
the residues incorporated at position 68, on the ability of VHR to self-associate, 
by chemical cross-linking with glutaraldehyde. Phe68 was systematically 
replaced with alanine, aspartate, tryptophan and cysteine. The experiment was 
conducted according to the protocol described in section 2.3.6. The samples 
were incubated with 0.025% (v/v) of glutaraldehyde in 20 mM HEPES pH 7.4 
for 30 min at 37°C and the final reaction volume of 50 μl. All proteins were used 
at three different concentrations (50, 100 and 250 μg/ml). The M69A variant 
was also analysed when profiling the involvement of the “variable insert” 
segment in dimerisation of VHR. The control samples are shown in Figure 48. 
The monomeric forms run as a band at apparent MW of approximately 20 kDa. 
A second population at about 40 kDa corresponds to the size of the dimer in 
the glutaraldehyde treated samples. Bands at higher MW (in the range 53-130 
kDa) correspond to the higher order oligomers and are the result of the non-
specific cross-linking by GA. The result is representative of two experiments. 
Western blot was done by using anti-VHR ab. 
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Figure 48: The control samples for Figure 47. They were processed in the 
same way, but without glutaraldehyde. For panel (a), the effect of the amino 
acid substitution on the potential of VHR to self-associate was checked by 
Western blot (anti-VHR). The results represent the minimum of two 
independent experiments. (b) To estimate that equal amounts of VHR variants 
were used for cross-linking, an 1 μg of of each sample (without glutaraldehyde) 
was resolved by 4-12% SDS-PAGE and allowed to stain with colloidal 
Coomassie overnight, with gentle agitation at room temperature, prior to 
distaining in ddH2O.  
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Figure 48b demonstrates that protein concentrations were equal. 
The control samples for the reaction with glutaraldehyde were incubated 
without the cross-linking reagent in the reaction buffer (Figure 48a) and 
exhibited no oligomer formation. It might be worth noting that in the control 
samples, F68C variant showed band at the expected size of a dimer, 
presumably due to disulfide bond association which could not be reversed upon 
boiling of the samples. Association through disulfide bond formation which was 
not completely reversible under reducing conditions was also reported for 
laforin (Liu, Wang et al., 2006). Intermolecular association through disulfide 
bond formation has been regarded as the most frequent principle governing 
intermolecular association (Nardozza et al., 2012). Moreover, the ROSs were 
recognised to mediate intermolecular association amongst PTPs through 
disulfide bond formation (Blanchetot et al., 2002; Deb et al., 2011; Sun, Wang 
et al., 2005).  
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3.2.7 Investigating dimerisation potential of the VHR variants with respect 
to oxidising conditions 
As a result from the previous experiments (shown in the Chapter 3.2.6), the 
next step was to investigate whether generating F68C mutant renders the 
protein more susceptible to intermolecular disulfide bond formation. 
The samples of the wtVHR and its F68C and F68pBPA variants were examined 
for dependence of the oligomerization state on the oxidising conditions. This 
was conducted by dialyzing the samples in the buffer without the reducing 
agent and by running SDS-PAGE under standard or non-reducing conditions. 
For the latter, the samples were incubated with 2 x SDS-PAGE sample buffer 
which did not contain any reducing agent, and the samples were not boiled at 
95°C, but just incubated for 30 min at 37°C. The result is shown in Figure 49. 
Arrows indicate the position of the apparent molecular weight of the dimer, 
triggered by oxidative conditions-mediated disulfide bond formation. Moreover, 
in the lane for the samples of F68C and F68pBPA variants ran under non-
reducing SDS-PAGE conditions, at least two bands could be distinguished 
corresponding to the oxidised (faster migrating) and reduced form.  
As indicated in Figure 49, the F68C mutant showed an increased potential for 
self-association via intermolecular disulfide-bond formation than the wt protein. 
Under reducing SDS-PAGE conditions, hardly any homodimers could be 
detected anymore, suggesting that the self-association of all VHR variants 
examined was reversible. Together with the results obtained in the cross-linking 
experiments, this observation strongly suggests that spatial proximity of two 
VHR molecules is such that the distance between the Cα atoms of the cysteine 
residues is within the range of 4.4-5.9 Å which can be spanned via disulfide 
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bond (Sun, Wang et al., 2005). Strikingly, the F68pBPA mutant exhibited a non-
reducing SDS-PAGE pattern more resembling that of the F68C variant than the 
one of the wild type protein. “Variable insert” region contains a small 
hydrophobic and protruding patch of non-conserved amino acid composition 
(Yuvaniyama et al., 1996). As stated previously, Phe68 is a part of this island. 
Exchanging phenylalanine for a more hydrophobic pBPA is likely to not only 
further increase hydrophobicity of the rim, but also to increase the extent of the 
hydrophobic interactions, thus further stabilizing intermolecular self-association 
of VHR. In addition to the catalytically active cysteine of the P-loop, VHR has 
three more cysteine residues at positions 22, 30 and 171. Careful structural 
examination would support that the localisation and solvent exposure of Cys22 
might suffice for an increase in disulfide mediated self-association observed for 
F68pBPA variant of VHR (Figure 49), possibly enabled by the stabilizing effect 
the F68pBPA substitution might have, like just discussed. 
For VHR it was reported previously that treatment with H2O2 triggered transient 
conversion of the catalytic site Cys124 to sulfenic acid (Denu and Tanner, 
1998). The same study reported that conversion of sulfenic acid to non-
reducible forms, namely to sulfinic and sulfonic acid, was not detected in VHR 
even under stringent oxidising conditions. The authors pointed out that the lack 
of excessive oxidation in VHR might be due to the active site Cys124 being 
protected from the solvent exposure. It is tempting to hypothesize that the 
shielding mechanism might be provided by the proximal self-associated unit of 
VHR.  
In addition, in PTPs there is a diversity of mechanisms reported which serve to 
protect the catalytic cysteine from excessive irreversible oxidation and to 
recuperate the catalytically active form (Bonham and Vacratsis, 2009; Buhrman 
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et al., 2005; Chen et al., 2009; Östman et al., 2011; Seth and Rudolph, 2006; 
Silver et al., 2013; Sun, Wang et al., 2005; Tonks, 2005). They span from the 
intramolecular disulfide bond formation, like in case of the PRLs (Sun, Wang et 
al., 2005) or PTEN (Lee, Yang et al., 2002), across cyclic sulphenamide, like 
for PTP1B (Tonks, 2005), to disulfide switches, reported for MKP-3 (Seth and 
Rudolph, 2006), disulfide bond formation between the backdoor cysteines, in 
case of SHPs (Chen et al., 2009) or more custom protective mechanisms, like 
reported for DUSP12, also known as human orthologue of yeast (hYVH1) 
(Bonham and Vacratsis, 2009), which was shown to form disulfide bonds within 
catalytic and zinc binding domains. Dimerisation could be an interesting 
mechanism to protect PTPs from irreversible oxidation. 
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Figure 49: Analysing dimerisation potential of the recombinant VHR variants 
with respect to oxidising conditions. The procedure is described in section 
2.3.8. 3 μg of the wtVHR, F68C and F68pBPA, stored with or without the 
presence of 0.1% (v/v) β-mercaptoethanol, were resolved by 4-12% SDS-
PAGE under non-reducing or standard conditions and stained with colloidal 
Coomassie (panels (b) and (a), respectively). Monomers run as a band at 
about 23 kDa. Under non-reducing SDS-PAGE (b) additional band probably 
corresponding to the sulfenic acid-form is also observed. Dimers run at about 
50 kDa and are mostly completely reversible under reducing SDS-PAGE 
conditions (a). The bands of higher MW (from 53 kDa) especially prominent in 
the sample of the F68C, and to a somewhat lesser extent to the F68pBPA, 
variants under non-reducing SDS-PAGE (b) most likely correspond to different 
disulfide-bond-based associations. The band at about 70 kDa, visible in the 
sample of F68pBPA variant, was detected regularly after purification. The result 
is representative of at least two independent experiments. 
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3.2.8 Investigating the dimerisation potential of VHR in cells 
The findings from the cross-linking experiments prompted an investigation if the 
homodimeric association of VHR could be detected in cells. For that purpose, 
mammalian COS-1 cells were transfected with myc- and Flag3-tagged VHR 
constructs. By IP with an anti-Flag ab and the subsequent probing of the 
immunoblots with an anti-myc ab, co-IP of Flag3-tagged VHR was 
demonstrated. Interestingly, self-association of VHR was detected only after 
oxidative stress stimulus induced by treating the cells with 10 mM H2O2 for 60 
min at 37°C prior to analysis (Figure 50), supporting the hypothesis that 
dimerisation could be a consequence of oxidative stress, as implicated from the 
previous results. To exclude the possibility that the detected self-association of 
VHR was the result of the selected experimental setup, 3Flag-PRL-3 ΔCAAX 
was utilized as a control. The ΔCAAX variant of PRL-3 had deleted four 
residues of the CAAX-box that are important for localizing the protein to the 
plasma membrane and structures resembling endosomes (Rios et al., 2013; 
Zeng et al., 2000). Moreover, for PRL-1 it was shown that trimerisation is 
required for PRL-1-mediated cell growth and migration (Sun, Luo et al., 2007), 
whereas the same study also demonstrated the intrinsic ability of PRL-3 to 
trimerize.  3Flag-PRL-3 ΔCAAX was transfected with myc-tagged VHR into 
COS-1 cells. As shown in Figure 51, 3Flag-PRL-3 ΔCAAX was not co-
immunoprecipitated when performing IP of the COS-1 lysates with an anti-myc 
ab, confirming the specificity of the interaction to VHR. 
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Figure 50: Self-association of VHR in H2O2-stimulated COS-1 cells. COS-1 
cells were transiently co-transfected with myc- and Flag3-tagged wtVHR. The 
analysis was conducted 24 h post-transfection. The cells were first placed in 
SFM for 2 h at 37°C, followed by stimulation with 10 mM H2O2 for 1 h at 37°C 
prior to lysis. IP was done by using ab against the Flag-tag. Elute 1 was done 
by applying the non-reducing 2 x SDS-PAGE sample buffer to the samples and 
incubating for 10 min at 65°C and Elute 2 by incubating for 5 min at 95°C. 
Immunoblots were probed for VHR dimerisation by using anti-myc ab. 
Afterwards, the membrane was stripped and re-blotted using ab against the 
Flag-tag. The detailed protocols are described in sections 2.3.11 and 2.3.12. 
The image is representing the result of two independent experiments.  
 
 
 
 252 
 
 
Figure 51: Assessing specificity of dimerisation to VHR, in cells. The detailed 
protocol is described in sections 2.3.11 and 2.3.12. COS-1 cells were co-
transfected with plasmids pSG5/wtVHR-myc and pCMV-3Flag-1A/PRL-3 
ΔCAAX. About 24 h after transfection, the cells were treated with 10 mM H2O2. 
IP of the COS-1 lysate was conducted overnight at 4°C by using anti-myc ab. 
The first analysis was done by using ant anti-Flag ab (top panle). After that the 
filter was stripped and re-blotted with an anti-myc ab (bottom panel)  (however, 
the presence of a band corresponding in size to the 3Flag-tagged PRL-3 in the 
bottom panel (marked with °) clearly indicates that stripping of the filter was not 
absolutely efficient or cross-reactivity of the ab). The bound material was eluted 
by applying the non-reducing 2 x SDS-PAGE sample buffer to the samples and 
by incubating for 10 min at 65°C. The band below the arrow indicating the light 
chain is non-specific and was observed in the IP experiments using anti-myc 
ab. Band at about 23 kDa corresponds to the 3Flag-tagged PRL-3 (marked with 
*) and at about 20 kDa to the myc-tagged VHR (marked with °). The image 
represents the result of two independent experiments.  
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3.2.9 Investigting the dimerisation potential of VHR in cells independently 
of the oxidative stress 
When it comes to detecting protein-protein interactions in vivo, PFA is the 
rather appealing choice of chemical cross-linker. It is a nonspecific cell-
permeable monofunctional reagent with the length of the spacer arm reportedly 
spanning 2.3-2.7 Å, thus enabling it to capture even transiently tethered 
spatially proximal complexes (Klockenbusch and Kast, 2010; Vasilescu et al., 
2004). Therefore, formaldehyde was selected as a suitable reagent to probe if 
self-association of VHR in cells could be detected also in the absence of H2O2-
induced oxidative stress. COS-1 cells were transfected with myc-tagged wtVHR 
and Flag3-tagged C124S mutant, as it had been shown previously that self-
association of VHR did not depend on the availability of the catalytic Cys124 
(Figures 38 and 45). To avoid losing the read-out (Klockenbusch and Kast, 
2010) of the in vivo association of two differentially tagged VHR constructs, the 
samples were split in two and subjected to heating at 60°C for the total of 20 
min and, alternatively, to heating at 95°C for 5 min, prior to being resolved by 
SDS-PAGE and analysed by Western blotting using ab against the affinity tags. 
Figure 52 shows that the self-association of VHR was stable under the 
conditions applied and no reversibility of the cross-links was observed when the 
samples were under more stringent temperature conditions. The control dish 
treated in an analogous fashion but with formaldehyde-free PBS resulted in 
detection of no complexes of higher molecular masses. Interestingly, in the 
samples incubated with PFA for 2.5 h, a reduction in the yield of the cross-
linked complexes was observed, compared to the sample with 30 min 
incubation with PFA. This was in accordance with the previously acknowledged 
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issues that ought to be considered in the reactions with chemical cross-linkers 
(Klockenbusch and Kast, 2010). For example, the cross-linked complexes may 
not be soluble or they may be so conformationally distorted so as to be 
rendered non-recognisable by the ab. 
Capturing two differentially tagged VHR variants by means of covalent bond 
formation induced via chemical cross-linking reagents is a direct and 
persuasive indication of their spatial proximity. Therefore, it is possible that self-
association of VHR can be stabilized through oxidative stress and/or by using 
already short-span cross-linking reagents, chemical or genetically encoded, as 
demonstrated. 
. 
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Figure 52: VHR can form dimers in cells in the absence of H2O2-induced 
oxidative stress. Investigating VHR dimerisation in COS-1 cells in the absence 
of H2O2-induced oxidative stress was done by cross-linking with PFA, 
according to the protocol in section 2.3.13. COS-1 cells (60 mm) were 
transfected with pCMV-3Flag-1A/wtVHR and after 24 h probed for dimeric 
association of VHR inside the cell. The cells were treated with 0.8% (w/v) 
PFA/PBS at 37°C and then lysed. Control sample was incubated only in the 
GM only for the total of 150 min. In order to preserve the cross-linked 
complexes, the aliquots of the soluble fraction (L) were mixed with 2 x SDS-
PAGE sample buffer, without reducing agent, and heated at 60°C for 20 min or 
at 95°C for 5 min. To ensure that the complexes are not in the pellet due to 
extensive, non-specific cross-linking, the pellet (P) was resuspended in 80 μl of 
non-reducing 2 x SDS-PAGE sample buffer and heated at 95°C for 5 min. 20 μl 
of the lysate (about 5.6% of the total lysate) and 10 μl of the resuspended 
pellets (12.5%) were resolved by 4-12% SDS-PAGE and probed with an anti-
Flag antibody. The result is indicative of two independent experiments.  
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3.2.10 Investigating functional implications of VHR dimerisation  
To assess the effect of the dimer formation on the enzymatic activity of the 
protein, the native VHR and its F68pBPA mutant, both at at 250 μg/mL, were 
subjected to 345 nm light for 30 min. Recovered samples were then subjected 
directly to the activity measurement by employing pNPP at 10 mM 
concentration as a substrate (sections 2.3.5 and 2.3.4, respectively). The 
protein concentration was adjusted so that to match the conditions from the 
kinetic profiling experiments (results of which were presented in Table 4 and 
Table 5 in section 3.2.2). As indicated in Figure 53, it was observed that the 
sample of the 68pBPA variant containing covalently cross-linked dimer 
exhibited reduced catalytic efficiency with respect to the non-irradiated sample. 
For the wtVHR, there was no difference in the catalytic activity against pNPP 
regardless of its exposure to the UV light. This observation indicated that 
exposure to 345 nm light did not hamper the catalytic performance of the 
protein, under the experimental setup applied, and, moreover, did not result in 
any damage to the protein. The latter reflected the results from the previous 
experiments (Figures 37-39). In addition, the efficiency of the non-irradiated 
sample of the F68pBPA variant in dephosphorylating pNPP was not altered 
compared to the native protein. Moreover, the level of the activity demonstrated 
for the non-irradiated sample of the F68pBPA variant well reflected the results 
obtained in the in-depth kinetic profiling conducted for all VHR variants (Table 
4).  
In order to obtain a more physiologically relevant model to further evaluate if 
self-association of VHR might have significant effect in modulating its catalytic 
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activity in cells, the levels of dephosphorylated Erk1/2 in COS-1 cell extracts 
after incubation with recombinant VHRs were assessed. It has been 
demonstrated that Erk1/2 are authentic substrates of VHR in vitro and in vivo 
(Todd et al., 1999). To inhibit the endogenous phosphatases, the approaches 
suggested in Blanchetot et al. proved successful (Blanchetot et al., 2005). By 
treating the cells with a mixture of sodium orthovanadate and H2O2, the 
endogenous phosphatases should be inhibited and the effect of 
dephosphorylation of a targeted substrate from the cell lysate would be the 
result of the added recombinant protein. 
Overall, reduction in the catalytic performance, excluding a derogative effect of 
the UV exposure on the protein stability, is clearly indicative of the non-
availability of the active site pocket to recognise and/or accommodate and 
dephosphorylate the substrate. Like indicated previously when explaining 
plausible lack of increase in the dimers formed when increasing the 
concentration of the F68pBPA variant from 250 to 500 μg/ml (Figure 37), one 
likely explanation might also be attributed to the intramolecular cross-linking. In 
the light of the results presented in Figures 53 and 54, the possibility remains 
that the observed reduction in the activity is also, at least in part, resulting from 
obstructions to the entrance into the crevice of the active site due to 
intramolecular cross-linking. 
The native protein and its F68pBPA variant were subjected to 30 min exposure 
to 345 nm light, at 250 μg/ml protein concentration, as described in section 
2.3.5.  
As indicated in Figure 54, in the buffer control samples no significant 
dephosphorylation of Erk1/2 was observed, thus suggesting that the 
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endogenous VHR and other Erk1/2-directed phosphatases had been 
transiently inhibited by pre-treatment of the cells with a mixture of 1 mM 
orthovanadate and 1 mM H2O2 for 30 min at 37°C, whilst simultaneously 
enriching for the pool of tyrosine-phosphorylated proteins (Blanchetot et al., 
2005). Exposure of the wt protein to 345 nm had no detrimental effect on the 
protein stability or catalytic activity, as demonstrated by probing with the anti-
VHR and anti-pErk1/2 ab, respectively. Interestingly, the level of 
phosphorylated Erk1/2 in the sample incubated with F68pBPA variant after its 
exposure to 345nm light was almost at the level of the buffer control and in 
stark contrast to its non-irradiated homologue, which in turn exhibited catalytic 
efficiency at the level of the wt protein. Based on the results presented in 
Figures 53 and 54, it can be postulated that the reduction in the catalytic 
activity of the irradiated F68pBPA variant arose from its UV exposure. One 
possible explanation would be a hypothesis addressing the possible topology of 
the dimeric association. Accordingly, the covalent capture of the two 
monomeric units into a dimer might curtail efficient catalytic performance by 
providing sterical hindrance to the active site pocket.  
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Figure 53: Assessing functional implications of VHR dimerisation against 
pNPP. The protocols are described in sections 2.3.4 and 2.3.5. The effect of 
dimer formation on the catalytic efficiency of the F68pBPA mutant of VHR was 
investigated by employing pNPP as a substrate. The protein samples were 
subjected to 345 nm light for 30 min at 250 μg/ml concentration in a 96 well-
plate format, followed by dilution to 500 nM before subjecting to the activity 
assay with pNPP at 10 mM. The data were analysed using GraphPad Prism 
5.0 software. For clearer representation, the result is shown as an end-point 
measurement for a discrete time point of 46 min. Three sets of triplicate were 
analysed for each sample. 
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Figure 54: Assessing the effect of VHR dimerisation on the ability to 
dephosphorylate Erk1/2. The detailed protocol is described in section 2.3.14. In 
brief, the cells were serum-starved for 16-24 h then treated for 30 min at 37°C 
with a mixture of 1 mM orthovanadate and 1 mM H2O2 in an SFM to inhibit the 
endogenous phosphatases. Lysates were incubated with 500 nM concentration 
of recombinant VHRs (with or without prior exposure to 345 nm light at 250 
μg/ml), or an equal volume of buffer, for 0, 30 and 90 min at 30°C. Time-
dependent reduction of pErk1/2 in COS-1 extracts was analayzed with anti-
pErk 1/2 ab (upper panel). Anti-Erk 1/2 (middle panel) and anti-VHR (lower 
panel) ab were used to assess equivalent amounts of lysates and bait used, 
respectively. The result is representative of three independent experiments.  
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3.2.11 Analysis of VHR dimers after separation by size-exclusion 
chromatography   
Two attempts to separate the covalently cross-linked dimer of F68pBPA variant 
of VHR by size-exclusion chromatography were conducted and none was 
successful in isolating pure complex of a dimer. Based on the size difference 
between the non-cross-linked monomeric form and the covalently cross-linked 
dimer of the F68pBPA variant of VHR, it was surprising that the separation did 
not succeed. This was attributed to a possible high mutual affinity of VHR 
entities present in the sample. However, in the second attempt, several 
fractions enriched for the dimer were obtained (Figure 55). In addition, pure 
sample of the monomeric form of the protein was also isolated. This enabled 
examining previously mentioned hypothesis of the intramolecular cross-linking 
in (i) stalling more efficient yield in the photo-induced cross-linking and (ii) 
causing reduced catalytic performance of the irradiated sample of F68pBPA 
(Figures 53 and 54). Figure 56 demonstrates that the fraction of the isolated 
monomeric form of F68pBPA also showed a reduced catalytic efficiency in 
comparison to the wt protein. The wtVHR was not irradiated in this case as it 
had been demonstrated previously that irradiation had  no derogative effect on 
its stability or catalytic performance (Figures 53 and 54). When comparing the 
results of the irradiated sample of F68pBPA (data shown in Figure 53) (the 
sample was assigned as “Mixture” in Figure 57) with the monomeric form 
isolated by size exclusion (Figure 56), and presenting the data as relative 
activity with respect to the wt, it can be seen that the sample of the 
F68pBPA_Mixture shows further reduction in the catalytic efficiency in 
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comparison to the irradiated monomeric form separated by size-exclusion 
(Figure 57).  
Therefore, the additional protein forms present in the mixture sample (dimer 
and the cross-link of the full length protein to the variant truncated at the 
position of the amber STOP codon) could cause a further reduction in the 
catalytic efficiency. For example, because the self-association tendency 
appeared to be such that the sample was not able to be purified by size-
exclusion chromatography, the truncated form might linger proximal to the 
monomeric form in a way that would block access of a substrate into the active 
site pocket. A reasonable explanation would be that the conformation of the 
covalently cross-linked dimer might be such that the entry into the crevice of 
the active site is not accessible.  
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Figure 55: Separation of F68pBPA dimer by size-exclusion chromatography. 
Detailed protocol is described iin section 2.3.9. The sample was subjected to 
345 nm light for 30 min in 96-well plate setup, with the protein concentration set 
to about 20 mg/ml. The recovered sample was diluted about 15-fold and 
subjected to separation by size-exclusion. (a) The sample was loaded at 0.5 
ml/min on a 16/60 Superdex 75 prep grade column, and the buffer used was 50 
mM Tris-HCl (pH 7.4), 500 mM NaCl and 0.1% (v/v) β-mercaptoethanol. (b) 
The collected fractions were concentrated (0.22 μm Millex-GP filters), and the 
concentration was measured by NanoDrop 1000 Spectrophotometer and 
additionally validated by resolving 2 μg of the protein by denaturing 4-12% 
SDS-PAGE and staining with colloidal Coomassie. Both fractions enriched for 
the monomeric form were combined (sample assigned as M), and used in the 
activity assays against pNPP. The fraction enriched for the dimer (sample 
assigned as D) was subjected to the determination of the full protein mass by 
LC-MS. 
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Figure 56: Assessing catalytic activity of the F68pBPA monomer isolated by 
size-exclusion chromatography. Figure 55 contains more details on the sample 
purification. wtVHR was not exposed to 345 nm light, and the sample of the 
F68pBPA variant was subjected to size-exclusion after UV exposure. The 
isolated fractions containing the pure monomer (assigned as M) were pulled 
and assayed against pNPP at 10 mM (section 2.3.4). The protein concentration 
was 500 nM. By denaturing SDS-PAGE analysis, it was validated that equal 
amounts of the proteins were used in the assays. The product of the reaction 
was measured for 2 h, acquiring a measurement every 2 min. A discrete time-
point (30 min) was selected for a better representation. Three sets of triplicate 
were analysed and the figure corresponds to a representative result of three 
experiments. The data was analysed using GraphPad 5 software. 
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Figure 57: Relative catalytic activity of the irradiated F68pBPA with respect to 
the irradiated wtVHR. The result of the kinetic measurement was originally 
plotted as absorbance versus time. Significant statistical differences are shown 
between the F68pBPA monomer (assigned as fraction M after size-exclusion, 
Figure 55) and the mixture sample (containing monomer, dimer and cross-link 
of monomer to the truncated form of the protein). The data was analysed using 
GraphPad 5 software which was also used to perform the statystical analysis. A 
Student’s upaired t-test was used to calculate the statystical significance and 
the asteriscs indicate ***p<0.001. 
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3.2.12 Analysis of VHR dimers after separation by size-exclusion 
chromatography by LC-MS/MS 
Significant effort was put to try to obtain the identity of the cross-linked peptide 
from two covalently cross-linked monomeric units of VHR. According to the 
procedure outlined in section 2.3.5b, after irradiating the sample of the 
F68pBPA variant for 30 min at 345 nm, the bands corresponding in size to the 
molecular weight of the monomer, cross-link of the full length protein to the 
truncated variant and the band of the cross-linked dimer were excised from the 
gel and subjected to analysis by LC-MS/MS, according to the procedure 
summarized in section 2.3.9. The analysis was also tried for the sample of the 
fraction D (Figure 55). Repeatedly, the peptide containing F68pBPA 
(SpBPAMHVNTNANFYK) could not be identified. Digestion with chymotrypsin 
was also tried, but without success. Identifying the mass corresponding to the 
cross-linked peptide was not straightforward because of the complexity 
considering (i) two molecules of pBPA, (ii) possible missed trypsin cleavage 
sites (because the conformation of the cross-linked complex(es) might be such 
that the cleaving site may not be accessible to trypsin or (iii) possible 
modifications (dehydration, deamidation, oxidation). The data had to be 
analysed manually. 
Whereas identifying a cross-linked peptide for the dimer was not successful, 
LC-MS/MS analysis revealed the intramolecular cross-link in the irradiated 
sample of F68pBPA, in the excised gel band corresponding to the monomer. 
As shown in Figures 22 and 58, the modification corresponding to the cross-link 
of F68pBPA to the neighbouring Met69 was identified. This finding nicely 
corroborated with the hypothesis of intramolecular cross-linking as source of 
reduced catalytic efficiency of the monomeric sample isolated by size-exclusion 
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chromatography. In addition, this sample was subjected to another round of the 
UV exposure, as described in section 2.3.5, but the yield of the formed dimers 
was bearly detectable (Figure 59). This indicated that F68pBPA was not 
available for cross-linking any more. Therefore, it is likely that additional 
intramolecular cross-links exist, in addition to the one we managed to identify.  
Finally, the fraction D enriched for the dimer (Figure 55) was subjected to full 
mass determination (described in section 2.1.15). Figure 60 shows that the 
mass corresponding to the covalently cross-linked dimer of the F68pBPA 
variant of VHR was obtained. Whereas the identification of the cross-linked 
amino acids in detail were not possible, this results proves that the covalent 
VHR dimer exists.   
 
 
 
 
 
 
 
 
 
 
 
 268 
 
 
 
 
Figure 58: Identification of the intramolecular cross-linking by LC-MS/MS. The 
sample was irradiated at 2.33 mg/ml. The recovered sample was diluted to 0.7 
mg/ml, mixed with 6 x SDS-PAGE sample buffer, 17.5 μg were resolved by 
SDS-PAGE, stained with colloidal Coomassie and the bands of interest were 
excised. The analysis was done as described in section 2.3.10. A peptide 
corresponding to the intramolecular cross-linking of 68pBPA to Met69 was 
found (452.164) (see Figure 22). The above structure represents a possible 
fragment matching the found MW. 
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Figure 59: Investigating the cross-linking ability of the monomeric fraction of 
F68pBPA isolated by size-exclusion chromatography. Details to sample 
purification are described in section 2.3.8. The fraction enriched for the 
monomeric form of the protein (see Figure 55) was subjected to another round 
of exposure to 345 nm light at the concentration of 250 μg/ml, as described in 
section 2.3.5. To check for cross-links, 250 ng of protein was resolved by 
denaturing 4-12% SDS-PAGE and analysed by Western blotting (anti-VHR). 
The non-irradiated samples were used as controls. The samples in lanes 1 and 
3 correspond to a different batch of F68pBPA for which purification by size-
exclusion was attempted after UV-induced cross-linking, and were used just as 
a comparison. Monomers run at about 23 kDa. A faint band at about 35 kDa 
corresponds to a cross-link between monomer and a truncated form. A faint 
band at about 50 kDa corresponds to covalently cross-linked two monomers. A 
faint band at about 14 kDa corresponds to a truncated form (containing 3Flag 
VHR 1-67) and at about 18 kDa (only visible in lanes 1 and 3) to a likely 
degradation product due to longer sample storage. The result is representative 
of two experiments.   
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Figure 60: Analysis of the intact sample of F68pBPA dimer by LC-MS. The 
solution sample of fraction D (Figure 55) enriched for the dimer was submitted 
for determination of full protein mass. The value obtained (48,841 Da) 
corresponds to the expected value, presented as an adduct with β-
mercaptoethanol which was used as a reducing agent in the storing buffer. The 
mass of 24,420 Da corresponds to the monomer and the mass of 35,273 Da to 
the crosslinked heterodimer of full length and truncated version, also containing 
β-mercaptoethanol as adduct. The detailed protocols are provided in sections 
2.1.15, 2.3.5 and 2.3.8. 
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3.3 Applicability of the photo-cross-linkable PRL-3 mutant in investigating 
protein-substrate and protein-protein interactions   
 
3.3.1 Assessing the cross-linking ability of the PRL-3 D72pBPA variant  
The D72pBPA variant of PRL-3 was expressed on a big scale in E. coli and 
purified as described in section 2.4.4. To probe how exchanging the conserved 
Asp72 of the WPD loop affected the catalytic performance of the enzyme, 
activity assay against artificial phosphatase substrate OMFP was performed 
(Figure 61). The D72pBPA variant of PRL-3 exhibited reduced catalytic activity 
compared to the native protein. This result was expected based on the previous 
results for the activity assays obtained for the wtPRL-3 and its D72A variant 
against OMFP in our lab (McParland, Varsano et al., 2011). The D72A variant 
of PRL-3 was inactive against OMFP, but still showed activity against PIPs. 
Investigation of the cross-linking ability of D72pBPA was conducted by 
performing a lipid-binding assay by using the lipid strips, according to the 
protocol described in section 2.4.6. This assay was selected because the 
preceeding attempts to cross-link D72pBPA to a soluble PI(4,5)P2, di-C8 
PI(4,5)P2, were not successful in demonstrating the cross-linking by MS 
analysis. Because the earlier results from our group (McParland, Varsano et 
al., 2011) demonstrated that the wtPRL-3 and to some extent its substrate-
trapping variant D72A, have the ability to recognise and dephosphorylate 
PI(4,5)P2 and PI(3,4,5)P3, it can be hypothesized that the lack of success in 
identifying the cross-linking by MS is a result of (i) too transient interaction 
between the protein and the lipid or (ii) because the orientation of pBPA is not 
the most optimal to covalently capture the lipid under the experimental 
conditions applied.  
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 In addition to the wtPRL-3 and its photo-excitable variant D72pBPA, the 
standard substrate-trap D72A was also used. Furthermore, to control for the 
non-specific reactivity of the ab, the sample without any protein was also 
included. PRL-1 was selected because it had already been profiled for its 
preference for binding to different membrane phospholipids (Sun, Luo et al., 
2007). A variant of PRL-3 with the triple mutation in the polybasic region 
(R157A R159A K161A) (referred to as PRL-3_3A) was assayed to compare its 
binding preferences with the one reported for PRL-1, for which the residues of 
the polybasec region were reported to be crucial for binding to PIPs (Sun, Luo 
et al., 2007). All constructs but PRL-3_3A were expressed and purified as N-
terminal Flag3-tagged fusion proteins. 
 
Figure 61: Assessing the activity of the D72pBPA variant of PRL-3 with OMFP. 
E. coli over-expression and purification, and the assessment of the catalytic 
activity against OMFP were conducted as described in detail in sections 2.4.5 
and 2.2.4, respectively. Protein was assayed at 6 μM and OMFP at 50 μM final 
concentration. Reaction volume was 100 μl. wtPRL-3 was used for comparison. 
The “blank” sample contained all the components but not the enzyme. The 
graph reflects the results of two experiments. The data was analysed by using 
GraphPad Prism 5.0 software and represented as an end point measurement, 
at the final point of the assay with SEM. 
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Figure 62: PRL-3 in lipid strips assay. Detailed description of the protocol is 
provided in section 2.4.6.  All proteins were expressed as N-terminal Flag3-
tagged fusion proteins and were incubated with the strips at 0.5 μg/mL for 30 
min in TBS-T (0.1%) buffer containing 3% (w/v) fatty acid-free BSA. The control 
sample contained no protein and was treated in the same way described 
above. D72pBPA sample was incubated with the strip for 10 min prior to 
exposure to 365 nm, which was conducted for the total time of 5 min (two 
intervals of 2.5 min, with 2.5 min break in-between). The non-irradiated control 
sample of D72pBPA was kept light protected throughout duration of the assay. 
Protein-lipid interactions were probed using anti-Flag ab and visualized with 
ECL Western Blotting Detection Reagents (developing time 1 min).  
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Figure 63: Assessing the effect of the triple mutation R157A R159A K161A on 
the lipid binding profile of PRL-3. (a) Detailed description of the protocol is 
provided in section 2.4.6.  All proteins were incubated with the strips at 0.5 
μg/mL for 30 min in TBS-T (0.1%) buffer containing 3% (w/v) fatty acid-free 
BSA. Protein-lipid interactions were probed using anti-PRL-3 ab and visualized 
with Western Lightning Plus-ECL Enhanced Chemiluminescence Substrate 
(developing time 5 min). (b) Assessing if the triple mutation had effect on the 
recognition by the PRL-3 ab by resolving 500 ng of the proteins, with or without 
the N-terminal His6-tag, by 4-12% SDS-PAGE and probing with anti-PRL-3 ab.  
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Figure 64: PRL-1 in lipid strips assay. A detailed description of the protocol is 
provided in section 2.4.6.  PRL-1 was expressed as N-terminal Flag3-tagged 
fusion proteins and was assayed under two different conditions of protein 
concentration and total incubation time. Strip A was incubated with the protein 
at 0.5 μg/mL for 30 min in TBS-T (0.1%) buffer containing 3% (w/v) fatty acid-
free BSA and strips B and C were incubated with the protein at 5 μg/mL for 60 
min in the same buffer as above. Protein-lipid interactions were probed using 
anti-Flag ab and visualized with ECL Western Blotting Detection Reagents (PIP 
strip B, developing time 1 min) and Western Lightning Plus-ECL Enhanced 
Chemiluminescence Substrate (PIP strips A and C; developing times 15 min 
and 5 min, respectively). The results indicates that, compared to PRL-3, PRL-1 
shows much less lipid-binding affinity, as tenn times more protein and double 
the incubation time were needed to detect weak signal (A). 
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The preliminary results obtained in the lipid binding assays are summarised in 
Figures 62-64. From 62, it can be seen that all PRL-3 variants screened 
seemed to prefer PIPs phosphorylated at the position 3 and/or 5 of the inositol 
ring (PI3P, PI5P and PI(3,5)P2), whereas seemingly showing the weakest 
preference for binding to PI(3,4)P2. Furthermore, wtPRL-3 (Figures 62 and 63) 
and PRL-1 (Figure 64) also showed non-specific binding to phosphatidic acid 
(PA). Binding of the D72A variant to PA was much weaker compared to the 
wtPRL-3, but the same effect was also observed for the other lipids on the strip 
(Figure 62). The D72pBPA variant showed bearly detectable binding to PA 
(Figure 62). Possible explanation for these differences in the non-specific 
binding to PA could be that the pBPA moiety imposes sterical effect on the 
binding to different lipids, but it has no negative effect on the recognition and 
binding to PIPs, which were demonstrated to be pysiologically relevant for PRL-
3 (McParland, Varsano et al., 2011). Furthermore, two different ab were used in 
probing for binding of different PRL-3 variants to lipids in lipid strips, anti-Flag 
(Figures 62 and 64) and anti-PRL-3 (Figure 63). As shown in Figure 63, binding 
of wtPRL-3 to PA looks much weaker with anti-PRL-3 ab. Because the control 
without the protein and analysed with anti-Flag ab showed no signal (Figure 
62), it can be hypothesized that non-specific binding of PRL-3 to PA might 
occur via different mechanism than its binding to PIPs and that these 
differences in the binding mechanism might have the effect on the recognition 
of the protein in the suubsequent analyses by different ab. 
It was reported previously that PRL-3 dephosphorylated PI(4,5)P2, and to a 
smaller extent PI(3,4,5)P3, in vitro (McParland, Varsano et al., 2011). It was 
also reported that PRL-1 and apparently PRL-3 showed the same lipid binding 
preferences in lipid strips assay (Sun, Luo et al., 2007). It would be interesting 
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to probe if there is a correlation between lipid binding and catalytic activity for 
PRL-3 like it was shown for PTEN and myotubularin, both of which are PIP 
phosphatases (Campbell et al., 2003). Furthermore, the basic residues in PRL-
3 seem to be important for binding of PRL-3 to PIPs, because PRL-3_3A 
exhibited no detectable binding (Figure 63), even after long exposure times. 
This result correlates with the reported binding profile for PRL-1 with various 
mutations in the polybasic region (Sun, Luo et al., 2007). However, this study 
reported that PRL-1 and, apparently, PRL-3 showed the strongest preference 
for binding to monophosphorylated PIPs, and the weakest one for binding to 
PI(3,4,5)P3, which is not really correlating with the results here. As indicated in 
Figure 62, the D72pBPA variant of PRL-3 after exposure to 365 nm light for the 
total time of 5 min showed a stronger signal than its non-irradiated control. The 
mutant showed largely the same binding profile like the native protein. These 
results indicated that the introduction of the photo-cross-linkable amino acid did 
not negatively affect the ability of PRL-3 to recognise and bind to PIPs.  
3.3.2 Assessing the applicability of PRL-3 D72pBPA with HEK293 cell 
lysate 
To probe if the photo-cross-linkable variant of PRL-3 could be used to capture 
(novel) interacting partners of this phosphatase, photo-induced cross-linking 
following incubation with the lysate from HEK293 cells was conducted. The 
detailed description of the experimental conditions, including the data analysis, 
is provided in section 2.4.7. In addition to the photo-cross-linkable variant of 
PRL-3 (used with or without exposure to 345 nm light for 30 min), the native 
protein and its D72A variant were utilized as controls. The wtPRL-3 was used 
without UV exposure, and its D72A variant with and without irradiation. The 
selected protein controls were expected to show if there would be difference in 
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the portfolio of the identified interacting partners following the pull-down with 
His-Select Nickel Affinity Gel for various PRL-3 variants and if there would be a 
UV-mediated derogative effect on the stability of the generated cross-links. Of 
note, various experimental conditions for assessing the applicability of the 
photo-cross-linkable variant of PRL-3 on a broader scale were tried (for 
example, the amount of protein used as bait, pre-clearing of the lysate, pre-
incubation prior to UV-exposure, pull-down of the associated or cross-linked 
complexes, buffer and washing conditions). In the irradiated sample, additional 
bands corresponding to the complexes generated by covalent cross-linking of 
pBPA moiety to the proximal C-H bonds were detected (Figure 65), whereas 
the intensity of some bands in the irradiated sample was intensified with 
respect to the control. However, when 60 μl of the elute for each sample was 
resolved by 8% SDS-PAGE and left to stain with colloidal Coomassie stain, the 
differences from the Western blot did not reflect in the differences of the stained 
gel. Moreover, for all five samples the gel bands of three ranges of molecular 
weight were excised and subjected to MS analysis with the aim of identifying 
(novel) interacting partners and/or potential substrates of PRL-3. However, the 
retrieved list of identified proteins bore no striking differences amongst all the 
samples analysed.  
Considering this, the fact that colloidal Coomassie stain and the subsequent 
MS analysis failed to demonstrate noticeable differences in the profile of 
identified interacting proteins for the diferent  PRL-3 variants screened could be 
an indication that (i) the introduced amino acid substitution had no effect on the 
ability of PRL-3 variants to recognise the intrinsic interacting partner(s) or that 
(ii) the yield of the cross-linked complexes generated after UV exposure was 
not high enough to render distinctions visible in the colloidal Coomassie 
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staining of SDS-PAGE gel. To enrich the UV-exposed sample for the covalently 
cross-linked complexes and, therefore, increase the odds of identifying novel 
interesting hits in the following MS analysis, the sample was subjected to pull-
down with His-Select Nickel Affinity Gel. However, this attempt was not 
completely successful. As evident from the Western blot analysis using anti-
PRL-3 ab, protein stock of the D72pBPA variant used as bait also contained a 
fraction without the His6-tag at the N-terminal end. This cleaved fraction also 
bound to the affinity beads and co-purified with the His6-tagged variant.  
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 Figure 65: Incubation of the PRL-3 variants with HEK293 lysate, with or 
without exposure to 345 nm light. The protocol is described in section 2.4.7. 
PRL-3 variants were used as bait at 200 μg, and were incubated with 1 ml of 
lysate from HEK293 cells (2 x 14 cm dishes were used for each sample) for 2 h 
at 4°C on a roller. The samples were irradiated for 30 min at 345 nm, and 
recovered samples were subjected to pull-down with Ni-affinity gel (200 μl 
slurry/sample) overnight at 4°C. After washing, the bound material was eluted 
by applying 100 μl of 2 x SDS-PAGE sample buffer and by incubating first for 
10 min at 65°C and 500 rpm. The first elute was recovered and the fresh 
portion of sample buffer was added and incubated for 5 min at 95°C and 500 
rpm. 2.5 μl of each elute was resolved by SDS-PAGE, and 5 μl of all other 
samples withdrawn. Western blot  was done by using anti-PRL-3 ab. By loading 
the sample of pure bait for each protein (1%), it can be excluded what 
impurities are derived from the bait-sample. In the UV-irradiated sample of 
D72pBPA, additional bands showing up in the higher MW range (above 41 
kDa) correspond to the covalently cross-linked complexes (they are also 
missing from the non-irradiated sample of D72pBPA). The cut-out gel bands 
were subjected to analysis by MS, but the identity of proteins corresponding to 
the individual bands visible by Western blot at higher MW at present cannot be 
assigned. 
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Chapter 4: Conclusion and outlook 
 
4.1 Critical comments of the preliminary experiments (Chapter 3.1 in the 
Results and discussion section) 
Overall, this section can be viewed as the weekest section of the thesis. This 
can in part be attributed to the learning process, as most of the experiments 
were conducted with next to nothing hands-on experience in molecular biology 
techniques in general. 
Generating mutants of PRL-3 with selected residues (Ile141, Asn142 and 
Gln145) exchanged first for tyrosine and assessing their suitability for the 
folowing substitution with an unnatural amino acid based on the (i) CD spectra 
of the mutants with respect to the native protein and (ii) their catalytic 
performance might be better substituted by designing an analogous set of 
experiments involving pACF. pACF might be more similar to pBPA in terms of 
hidrophobicity. It may not be the most optimal choice due to the sterical bulk of 
pBPA, but it could still be regarded as more suitable than substitutions of the 
selected residues with any of the canonical amino acids (for example, 
introducing tryptophane might impose more sterical constrain due to its 
structure comprised of two fused rings, whereas in pBPA the two phenyl rings 
are separated by a carbonyl moiety). Furthermore, for the assessment of the 
catalytic activity, a more optimised set of assay conditions would need to be 
applied. The strength of the signal, measured as absorbance at a particular 
wavelength (as determined by the phosphatase substrate used in the assay) 
was very weak even for the wt protein, making any strong conclusions about 
the behaviour of  the mutants, with respect to the native protein, more difficult.  
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Another weak spot in this section is the data analysis. Like already mentioned, 
no miningful conclusion can be drawn by conducting an assay once. Thus, it 
would be advisable to use a more suitable activity assay and to generate 
several replicates for each of the mutants investigated. 
 
4.2 Implications for VHR biology: findings enabled by application of the 
amber suppression methodology 
The results presented in the Chapter 3.2 provided a clear demonstration of 
dimerisation as a potential novel regulatory feature of the VHR phosphatase. 
This finding was enabled by selective incorporation of photo-cross-linkable 
pBPA. Unlike chemical cross-linkers, use of photo-excitable pBPA also enabled 
investigation of how dimerisation affects the catalytic activity of VHR. 
Oxidative stress could have a stabilizing effect on the intermolecular self-
association of VHR, which in turn might impose steric hindrance to the active 
site cleft, thus providing a mechanism to protect catalytically essential cysteine 
of the P-loop from irreversible oxidation of sulfenic acid to sulfinic or sulfonic 
acid. There is a growing number of reports elucidating the mechanisms through 
which H2O2, and ROS in general, modulate cellular signaling (Adler et al., 1999; 
den Hertog et al., 2008; Gough and Cotter, 2011). Moreover, H2O2 has been 
demonstrated to not only induce a mitogen-activated signaling cascade, but to 
also be required, or participate, in normal receptor-mediated signal transduction 
(Denu and Tanner, 1998; Todd et al., 1999). Self-association of VHR to form 
dimers would also result in a high local concentration of the enzymatically 
active form after release of the oxidative stress, which could act rapidly to elicit 
a specific cellular response after the dimeric complex is disassembled into 
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monomers. Further investigations involving, for example, structural analysis of 
the native VHR protein with catalytic cysteine oxidised to sulfenic acid or of the 
covalent complex of the homodimer, are needed to evaluate: (i) if oxidation of 
the active site cysteine to sulfenic acid causes local structural changes or 
affects electrostatic interactions which may have positive implications for the 
dimer assembly; (ii) how self-association of VHR influences the overall 
structure of the complex; (iii) how the cellular redox-state and extracellular 
stimuli-induced production of ROS ultimately inflict a network of interactions 
due to spatio-temporally and mechanistically distinct regulatory principles of 
PTPases. The accumulating knowledge of the mechanisms through which 
ROS, such as H2O2, finely modulate signaling cascades demonstrates an 
immense complexity and transform the view of H2O2 as a malignant molecule 
(Adler et al., 1999; den Hertog et al., 2008; Denu and Tanner, 1998; Gough 
and Cotter, 2011; Meng et al., 2006). H2O2 is acknowledged as a secondary 
messenger that mediates signal transducing cascades triggered in response to 
a broad range of extracellular stimuli. Moreover, H2O2 production needs to be 
under strict spatio-temporal control in order to maintain homeostatic levels of 
ROS and redox balance. The unique microenvironment of the conserved active 
site cysteine residue decreases its pKa for more than 3 pH units than the pH 
value of a normal cysteine, so that it exists in the form of a thiolate ion under 
physiological conditions (Denu and Tanner, 1998). This renders it more 
sensitive to H2O2 than the protonated thiol would be, thus making PTPs 
appealing targets for redox-mediated regulation of cell signaling. Furthermore, 
formation of dimers, and higher order oligomers, amongst PTPs in response to 
H2O2-imposed oxidative stress has been reported previously (Blanchetot et al., 
2002; Deb et al., 2011; Liu, Wang et al., 2006; Nardozza et al., 2012; Östman 
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et al., 2011). For example, it was demonstrated that the endogenous SHP-2 
could dimerize, with concomitant decrease in the phosphatase activity, and that 
the monomer-dimer equilibrium was modulated by the redox status of the cell 
and by growth factors, thus proposing a novel model for redox-based structure-
activity regulation (Nardozza et al., 2012). Next, it was proposed that H2O2 
induced inactivation of RPTPα by oxidising the catalytically active cysteine 
residue in D1 domain, thus allowing propagation of downstream signaling, and 
by inducing conformational changes in D2 domain, with stabilizing effect on the 
dimer assembly (Blanchetot et al., 2002). Recently, the membrane-associated 
isoform of the neuron-specific Striatal Enriched Phosphatase (STEP), STEP61, 
was shown to dimerize via intermolecular disulfide bond formation, with the 
considerable increase in the order of the oligomers detected after H2O2-induced 
oxidative stress and the accompanying reduction of the catalytic activity (Deb et 
al., 2011). VHR is classified as atypical DUSP, a subgroup of DUSPs with a 
growing interest of research community in deciphering the principle of their role 
and regulation under physiological and pathological conditions (Patterson et al., 
2009). However, the current knowledge is still overwhelming with conflicting 
data, especially regarding discrepancy on substrate specificity of DUSPs 
towards MAPKs in vitro and in vivo. Additional layer of complexity is underlined 
by a conclusion that atypical DUSPs may exert stimuli-dependent-, cell-type-, 
or context-specific effects on MAPKs, have a broader repertoire of substrates 
or that they can act as scaffolds or require additional binding partner(s) within a 
particular signaling cascade. Rapidly increasing data on structural 
characterisation of atypical DUSPs suggests a potential for vastly different 
means of regulation of their biological functions. Moreover, according to the 
“fingerprint”-based computational analysis, aiming to classify atypical DUSPs 
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with respect to their amino acid sequence, two subfamilies of DUSPs emerged 
(Romá-Mateo et al., 2007). Interestingly, VHR was classified as a member of 
atypical DUSP I subfamily, alongside, amongst others, DUSP13a, DUSP13b, 
DUSP26 or DUSP27, for all of which dimer-forming propensity has been 
demonstrated (Kim et al., 2007; Lokareddy et al., 2013; Lountos et al., 2011). 
VHR was identified as the closest structural homologue of DUSP27 and testis 
and skeletal muscle specific DUSP (TMDP), also known as DUSP13b, both of 
which (i) do not have an N-terminal MKB domain, (ii) cannot be aligned with 
VHR in the region of β3-α4 loop and (iii) were demonstrated to form dimers. In 
TMDP, β3-α4 is shorter, rendering surface around the active site more planar 
when compared with VHR (Kim et al., 2007; Lountos et al., 2011; Patterson et 
al., 2009). Together with the α1-β1 loop, known as “substrate recognition 
region” in VHR, being displaced further from the active site, these differences 
contribute to the broader active site pocket in TMDP and to its equal preference 
for pTyr and pSer/pThr substrates. Intriguingly, the dimer-driving interactions 
were not sufficient to maintain the association of TMDP in solution. There is a 
number of reports on the attempts to identify features common to protein-
protein interfaces or trying to address properties of homo- or heterodimeric 
protein assemblies by computational analysis (Dey et al., 2010; Ozbabacan et 
al., 2011). In summary, one could substantiate that the subunit interfaces are 
more hydrophobic than the surface accessible areas, those of weak dimers 
being slightly more polar, but still with the similar amino acid composition and 
hydrogen bonding capacity. Why weak dimers are weak can be explained 
probably by buried surface area alone, where homodimers bury less than 1000 
Å, resulting in fewer stabilizing interactions. In TMDP, the dimers have interface 
of 841 Å, making inability to preserve self-association in solution plausible (Kim 
 286 
et al., 2007).  Another contributing factor is the quality of the atomic packing 
(Dey et al., 2010). Namely, loose contacts will result in a more flexible 
geometry of the dimeric association, more hydrated protein surface and less 
than optimal interactions comparing to the close-packed interface.  
In summary, based on the current study, dimerisation could represent a novel 
regulatory mechanism of VHR. In a non-stimulated state, VHR might be 
present as a monomer, or loosely packed dimer, with the overall catalytic 
activity dependent on the mutual orientation of the self-associating units. It is 
known that the conserved cysteine residue of the P-loop of VHR is sensitive to 
H2O2-induced oxidative inhibition (Denu and Tanner, 1998). Here, it was clearly 
demonstrated that oxidative stress has a stabilizing effect on the interacting two 
monomers of VHR, plausibly, but not necessarily, via disulfide bond assembly. 
We were able to demonstrate self-association of VHR in cells by co-IP only 
after H2O2-induced stress, but also after treatment with formaldehyde and in the 
absence of oxidative stress.  
When analysing the effect of the reducing conditions on the assembly of the 
homomeric VHR dimers, the profile of the F68pBPA mutant of VHR, when 
compared to the native protein and to the F68C mutant, was quite surprising. 
Simultaneously, this analysis helped to postulate one possible suggestion how 
dimeric association of VHR might come to occur, namely through a disulfide 
bond-based association that would be enabled by hydrophobic interactions of 
the rim spanning residues of the “variable insert” segment. In order to validate 
this hypothesis further, candidate cysteine residues in VHR might be 
exchanged by SDM to a residue that lacks dislfide-bonding capacity.  Assuming 
that those substitutions would not have any negative effect on the stability of 
the mutants or on their catalytic behaviour, a set of in vitro experiments might 
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be conducted to examine the profile those mutants would show when analysed 
under reducing or native SDS-PAGE conditions. 
In the future, it will be interesting to further dissect physiological implications of 
diverse regulatory principles of VHR as well as to see if this mode of regulation 
could be extrapolated to other atypical DUSPs, with special emphasis on 
probing non-conserved structural features. For example, amongst atypical 
DUSPs that share significant sequence similarity with VHR are DUSP27 and 
DUSP13b (Friedberg et al., 2007; Kim et al., 2007; Lountos et al., 2011). 
Moreover, VHR was also identified as a close structural homologue of MKP2 
(Jeong, Jung et al., 2009). For the former two phosphatases, dimer-forming 
ability was demonstrated, whereas for MKP-2, it was shown that it could form a 
24-mer assembly. It is interesting to note that the segment corresponding to the 
“variable insert” region in VHR regularly cannot be perfectly aligned with the 
corresponding segment in those three atypical DUSPs. This observation at 
present might further (i) strengthen our observation of VHR dimerisation as a 
potential novel regulatory mechanism and (ii) support the hypothesis that 
combining detailed structural investigation, with special focus on the uinque 
residues or regions in the protein, with expanded genetic code methodology 
might accelerate our understanding of the aforementioned unique structural 
characteristics. 
Furthermore, investigating dimerisation at the level of endogenous protein 
represents another challenge, which is currently being undertaken in our lab. 
Finally, identifying if, and how, distinct stimuli, or PTMs, could affect dimer 
topology, stability or the outcome of downstream signaling cascades would 
further clarify the patho-physiological role of VHR. In addition, any knowledge 
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sprouting from such investigations can be useful for potential design of 
compounds that could promote or inhibit dimeric association of VHR. 
 
4.3 Applicability of the PRL-3 mutants containing photo-cross-linkable 
amino acid in investigating protein-substrate interactions 
At present, it is not established if D72pBPA with and without the N-terminal 
His6-tag have the same cross-linking efficiencies. Considering that the tag is 
positioned far from the region bearing cross-linkable amino acid, interferences 
with the substrate recognition and/or binding to the active site crevice are 
however not likely. Importantly, control pull-down without protein might help 
filter out the non-specific interactions.  
The introduction of amino acid substitutions with respect to the native protein, 
with the aim of expanding the portfolio of known interacting partners of a 
protein, must not distort naturally existing interactions. In order to have a 
protein variant that would serve as a “substrate trap”, the longevity of the 
substrate-protein association needs to be prolonged. Moreover, protein variants 
bearing mutations that retain the ability to bind substrates, but have hindered 
catalytic processing of a transient cysteinylphosphate intermediate, were 
broadly used in studying phosphatase-substrate interactions (Blanchetot et al., 
2005; Zhang, 2003).  
The C104S variant of PRL-3 was shown to be misfolded (McParland, Varsano 
et al., 2011), whereas the same study demonstrated still some in vitro activity 
od the D72A variant against PIPs. This residual acctivity observed for both D72 
variants of PRL-3 (A and pBPA) could result in protein-substrate or protein-
protein interactions being too transient. To potentially overcome this, additional 
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combinations of mutations might be explored, combining for example mutations 
of the conserved catalytic residues with a photo-cross-linkable amino acid 
introduced proximal to the entry into the active site pocket. Moreover, if the 
focus of investigation are potential interacting partners of PRL-3, it might be  
beneficial to introduce photo-cross-linkable amino acid at positions in the 
protein that are not directly involved in the catalytic mechanism.  
Moreover, the approach might also be applicable to investigate possible PTMs 
and/or to capture PKs that are responsible for phosphorylation of specific 
residues in PRL-3. It was noted previously that, when the sequences of all 
three PRLs were compared, several potential consensus sites for modification 
by phosphorylation were suggested (Zeng et al., 1998). Further investigation of 
(i) potential modification by phosphorylation in PRL-3, and especially in PRL-1 
and PRL-2 and of (ii) possible functional implication such modification might 
have is lacking. Moreover, it would be interesting to extrapolate the approach to 
PRL-1 and PRL-2. The residues which could be substituted for a photo-cross-
linkable amino acid might be divided into two categories. One might comprise 
residues that are known to be involved in the catalytic mechanism, in a manner 
similar to the one used for PRL-3 in the course of this project. It is known that 
PRLs share high degree of amino acid sequence identity and that the most 
prominent differences in the sequences can be mapped onto the face opposite 
to the active site pocket (Kozlov et al., 2004). The other set of residues that 
could be replaced with an unnatural amino acid could comprise the 
aforementioned unique residues amongst the PRLs. It would be interesting to 
investigate if this approach would render differences (and if so, to what extent) 
amongst the portfolio of the photo-induced cross-linked proteins. 
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In the course of this PhD, these issues could not be further addressed since the 
focus was directed towards detailed investigations of VHR. 
 
4.4 General applicability of the amber supression methodology to develop 
(more) efficient substrate trapping mutants of PTPs 
Selective incorporation of the photo-cross-linkable amino acid pBPA into VHR 
enabled investigation of dimerisation as a potential regulatory mechanism of 
this phosphatase. It is important to note that without pBPA-containing mutants 
of VHR this observation would not be rendered likely, because all the results 
generated for VHR in the course of this project point towards transient 
homodimeric assembly.  
Importantly, the effect of dimerisation on the catalytic activity of VHR could also 
be investigated, which would not be possible by using chemical cross-linkers 
due to their non-specific and extensive cross-linking, like it was demonstrated 
in the cross-linking experiments with glutaraldehyde in the course of this 
project. Moreover, another obstacle in using chemical cross-linking reagents is 
need for extensive optimisation. This includes, for example, fine-tuning protein 
concentration, type and concentration of the cross-linker, duration of the cross-
linking reaction, temperature and buffer conditions or the conditions for the 
subsequent analysis by, for example, Western blotting.  
Selective incorporation of pBPA could also be a valuable tool in investigating 
(substrate) interactions of PRL-3. The D72pBPA variant of PRL-3 was able to 
recognise and bind to PIPs, with the increase in the signal clearly detected after 
exposure of the sample to 365 nm light for only 5 min. Moreover, the D72pBPA 
variants showed reduced level of the nonspecific binding to PA. This could be 
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due to loss of determinants necessary to recognise PA, but also due to sterical 
reasons as a result of selective incorporation of pBPA. Considering the 
demonstrated success of the D72pBPA variant in forming UV-induced covalent 
complexes with either already reported substrates (PIPs) or upon incubation 
with the cell lysate, it might also be successful in structural studies as a result 
of the stabilizing effect of the protein-substrate association upon UV exposure. 
The D72pBPA variant could be a promising tool in expanding the known 
interacting space of PRL-3. Subsequently, the signaling networks affected by 
PRL-3 might be constructed, especially considering the advantages of photo-
cross-linkable benzophenone moiety.  
Through the successful application of the expanded genetic code toolkit, the 
advantages of exploiting the technology of selective incorporation of photo-
activatable non-canonical amino acid pBPA were clearly demonstrated. 
Moreover, uniting the expanded genetic code toolkit with the more conventional 
approaches of investigating transient protein-protein interactions by means of 
diverse chemical cross-linking reagents was successful. 
Based on the study presented here, it is reasonable to assume that the 
selective incorporation of photo-cross-linkable amino acids would be a useful 
tool in investigating interactions of PTPs in general. These investigations would 
be greatly supported by the availabilities of protein structures to speed up the 
selection of the amino acid residues that would be most suitable to be 
exchanged with a photo-cross-linkable amino acid. In addition, other photo-
cross-linkable amino acids, such as the recently reported aliphatic diazirine 
(Chou et al., 2011), which might circumvent the disadvantage of sterical bulk of 
pBPA and which have the photo-excitable moiety at the end of a longer chain, 
might also be explored. 
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